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PART I: DIPEPTIDE PRODRUG APPROACH TO IMPROVE INTESTINAL 
ABSORPTION OF LOPINAVIR 
Abhirup Mandal, Candidate for the Doctor of Philosophy Degree 
University of Missouri – Kansas City, 2018. 
 
ABSTRACT 
Lopinavir (LPV), a highly potent second-generation HIV-1 protease inhibitor, is 
currently indicated in HIV-1 infection. However, poor systemic exposure following oral 
LPV dosing is a major concern. One of the major factors limiting intestinal permeability is 
the high substrate affinity of LPV towards major drug efflux pumps such as P-gp and 
MRP2. To address these issues, a histidine-leucine-LPV (His-Leu-LPV) dipeptide prodrug 
was synthesized and evaluated. His-Leu-LPV was identified by 1H-NMR and LCMS/MS 
techniques. Aqueous solubility generated by this prodrug was markedly higher relative to 
unmodified LPV. Importantly, His-Leu-LPV displayed significantly lower affinity towards 
P-gp and MRP2 as evident from higher uptake and transport rates. [3H]-GlySar and [3H]-
L-His uptake receded to approximately 30% in the presence of His-Leu-LPV supporting 
the PepT1/PHT1 mediated uptake process. A steady regeneration of LPV and Leu-LPV in 
Caco-2 cell homogenates indicated His-Leu-LPV undergoes both esterase and peptidase-
mediated hydrolysis. Based on these results, it appeared that histidine based dipeptide 
prodrug approach might be an alternative to improve LPV absorption across poorly 
permeable barriers such as intestinal and blood-brain barriers (BBB).  
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PART II: NANOFORMULATIONS TO IMPROVE OCULAR DELIVERY OF 
CIDOFOVIR AND OCTREOTIDE 
Abhirup Mandal, Candidate for the Doctor of Philosophy Degree 
University of Missouri – Kansas City, 2018. 
 
ABSTRACT 
Cidofovir (CDF) has demonstrated significant antiviral activity against 
cytomegalovirus (CMV) and is indicated for the treatment of CMV retinitis. Nonetheless, 
high water solubility of CDF limits its absorption through passive transcellular transport.  
While repeated intravitreal (IVT) injections leads to serious adverse events, back of the eye 
delivery after topical application remains a major challenge. Therefore, a prodrug 
containing C12 (twelve carbon chain length) lipid linker and biotin (ligand) for targeting 
sodium dependent multivitamin transporter (SMVT) was formulated with polymeric 
nanomicelles for topical application. Apart from serving as an inert nanocarrier for 
hydrophobic therapeutic agents, polymeric nanomicelles being extremely small in size 
promotes circumvention of mononuclear phagocytic system (MPS) and efflux transporters 
thereby improving drug bioavailability.     Therefore, we prepared polymeric nanomicelles 
using polyoxyethylene hydrogenated castor oil 40 (HCO-40) and octoxynol 40 (OC-40). 
In vitro release studies revealed that B-C12-cCDF-loaded nanomicelles released B-C12-
cCDF at a faster rate in stimulated tear fluid in comparison to PBS. MTT and LDH assays 
demonstrated negligible cytotoxicity of B-C12-cCDF-loaded nanomicelles relative to CDF 
and B-C12-cCDF in D407 (retinal pigment epithelial), SV-40 (immortalized human 
corneal epithelial) and CCL 20.2 (conjunctival epithelial) cells. Confocal laser scanning 
microscopy and flow cytometry analyses indicated that B-C12-cCDF-loaded nanomicelles 
were efficiently internalized into D407 and SV-40 cells in contrast to CDF and B-C12-
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cCDF. Moreover, little B-C12-cCDF was also observed in the nuclei after 24 h of 
incubation. Polymeric nanomicelles carrying the transporter targeted prodrug did not 
produce any cytotoxic effects and were internalized into the cells effectively. Permeability 
experiments across SV-40 cells further confirmed significant transport of prodrug loaded 
nanomicelles and their subsequent uptake into D407 cells. These findings indicate that 
HCO-40/OC-40 based polymeric nanomicelles could become a promising topical delivery 
system for ocular administration of anti-viral agents. 
 Additionally, octreotide, a somatostatin peptide analogue is a promising therapeutic 
agent for treating proliferative diabetic retinopathy (PDR) by the activation of pituitary 
somatostatin receptor (SSTR) and inhibition of the GH-insulin-like growth factor (IGF)-1 
axis. However, delivery related issues such as short half-life, low stability due to 
hydrophilicity, high molecular weight and minimal permeability across blood-retinal 
barrier are some of the major concerns. To overcome these challenges, we developed self-
assembling multi-layered nanomicelles composed of two polymers, HCO-40 and OC-40 
designed to combine hydrophilic interaction and solvent induced encapsulation of peptides 
and proteins. HCO-40 and OC-40 polymers are employed to encapsulate peptides and 
proteins in the core of the organo-nanomicelles with chloroform as a dispersant. The 
individual organo-nanomicelles are further encapsulated with another layer of the same 
polymers leading to the formation of an aqueous stable amphiphilic nanomicellar solution. 
The size of the multi-layered nanomicelles ranged from ~16-20 nm with zeta potential close 
to neutral (~-2.44-0.39 mV). In vitro release studies revealed that octreotide loaded multi-
layered nanomicelles released octreotide at much slower rate in STF (~27 days) compared 
to PBST (~11 days) in its native form. MTT assay demonstrated negligible toxicity of the 
multi-layered nanomicelles at lower concentrations in HRPE (Human retinal pigment 
epithelial, D407), CCL 20.2 (Human conjunctival epithelial) and RF/6A (rhesus choroid-
vi 
 
retinal endothelial) cells. This work demonstrates an efficient peptide delivery platform 
with significant advantages over existing approaches, as it does not require modification of 
the peptide, is biodegradable, has small size and a high loading capacity.   
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CHAPTER 1 
1. EXPANDING ROLE OF PRODRUGS IN HIV/AIDS THERAPY  
1.1. Rationale 
Prodrug based delivery approaches have been extensively employed to improve 
pharmacokinetic, pharmaceutical and physicochemical profiles of small molecules. Prodrugs 
are usually produced by chemically modifying the parent drug with small targeting or non-
targeting moieties. In most cases, these compounds are biologically inactive and need chemical 
and/or enzymatic biotransformation in vivo to regenerate parent drug for desired 
pharmacological response. Depending on the type of the prodrug, nature of the linkage and 
pro-moiety (targeting vs non-targeting), the rate and site of reversion may be optimized 7-8. In 
general, the major principle behind prodrug design and development is to optimize 
pharmacokinetic properties and improve drug specificity and selectivity. This process in turn 
promotes drug bioavailability and minimizes unacceptable drug-related toxicities. In the last 
decade, considerable attention has been paid to the development of prodrugs for improving 
drug delivery and efficacy. During 2000 to 2008, prodrugs constituted one-fifth of the total 
approved small molecule drugs 9. Currently, prodrugs represent about 10% of the clinically 
available therapeutic agents 9. Moreover, extensive efforts have been directed in preclinical 
stages to develop various types of prodrugs capable of generating superior efficacy. In this 
chapter, an attempt has been made to understand the prevalence and life cycle of HIV-1, 
challenges associated with current therapeutic regimens and the role of prodrugs.   
1.2. Prevalence of acquired immunodeficiency syndrome (AIDS)  
AIDS is a life threatening condition triggered by human immunodeficiency virus (HIV-
1). HIV-1 invades the body’s immune system, specifically the CD4+ T cells, which are 
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responsible for maintaining the integrity of the immune system to fight off infections. Over 
time, HIV-1 depletes CD4+ cells to an extent, where a person is more likely to get other 
opportunistic infections or infection related cancers 10. Eventually the weak immune system 
fails to resist secondary infections and diseases, leading to the last stage of the HIV-1 infection, 
AIDS 11.  
HIV/AIDS continues to be a major global public health issue. More than 36.7 million 
people worldwide were living with HIV/AIDS at the end of 2016 (Figure 1-1). Of these, 2.1 
million were children (<15 years old). According to The Joint United Nations Programme on 
HIV/AIDS (UNAIDS); an estimated 1.8 million individuals worldwide became newly infected 
with HIV in 2016 – about 5,000 new infections per day. Importantly, 1.1 million adults and 
adolescents have been estimated to be living with HIV in the United States in 2016. Of those, 
approximately 18,160 people received an AIDS diagnosis and 6,721 deaths were reported in 
2014 due to HIV-related illness 12-13.  
 
 
 
 
 
 
 
 
Figure 1-1 Number of people living with HIV in 2016 (UNAIDS Data 2017) 
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1.3. HIV virus structure and function 
HIV type 1 (HIV-1) is an enveloped retrovirus belonging to the lentivirus sub family. 
It consists of two identical single stranded ribonucleic acid (RNA) molecules in the core of the 
virus particle, which are reverse transcribed to DNA by the reverse transcriptase enzyme 
following infection into the host cell 14. While the genome (a core of RNA) carries the genetic 
information of the virus, the capsid, a protein component surrounds and protects the genome 
giving the virus its shape. The HIV-1 genome includes nine distinct genes encoding for three 
structural proteins: capsid proteins (gag), polymerase gene proteins (pol) and envelope 
glycoproteins (env); four accessory proteins (Vif, Vpr, Nef and Vpu/p7) and two regulatory 
proteins (Rev and Tat) 4(Figure 1-2).   
The gag gene encodes for the outer core membrane protein (MA, p17), the capsid 
protein (CA, p24), the nucleocapsid (NC, p7) and a nucleic acid-stabilizing protein (p6) 15-16. 
The gag gene is followed by the pol gene, which codes for the enzymes protease (PR, p11), 
reverse transcriptase (RT, p51) and RNase H (p15) or RT plus RNase H (together p66) and 
integrase (IN, p31). Adjacent to pol gene, the env gene codes for the two-envelope 
glycoproteins gp120 (surface protein, SU) and gp41 (transmembrane protein. TM). 
Additionally, HIV genome codes for other regulatory proteins including Tat (transactivator 
protein) and Rev (RNA splicing-regulator) that are responsible for initiating HIV replication 
17. Regulatory proteins including Nef (negative regulating factor), Vif (viral infectivity factor), 
Vpr (virus protein R) and Vpu (virus protein unique) are involved in the promotion of viral 
replication, propagation, budding and pathogenesis 18. The presence of Vpx (virus protein X) 
instead of Vpu in HIV-2 is partially responsible for its reduced pathogenicity 19-20.  
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1.4. Stages of HIV-1 life cycle 
The first step of the HIV-1 replication cycle is the attachment of the viral Env 
glycoprotein to the CD4 cell surface proteins and a co-receptor {either CC-chemokine receptor 
5 (CCR5) or CXC-chemokine receptor 4 (CXCR4)}. HIV-1 co-receptor antagonists can inhibit 
this process of viral attachment 21. The second step involves the fusion of the viral and host 
cell membranes allowing viral capsid entry into the cell, which can be restricted by fusion 
inhibitors. Once inside the cell, the viral RNA genome is reverse transcribed to double-stranded 
DNA, which is further integrated into the host genome. Nucleoside analogue reverse 
transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Figure 1-2 Structure of HIV-1 virus. Reporduced with permission from Robinson 
et al. 4 
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are generally utilized to inhibit the process of reverse transcription whereas integrase strand 
transfer inhibitors (InSTIs) and allosteric integrase inhibitors (ALLINIs) can inhibit the viral 
integrase 22. Following successful integration, transcription of proviral components yields viral 
RNAs, which are further translated into viral proteins. Proteolytic processing of viral 
polyproteins yields mature virions that are capable of infecting new host cells. The maturation 
step can be blocked by the protease inhibitors which can eventually result in inhibition of 
reverse transcription and possibly other downstream processes in the HIV-1 life cycle 5(Figure 
1-3).  
 
 
 
1.5. Lopinavir (LPV): current issues and challenges  
LPV is a second-generation protease inhibitor with high specificity for HIV-1 protease. 
It is a hydrophobic compound (log P = 3.91) and a very good substrate of efflux proteins (P-
Figure 1-3 Stages of the HIV‑1 life cycle targeted by antiretroviral drugs. Reporduced with 
permission from Laskey et al. 5 
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gp and MRP-2) and liver metabolizing enzymes (CYP3A4). LPV has been reported to generate 
poor oral bioavailability in rats, dogs and healthy volunteers when administered alone. Thus, 
it is commonly indicated in combination with ritonavir under the trade name Kaletra® for HIV-
1 treatment 23. Ritonavir is responsible for inhibiting the efflux pumps and hepatic metabolism 
and thus decreases LPV intrinsic clearance. However, such modulation of the endogenous 
expression and functionality of efflux proteins and/or metabolizing enzymes pose a greater risk 
of generating adverse side effects 24. Additionally, the higher expression of efflux proteins on 
the luminal side of intestinal epithelial cells diminishes LPV intestinal absorption thereby 
reducing its therapeutic efficacy. A cumulative effect of oxidative metabolism by CYP3A4 
and efflux proteins drastically lowers oral bioavailability of LPV. 
In fact, LPV being practically insoluble in water is mostly administered in the form of 
approximately 40% v/v alcoholic solution. Such high alcoholic concentrations could lead to 
harmful adverse effects in pediatrics and adolescents 25. Moreover, ethanol consumption has 
been reported to aggravate CPY3A4 metabolizing activity. Such escalation in CYP3A4 levels 
might contribute significantly in LPV metabolism and clearance.  
1.6. Peptide prodrug approach   
The additive effect of poor aqueous solubility and contribution of efflux proteins and 
CYP3A4 metabolizing enzymes result in low oral and brain bioavailability of LPV. 
Additionally, higher expression of efflux proteins including P-gp and MRP2 on the intestinal 
epithelium and the blood-brain barrier (BBB) presents a major challenge in the transport of 
LPV 26-27. Hence, we propose to develop amino acid and peptide prodrugs of LPV. We 
hypothesize that these prodrugs will generate significantly improved systemic and brain 
concentrations of LPV. The ligand coupled prodrugs are anticipated to permeate intestinal 
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epithelial and brain capillary endothelial cells by efficiently binding and translocating via 
influx transporters and simultaneously evading the efflux pumps, P-gp and MRP-2. The 
hypothetical approach is depicted in Figure 1-4, where LPV, an excellent substrate for efflux 
pumps, is modified by conjugating a targeting moiety in order to target the membrane influx 
transporters (peptide and amino acid). The resulting peptide prodrug bypasses the efflux pumps 
and efficiently translocates across the membrane barriers.  
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Figure 1-4 Hypothetical mechanisms involved in histidine peptide prodrug approach to improve oral 
and brain bioavailability, simultaneously 
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This strategy can also be called as histidine based peptide prodrug approach. Amino 
acids are selected such that they target specific influx transporters. In this approach, it is 
hypothesized that following oral administration, histidine based peptide prodrug will target 
specifically peptide/histidine (PHT1) and peptide influx transporters (PepT1) and 
simultaneously evade efflux pumps at intestinal epithelium. Such evasion of efflux proteins 
would allow improved concentration of peptide prodrug (His-Leu-LPV) in the systemic 
circulation where they may undergo enzymatic hydrolysis to regenerate finite amount of single 
amino acid prodrug (Leu-LPV) and the parent drug (LPV). Amino acid transporters (LAT1), 
highly expressed on the BBB, will further recognize systemically regenerated amino acid 
prodrug and will simultaneously assist in circumventing efflux pumps. Additionally, PHT1 
transporters that are also expressed on the BBB can recognize the non-hydrolyzed histidine-
peptide prodrug and allow significantly improved LPV transport across the BBB. The most 
critical advantage of the histidine based peptide prodrug over other peptide prodrugs is the 
ability to target more than one transporter at the same time expressed on different cell 
membranes (intestinal and brain capillary endothelial cells). Such targeting using amino acids 
may aid in circumventing efflux pumps highly expressed on these membranes and generate 
non-toxic by-products. Designing of such transporter targeted prodrugs capable of targeting 
two active transport processes, especially PHT1 which is exclusively expressed on the 
intestinal and brain endothelial cells represent a paradigm shift from traditional delivery 
approaches. The efflux and influx transporters described in the following chapter are 
considered especially in the design of such LPV prodrugs.      
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CHAPTER 2 
2. ROLE OF TRANSPORTERS IN DETERMINING CELL PERMEABILITY IN 
DRUG DELIVERY 
2.1. Rationale 
Transporter studies for drug development and delivery is a rapidly growing field. It has 
contributed largely towards better understanding of cell permeability and drug disposition. So 
far more than 400 membrane transporters have been identified and classified into two major 
superfamilies: ATP-binding cassette (ABC) and solute carrier (SLC) 28. Transporter 
expression, particularly in epithelia of intestine, liver and kidney as well as endothelium of 
blood-brain barrier are the major determinants of cell permeability which consequently impacts 
drug pharmacokinetics. Despite the progress, the field suffers from a limited range of integral 
assays for measuring permeability effects 29. As a result, conflicting opinions are postulated 
regarding the importance of transporters on drug disposition.  
Drug transport mainly involves three processes: absorption, distribution, and 
elimination of which diffusion through the bilayer membrane is considered to be the dominant 
process. Several theories have been proposed to date to understand the mechanism of drug 
absorption and distribution. Lipinski’s rule of five (R05) is one such theory for predicting the 
permeability of orally administered drugs. The R05 rule states that orally active drugs cannot 
violate more than one of the following criteria: molecular mass < 500 Daltons, octanol-water 
partition coefficient log P < 5, number of hydrogen bond donors <5, number of hydrogen bond 
acceptors <10. These empirical guidelines assist formulators to assess molecular properties of 
drug molecules for transport of drug across biological membranes and disposition within 
different organs and tissues 30-31.  
12 
However, a few drug classes in spite of violating R05, are highly orally active. These 
drugs possess unique structural features that allow these molecules to be recognized as 
substrates by transporters expressed at various biological barriers. Several evidences of such 
accumulation of drugs are available. Enhanced intracellular uptake of prodrugs with targeting 
moieties as known substrates carriers have implicated prominent role of carrier-mediated 
uptake than is assumed to be 32-33. For instance, Vadlapudi et al. synthesized biotin conjugated 
prodrugs of acyclovir for targeting sodium dependent multi-vitamin transporter expressed on 
the corneal epithelium 34.  
Furthermore, several transporters belonging to ABC family are also responsible for 
drug elimination across brush border membrane of proximal tubule and canalicular membrane 
of hepatocytes.  These efflux transporters are usually localized to intestine, liver, kidney, 
blood-brain barrier, and placenta and are primarily responsible for low absorption and poor 
drug bioavailability leading to drug resistance 35.  
Numerous in vivo studies have demonstrated the vital role of transporters in drug 
disposition, therapeutic efficacy, drug-drug interactions, drug toxicity and adverse drug 
reactions. Animal models including knockout mice and human genetic variants have indicated 
the role of transporters in conjunction with drug metabolizing enzymes (DMEs) in drug 
disposition. Based on current research reports and clinical studies, US Food and Drug 
Administration (USFDA) has issued several guidelines for conducting research on drug 
interaction with transporters and metabolizing enzymes 36. Despite substantial literature and 
guidance, pharmaceutical scientists are still facing difficulties in conducting in vivo studies 
concerning transporters and metabolizing enzymes in drug development and delivery. In 
particular, some of the concerns raised are: which transporters are clinically relevant in drug 
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absorption and disposition? What are the viable methods for studying in vitro drug interactions 
with transporters? What follow-up clinical studies should be conducted and what are the 
criteria to assess PK-PD relationships? 
In this chapter, we will focus on the role of transporters on cell permeability with 
respect to substrate, inhibitor interactions with a special emphasis on efflux and influx 
transporters that are critical in the area of drug development and delivery.  
 
2.2. Overview of drug transporters  
A prerequisite for orally administered drugs to be effective is to smoothly cross a 
sequential series of barriers in the intestine, liver and kidney. Systemic bioavailability of orally 
administered drugs is primarily considered to be a function of intestinal drug absorption and 
subsequent phase I metabolism in the liver. However, human intestine has been recognized to 
be a major contributor to first pass extraction. Both influx and efflux transporters primarily 
belonging to ABC and SLC transporter family are abundantly expressed in human intestine 37. 
Additionally, presence of these transporters in kidney also contributes to transport and/or 
clearance of orally administered drugs. Apart from these barriers, CNS drugs pose further 
challenge due to the complexity of brain and presence of the blood-brain barrier 38. Thus, drug 
transporters are of escalating interest in identifying their role in influencing drug permeability 
across biological barriers and pharmacokinetics. Figure 2-1 illustrates the localization of 
various transporters in intestinal lumen, hepatocytes, kidney proximal tubules, brain capillary 
endothelial cells and tumor and ocular tissues. Table 2-1 summarizes various substrates and 
inhibitors of efflux transporters, which have been identified in literature to date.  
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The two major processes involving drug-passage across membranes are carrier-mediated 
transport and passive diffusion. Carrier-mediated transport can be categorized into: facilitated 
and active mechanisms. Facilitated transport occurs when nutrients such as glucose, urea and 
amino acids permeate a bio-membrane without coupling to the breakdown of ATP down the 
electrochemical gradient. In contrast, active transport involves energy coupling mechanisms 
to transport molecules against the concentration gradient. It can be either primary which 
involves energy from ATP hydrolysis or secondary which utilizes previously generated energy 
by dissipation of ion gradients via ion pumps 39.  
2.2.1. Efflux transporters: ATP binding cassette transporters (ABC) 
ABC family of efflux transporters are one of the first identified and most investigated 
transporters expressed at the apical membranes of intestine, liver, kidney and the blood-brain 
barrier27. These include P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) 
and breast cancer resistance protein (BCRP). These transporters are expressed abundantly on 
the apical membranes of these organs in contrast to basolateral side. However, there are several 
isoforms of MRP (i.e., MRP1, MRP3-MRP6) that are expressed on the basolateral surface of 
intestine40. These transporters play an important role in limiting the absorption of a wide 
variety of clinically important and frequently prescribed drugs. In fact, intestinal, biliary and 
urinary secretions of drugs like statins, antibiotics, immuno-suppressants, anti-cancer and 
cardiovascular drugs are majorly affected by these efflux transporters41. Additionally, brain 
absorption of CNS drugs including HIV protease inhibitors are limited due to the presence of 
these efflux transporters at the blood-brain barrier. Recently the presence of efflux transporters 
has been quantified in various organs. Expression and functionality of these efflux proteins can 
be modulated by various agents which can simultaneously serve as substrate and/or inhibitor 
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of more than one efflux transporters. Such modulation can lead to altered pharmacokinetics of 
a broad range of therapeutic agents 42-44. Moreover, age and sex differences in the expression 
of transporters are thought to be important determinants accounting for individual disparity in 
transporter expression. Several transporter genes including ABCA5, ABCB6, MRP1, MRP5, 
OST-beta, ATP2B2, SLC10A1, SLC6A16, SLC22A12, SLC22A9, SLC31A1, SLC31A2, 
SLC35F5, SLC43A1, SLC4A1AP, SLC5A10, SLC5A6, and SLC16A11 are highly expressed 
in males compared to females 45. Sex differences are also exhibited by the serotonin 5- HT1A 
receptor and serotonin transporter (5-HTT), a target for psychotic drugs. Women exhibit 
significantly higher 5-HT1A receptor and lower 5-HTT binding potentials thereby contributing 
to sex differences in psychiatric disorders 46. Additionally, transporter genes, ATP7B and 
SLC9A1 exhibit higher expression in females compared to males. However, few genes 
(ABCB1, SLC22A2, and SLC25A13) are found to be similarly expressed in both sexes. Aging 
is another critical factor governing the expression of transporters. Joseph et al. have reported 
the mRNA expression levels of MRP5, OST-Beta, SLC22A9, SLC31A1, SLC31A2, 
SLC35F5, SLC43A1, SLC4A1AP, SLC5A6, and SLC16A11 to be higher in age ≥ 50 years 
compared to age <50 years. While, MRP1, MRP5, SLC10A1, SLC6A16, SLC22A2, 
SLC22A12, and SLC25A13 mRNA expression levels were found to be higher in age <50 years 
compared to age ≥ 50 years, a few of them (ABCA5, ABCB1, ABCB6, SLC5A10, and 
SLC9A1) were similarly expressed in both age groups.  
2.2.1.1. Permeability-glycoprotein (P-gp; ABCB1)  
P-gp also known as multi-drug resistance protein 1 (MDR1) is the most important and 
abundantly expressed efflux transporter on the apical membrane of intestine, liver, and kidney. 
This efflux pump primarily utilizes ATP as energy source to export xenobiotics back into the 
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intestinal lumen. It can also expel drugs from hepatocytes to bile ducts. Moreover, this pump 
can excrete drugs from kidney proximal tubules into urinary ducts and from capillary 
endothelial cells back into capillaries47. The primary isoforms of MDR are abbreviated as mdr1 
(a and b) and mdr2/3 in rodents. The class I isoform (mdr1/ABCB1) is largely responsible for 
drug transport while the class II isoform (mdr2/3/ABCB4) is accountable for efflux of 
phosphatidylcholine into the bile48. Numerous studies have demonstrated the broad substrate 
specificity of P-gp particularly for hydrophobic and amphipathic molecules. Multiple binding 
sites on P-gp for substrates/inhibitors have been identified49. Hydrogen bonding and 
partitioning in lipoid membrane are usually the rate-limiting steps 50. Seelig et al. have reported 
a general pattern of P-gp recognition by analyzing more than a hundred known substrates 51. 
Well-defined electron donor groups (recognition elements) are generally prerequisite for a 
substrate for P-gp binding. These recognition elements are classified into two groups i.e. Type 
I and II. Type I units demonstrate two electron donor groups with a spatial separation of 2.5 ± 
0.3 Ǻ whereas type II units display two or three electron donor groups with a spatial separation 
of 4.6 ± 0.6 Ǻ. According to the type and number of recognition elements, drugs can be 
classified as weak, strong and non-substrates. A series of clinically important drugs including 
statins (simvastatin lactone, atorvastatin, lovastatin lactone), antibiotics (dicloxacillin, 
fluoroqinolones, ivermectin), anti-cancer agents (doxorubicin, prazosin, reserpine), anti-HIV 
agents (indinavir, nelfinavir, saquinavir, darunavir, lopinavir, zidovudine, lamivudine, 
tipranavir, maraviroc, dolutegravir, raltegravir), tacrolimus, hydrocortisone, talinolol, 
fexofenadine, colchicine, loperamide, aldosterone, dibucaine and temocapril are known 
substrates of P-gp. P-gp inhibitors include various immunosuppressive agents and other well-
known compounds such as SDZ, PSC833, GF120918 and LY33597935. Additionally, statins 
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(atorvastatin), fluoroquinolones, cyclosporine, quinidine, verapamil and several anti-HIV 
agents (abacavir, rilpivirine, atazanavir, ritonavir, cobicistat) have shown to inhibit P-gp 
activity (Table 2-1). In vitro studies have successfully demonstrated the effects of 
substrates/inhibitors on P-gp. Oral co- administration of doxorubicin with verapamil, resulted 
in an increase in plasma peak level, elimination half-life, and volume of distribution of 
doxorubicin 48. Several factors such as environmental stress, hormones, cell-culture conditions 
and xenobiotics including rifampicin, St. John’s wort, atazanavir, nelfinavir and amprenavir 
can also induce P-gp transporter expression. One of the most recognized P-gp induction 
interactions is the co-administration of rifampin with digoxin. A significant reduction in AUC 
of oral digoxin is further confirmed by a 3.5-fold increase in P-gp expression 52. Among in 
vivo studies, mice deficient in mdr1a or mdr1a/b have been selected as powerful models for 
determining the role of P-gp. Hendrikse et al. demonstrated 7.7 fold-higher accumulation of 
11-C-verapamil in mdr1a (-/-) mice relative to mdr1a (+/+) mice. While, 11-C-verapamil 
accumulation elevated by 5.3 fold in mdr1a (+/+) mice in presence of cyclosporine (P-gp 
inhibitor), no such increase was reported for mdr1a (-/-) mice 53. Additionally, studies 
conducted by Sasongko et al. have shown approx. 2-fold (88 ± 20%) larger AUC brain/AUC 
blood of 11C-verapamil accumulation in human in the presence of cyclosporine 54.  
2.2.1.2. Multidrug resistance-associated protein (MRP; ABCC2)  
Until now, nine members have been identified within the MRP family. Among these, 
MRPs 1-5 can play a significant role in cell permeation. MRPs are mainly responsible for the 
extrusion of lipophilic, amphipathic anionic molecules55. Although, MRP’s 1-5 are expressed 
either on basolateral or apical membranes, MRP2 is considered to be the most abundantly 
expressed transporter on the apical membrane acting as a major barrier to drug absorption56. 
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Clinical importance of MRP2 is attributed to its ability to modulate the pharmacokinetics of 
various drug molecules 57. MRP2 was shown to mediate the transport of statins (pravastatin), 
ceftriaxone, ampicillin, grepafloxacin, vinblastine, irinotecan, SN-38, methotrexate, 7-
hydroxymethotrexate, ezetimibe, fosinopril and anti-HIV agents including lopinavir and 
darunavir35. Some other substrates include fexofenadine, sulfasalazine and colchicine. In 
addition, activity and expression are altered by certain compounds and disease states 58. Some 
examples of MRP2 inhibitors include cyclosporine, probenecid, furosemide, ritonavir, 
saquinavir, lamivudine, abacavir, cidofovir, emtricitabine, adefovir, tenofovir, efavirenz, 
delavirdine and MK-571. A study conducted by Shibayama et al. demonstrated reduced MRP2 
expression levels after induction of cholestasis by 5-FU in vitro 59. Approximately 3-fold 
enhanced permeability coefficient (Peff) of sulfasalazine was reported in a recent study 
following in situ perfusion to rat jejunum in presence of MK-571 (MRP2 inhibitor) 55. 
Additionally, Vlaming et al. demonstrated 1.8-fold higher plasma AUC in Mrp2-/- mice (1345 
± 207 versus 734 ± 81 min ·μg/ml) after i.v. administration of [3H] methotrexate (50mg/kg), 
indicating Mrp2-/- mouse model to be a valuable tool in determining impact of Mrp2 on the 
disposition of drugs and other toxins 60. Recent studies have also indicated the efficacy of 
spironolactone and 1, 25(OH) 2D3 in inducing Mrp2 transporter expression in rats 61.  
2.2.1.3. Breast cancer resistance protein (BCRP; ABCG2) 
BCRP, a multidrug resistance protein is a member of ABC class of efflux transporters 
and is also known as “half ABC transporter”.  It is primarily expressed on the apical membrane 
of intestine, liver, kidney and the blood-brain barrier. This efflux protein also plays a vital role 
in limiting oral as well as brain bioavailability of a broad range of therapeutic agents. The 
human intestine expresses higher BCRP mRNA levels than any other efflux transporter. 
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Overlapping substrate specificity of BCRP with P-gp results into a synergistic cumulative 
effect of the efflux transporters further limiting the absorption of therapeutic agents across 
various barriers. BCRP transports a highly diverse range of substrates including statins, 
fluoroquinolones, ciprofloxacin, anti-cancer agents (imatinib, methotrexate, mitoxantrone, 
SN-38, topotecan, irinotecan, doxorubicin, daunorubicin, gefitinib, tandutinib, ezetinib, 
lapatinib), cardiac agents (prazosin, dipyridamole) and anti-HIV agents (zidovudine, 
lamivudine, efavirenz)35. Other substrates include glyburide, sulfasalazine and temocapril 
(Table 2-1). Polarized and non-polarized cell lines including membrane vesicles constitutively 
expressing BCRP have been utilized as a model for in vitro assays 62. In vivo studies in Bcrp 
(-/-) mice demonstrated 10- and 110-folds rise in relative AUCs for topotecan and sulfasalazine 
respectively. Further studies in patients with solid tumors revealed an increase of approx. 2.5-
fold in oral bioavailability and 3-fold in mean Cmax of topotecan in the presence of GF120918 
(dual inhibitor of P-gp/BCRP) 63. Known BCRP inhibitors include estrone, gefitinib, 
novobiocin, pantoprazole, GG918, cyclosporine, dipyridamole CI1033 and ritonavir35. 
Fumitremorgin C and Ko143 (FTC analog) selectively inhibit BCRP with no overlapping 
affinity for MRP1 or P-gp (Table 2-1). Efavirenz is a well-known inducer of BCRP and has 
been reported promote expression of BCRP in the rat intestine 64. 
 
2.2.2. Influx transporters: Solute carrier transporters (SLC; SLCO) 
The major influx transporters primarily responsible for xenobiotic transport belong to 
two solute carrier families: SLC and SLCO. While SLC family members are typically involved 
in the transport of Type I organic anions, cations and zwitter ions, the SLCO family members 
are responsible for the transport of Type II organic anions. The members of these families 
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utilize a variety of porter mechanisms such as uniporter, symporter and antiporter to transport 
a wide range of substrates including amino acids, vitamins, bile acids and other xenobiotics 65. 
The SLC superfamily encompasses a variety of pharmacokinetically important transporters, 
including organic anion transporters (OAT; SLC22A), organic cation transporters (OCT; 
SLC22A), electroneutral organic cation transporters (OCTN; SLC22A), equilibrate nucleoside 
transporters (ENT; SLC29A), concentrative nucleoside transporters (CNT; SLC28A), apical 
Na+-dependent bile salt transporters (ASBT; SLC10), plasma membrane monoamine 
transporters (PMAT; SLC29), monocarboxylate transporters (MCT; SLC16A), urate 
transporters (URAT1; SLC22A12) and peptide transporters (PEPT, SLC15A)66. The SLCO 
superfamily also carries organic anion transporter polypeptide (OATP; SLCO)67.  
2.2.2.1. Peptide transporter (PepT, SLC15) 
Peptide transporters including PepT1 and PepT2 are members of the proton-coupled 
oligopeptide transporter (POT) family and are predominantly expressed on intestinal epithelial 
cells68. The PepT1 acts as a low-affinity/high-capacity transporter and PepT2 as a high-
affinity/low-capacity transporter for di- and tripeptides. Peptide transporters can be exploited 
as potential target for peptide based prodrugs or peptidomimetics as they are highly expressed 
on intestinal epithelial cells69. PepT1 is predominantly expressed on the epithelial mucosa of 
small intestine and transports peptidomimetics such as β-lactam antibiotics (e.g., penicillin and 
cephalosporin), angiotensin-converting enzyme inhibitors, aminopeptidase inhibitors, and 
ester prodrugs. PepT2 is mainly expressed in the kidney and brain with a little expression in 
other tissues including the enteric nervous system, lung, mammary gland, and spleen and 
transports many of the same substrates as PepT170. Following transport across intestinal barrier 
through peptide transporters, the peptide prodrugs may be enzymatically cleaved by esterases 
21 
or aminopeptidases to regenerate the active parent drug. Valine-valine peptide prodrugs of 
Saquinavir (SQV) and Lopinavir (LPV) have demonstrated higher intestinal transport relative 
to the parent drugs itself 71.  
2.2.2.2. Peptide histidine transporter (PHT, SLC15A4) 
Peptide/histidine transporters, PHT1 (SLC15A4) and PHT2 (SLC15A3) also belong to 
the POT family. Recently their splice variants were identified in the rat (rPHT1 and rPHT2) 
and human (hPHT1 and hPHT2) genome72. However, these transporters are less extensively 
explored for their specific tissue expression, molecular and functional characteristics and 
cellular localization in contrast to peptide transporters. Some studies have demonstrated the 
role of hPHT1 in H+-dependent and Na+-independent uptake of histidine and dipeptide 
carnosine73-74. Additionally, valacyclovir, the valine substituted amino acid prodrug of 
acyclovir, also appeared to be a substrate for hPHT1. Yamashita et al. reported rPHT1 and 
hPHT1 mRNA expression in the brain, eye, lung, spleen and intestine by Northern blot analysis 
indicating their potential role in transporting histidine and/or histidine based prodrugs in these 
tissues75.   
2.2.2.3. Large neutral amino acid transporter (LAT1, SLC3A2/SLC7A5) 
Amino acid transporters are highly expressed on brain capillary endothelial cells and 
can be exploited to improve brain absorption of nutrients, drugs and prodrugs. They can be 
broadly classified as anionic, cationic and neutral amino acid transporters depending on the 
charge of the amino acid that is being transported76. Large neutral amino acid transporter 
(LAT) is highly expressed on the luminal surface of brain endothelial cells and assist in the 
transport of large neutral amino acids with aliphatic and aromatic side chains. Additionally, 
anionic (system x-), neutral (system A) and cationic (system BO+) amino acid transporters are 
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also reported to be expressed on the BBB. LAT is primarily responsible for transporting neutral 
amino acids including phenylalanine, tyrosine, leucine, isoleucine, tryptophan and methionine 
across the brain77. 
2.3. Summary 
Limited quantitative pharmacological evidences for drug uptake and efflux by transporters 
represents an area of further basic and clinical research. Significant efforts are being made to 
understand the role of transporters, their iterative interplay with metabolizing enzymes through 
molecular enzymology, binding and structure-activity relationship studies. While the substrate 
and inhibitor profiles of transporters are being updated progressively, new transporters are still 
being discovered. In addition, further research is imperative to develop means of improving 
transporter utilization or activity that might positively impact drug effects and reduce adverse 
effects. 
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Figure 2-1 Major drug transporters expressed in different tissues: Major transporters in plasma 
membrane of intestinal epithelia, hepatocytes, kidney proximal tubules, brain capillary endothelial cells 
and tumor tissues are represented. Orange colored arrows represent efflux while green colored arrows 
represent influx. Those in Bold letters are discussed in detail 
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Table 2-1 Drug efflux transporters of emerging importance in drug transport and disposition35  
Drug 
Transp
orter 
Gene Organs/Tissues 
Localiza
tion 
Substra
tes 
Inhibitors Inducers 
P-
gp/MD
R1 
ABCB1 Intestinal enterocytes, 
Kidney proximal 
tubules, Hepatocytes, 
Brain endothelia, 
placenta, adrenal, testes 
Apical a.  b. Rifampicin, 
Monensin, St. 
John’s wort, 
atazanavir, 
nelfinavir, 
amprenavir 
BCRP ABCG2 Intestinal enterocytes, 
Kidney proximal 
tubules, Hepatocytes, 
Brain endothelia, 
placenta, stem cells, 
mammary glands 
Apical c. Estrone, GG918, 
fumitremorgin C, Ko143, 
novobiocin, pantoprazole, 
CI1033, gefitinib, 
quercetin, cyclosporine, 
dipyridamole, ritonavir 
Efavirenz 
MRP2 ABCC2 Intestinal enterocytes, 
Kidney proximal 
tubules, Hepatocytes, 
Brain endothelia 
Apical d. Cyclosporine, probenecid, 
furosemide, ritonavir, 
saquinavir, lamivudine, 
abacavir, emtricitabine, 
efavirenz, delavirdine, 
nevirapine, cidofovir, 
adefovir, tenofovir, MK-
571 
Rifampin, 
spironolacton
e, 
1,25(OH)2D3 
 
a. Substrates: Statins: simvastatin lactone, atorvastatin, lovastatin lactone; Antibiotics: dicloxacillin, 
fluoroquinolones (grepafloxacin, levofloxacin and sparfloxacin), erythromycin, cyclosporine, 
oxytetracycline, doxycycline, valinomycin, ivermectin; Anti-cancer agents: doxorubicin, daunorubicin, 
paclitaxel, vincristine, vinblastine, idarubicin, topotecan, tandutinib, imatinib, methotrexate, 
mitoxantrone, SN-38, lapatinib; Cardiac agents:  digoxin, prazosin, reserpine; Anti-HIV agents: 
indinavir, nelfinavir, saquinavir, darunavir, lopinavir, zidovudine, lamivudine, tipranavir, maraviroc, 
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dolutegravir, raltegravir; Others: tacrolimus, hydrocortisone, talinolol, fexofenadine, colchicine, 
loperamide, aldosterone, dibucaine, temocapril.  
b. Inhibitors: Statins: atorvastatin; Antibiotics: fluoroquinolones (grepafloxacin, levofloxacin and 
sparfloxacin), cyclosporine; Cardiac agents: quinidine, verapamil; Anti-HIV agents: abacavir, 
rilpivirine, atazanavir, ritonavir, cobicistat; Others: tariquidar, GF120918, immunosuppressive agents, 
SDZ, PSC 833, LY335979 
c. Substrates: Statins: simvastatin lactone, atorvastatin, lovastatin lactone, pravastatin or fluvastatin, 
rosuvastatin; Antibiotics: fluoroquinolones (grepafloxacin, levofloxacin and sparfloxacin), ciprofloxacin; 
Anti-cancer agents: imatinib, methotrexate, mitoxantrone, SN-38, topotecan, irinotecan, doxorubicin, 
daunorubicin, gefitinib, tandutinib, ezetimibe, 9-aminocamptothecin, lapatinib; Cardiac agents: prazosin, 
dipyridamole; Anti-HIV agents: zidovudine, lamivudine, efavirenz; Others: glyburide, temocapril, 
sulfasalazine  
d. Substrates: Statins: pravastatin; Antibiotics: ceftriaxone, ampicillin, grepafloxacin; Anti-cancer 
agents: vinblastine, irinotecan, SN-38, methotrexate, 7-hydroxymethotrexate, ezetimibe; Cardiac 
agents: fosinopril; Anti-HIV agents: lopinavir, darunavir; Others: fexofenadine, sulfasalazine, 
colchicine  
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CHAPTER 3 
3. HISTIDINE BASED PEPTIDE PRODRUG: A DUAL TARGETED APPROACH 
TO IMPROVE INTESTINAL ABSORPTION OF LOPINAVIR 
 
3.1. Rationale 
Lopinavir (LPV) is currently indicated in highly active antiretroviral therapy (HAART) 
in combination with ritonavir 78. Despite potent efficacy against HIV-1, oral administration 
results in poor intestinal absorption and negligible LPV levels in the body. One of the major 
factors that potentially limit intestinal absorption is the high substrate affinity of LPV towards 
P-gp and MRP2 79. P-gp and MRP2 are extensively expressed on the villus tip of enterocytes, 
the primary absorption site for orally administered drugs 80. These efflux pumps, limit the entry 
of harmful substances and xenobiotics and prevent LPV from getting transported across the 
intestinal epithelium thus secreting it back into the intestinal lumen. Hence, to overcome these 
efflux pumps, a significantly higher dose of LPV needs to be administered. Although high 
doses of LPV have made it possible to achieve therapeutic plasma concentrations, at the same 
time it has resulted in severe cellular and/or systemic toxicities 25, 81.  
Combination strategies capable of modulating the expression and functional activity of 
efflux pumps present a unique approach to improve absorption and efficacy of LPV. However, 
such strategies may pose a risk of generating serious systemic adverse events 82-84. For instance, 
Bertrand et al. reported an excessive increase in vincristine neuropathy when administered 
along with cyclosporine to modulate MDR 85. Similarly, Kerr et al. demonstrated an 
unassuming pharmacokinetic interaction between verapamil (efflux pump inhibitor) and 
doxorubicin in humans. Although, oral verapamil able to increase the AUC, terminal t1/2 and 
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volume of distribution of verapamil, the plasma drug clearance significantly dropped due to 
inhibition of efflux pumps leading to various side effects 86. In the past few decades, prodrug- 
based approaches have garnered considerable interest to improve pharmacokinetic as well as 
pharmacological profiles of poorly permeable therapeutic agents 8, 33. Interestingly, prodrugs 
have been designed such that various endogenous transporters, co-expressed with efflux 
pumps, are targeted to improve drug absorption. In this regard, peptide transporters have been 
extensively utilized in our laboratory to improve cellular permeability of various antiviral 
agents such as saquinavir 71, 87, lopinavir 88-89, acyclovir 90-91 and ganciclovir 92. The peptide 
prodrug conjugates may extend an additional advantage of generating non-toxic nutrient 
byproducts at the target site where prodrugs are getting converted to the parent drug and pro-
moieties. The binding of a target agent to an influx transporter confers a structural change to 
the transporter leading to the translocation of molecule across the membrane and thus its 
subsequent release into the cytoplasm. Moreover, suitable combinations of amino acids in 
dipeptide prodrugs can modulate physicochemical properties of the parent drug.  
Recently, brain and intestinal expression of a peptide/histidine transporter (PHT1, 
SLC15A4) have been reported 70, 93-95. Such unique expression renders PHT1 a potential target 
to improve delivery of P-gp and MRP2 substrates such as LPV. Exploiting the role of 
peptide/histidine transporter in transporting various P-gp and MRP2 substrates remains 
elusive. 
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3.2. Objectives  
(i) A histidine based dipeptide prodrug, His-Leu-LPV, was synthesized and evaluated by 1H-
NMR and LCMS/MS techniques in the present study.  
(ii) Aqueous solubility, buffer stability and cell cytotoxicity of prodrug were examined. 
(iii) Uptake and transport studies were carried out in Madin-Darby canine kidney type II 
(MDCKII) cell lines overexpressing P-gp (MDCKII-MDR1) and MRP2 (MDCKII-MRP2) in 
presence of efflux inhibitors to determine the affinity of His-Leu-LPV towards these efflux 
transporters. 
(iv) The presence of histidine as a terminal targeting moiety is hypothesized to improve 
recognition of the prodrug by PHT17.  Furthermore, His-Leu-LPV being a dipeptide prodrug 
is also anticipated to be transported by peptide transporters (PepT1 and PepT2). Such dual 
recognition of His-Leu-LPV might significantly improve absorption of His-Leu-LPV across 
poorly permeable membranes. Thus, uptake studies of His-Leu-LPV were carried out in 
presence of PHT and PepT influx transporter substrates. 
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3.3. Experimental 
3.3.1 Materials 
Unlabeled LPV and P-gp inhibitor, GF120918 were generous gift from Abbott 
Laboratories Inc. (North Chicago, IL, USA). [3H]-LPV (0.5 Ci/mmol), [3H]-glycylsarcosine 
(3H-GlySar) (29.4 Ci/mmol) and [3H]-Histidine (3H-His) (47.7 Ci/mmol) were purchased 
from Moravek Biochemicals (Brea, CA, USA). Streptomycin, penicillin, HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid), triton X-100, D-glucose, sodium bicarbonate 
(NaHCO3), MK571, Boc-histidine, Boc-leucine, ethyl acetate, dichloromethane (DCM), 
dicyclohexylcarbodimide (DCC), 4-(N,N-dimethylamino)pyridine (DMAP), glucose, sodium 
chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2), sodium phosphate (Na2 
HPO4), potassium phosphate (KH2PO4), magnesium sulfate (MgSO4) and Amberlyst® A21 
resin were obtained from Sigma Chemical Co. (St. Louis, MO, USA). HPLC grade methanol 
and DMSO were purchased from Fisher Scientific Co. (Pittsburgh, PA, USA). Trypsin-EDTA 
solution, Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Invitrogen 
(Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Atlanta Biologics 
(Lawrenceville, GA, USA). Premium siliconized microcentrifuge tubes were procured from 
MIDSCI (St. Louis, MO, USA).  Uptake plates and Transwell® inserts were obtained from 
Corning Costar Corp. (Cambridge, MA, USA). All other chemicals were of analytical reagent 
grade procured from Thermo Fischer Scientific or Sigma Aldrich and were utilized without 
any further purification.  
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3.3.2. Synthesis of His-Leu-LPV 
3.3.2.1. Synthesis 
His-Leu-LPV was synthesized according to a protocol previously published from our 
laboratory with minor modifications 89. His-Leu-LPV synthesis included two steps (a) coupling 
of leucine to LPV through an ester bond to produce Leu-LPV (b) coupling of histidine to Leu-
LPV intermediate via an amide bond to generate His-Leu-LPV. Leu-LPV was synthesized 
using a procedure published from our laboratory88. To synthesize His-Leu-LPV, commercially 
available Boc-His-OH (341mg, 1.35mmol) and DCC (420 mg, 2.025 mmol) were dissolved in 
DCM (6 mL) in a round bottom flask. The mixture was stirred for 1h at 0ºC in an ice bath 
(mixture 1). In a separate round bottom flask, Leu-LPV (500 mg, 0.067mmol) was dissolved 
in DCM and triethylamine (2 mL) was added to the resulting solution (mixture 2). Mixture 2 
was stirred for 30 min at room temperature (RT) under nitrogen atmosphere and added 
dropwise to the mixture 1. The reaction mixture was stirred for 24h at RT while monitoring 
every 6h with TLC and LCMS/MS. The reaction mixture was filtered and DCM was 
evaporated at RT under reduced pressure to obtain crude product. The product Boc-His-Leu-
LPV was purified using silica column chromatography with 5% methanol/dichloromethane 
(MeOH/DCM) as an eluent.  
3.3.2.2. Deprotection of the N-Boc group 
Boc-His-Leu-LPV was dissolved in 60% trifluoroacetic acid (TFA) in DCM and stirred 
at 0ºC for 1h in order to remove the N-Boc protecting group. The mixture was evaporated to 
obtain a solid form of TFA salt of His-Leu-LPV. The TFA salt was further dissolved in 
anhydrous DCM and mixed with Amberlyst® A21 resin (weakly basic resin) for 15-30 min. 
The mixture was filtered and quickly evaporated under reduced pressure and the final product 
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was obtained following recrystallization in cold diethyl ether. The final product was stored in 
-20ºC until any further use. Reaction scheme for synthesis of Leu-LPV and His-Leu-LPV has 
been depicted in Figure 3-1. 
3.3.3. Identification of the prodrugs 
Leu-LPV and His-Leu-LPV were characterized by 1H-NMR analysis. Spectra was 
recorded on Varian Mercury 400 Plus spectrometer using tetra methyl silane. Chemical shifts 
(δ) are reported in parts per million relative to the NMR solvent signal (CD3OD, 3.31ppm for 
proton and 49.15ppm for carbon NMR spectra). Mass analysis was carried out using 
LCMS/MS spectrometer with electron-spray ionization (ESI) as an ion source in positive 
mode.  
Leu-LPV: Low melting point solid; LC/MS (m/z): 742.6; 1H NMR (400 MHz, chloroform-d) 
δ ppm 0.78 (br. s., 3 H) 0.93 (br. s., 5 H) 1.22 (br. s., 5 H) 1.95 (br. s., 2 H) 2.09 (d, J=10.54 
Hz, 4 H) 2.57 - 2.75 (m, 12 H) 2.80 (br. s., 2 H) 3.17 (br. s., 1 H) 3.31 (br. s., 1 H) 4.05 (d, 
J=12.10 Hz, 1 H) 4.17 (d, J=15.23 Hz, 1 H) 4.26 - 4.70 (m, 7 H) 4.81 (br. s., 1 H) 5.01 - 5.14 
(m, 1 H) 6.93 (d, J=10.54 Hz, 2 H) 7.04 - 7.30 (m, 7 H). 
His-Leu-LPV: Low melting point solid; LC/MS (m/z): 879.7; 1H NMR (400 MHz, chloroform-
d) δ ppm 0.65 - 0.96 (m, 5 H) 1.06 - 1.40 (m, 11 H) 1.51 - 1.61 (m, 2 H) 1.70 (br. s., 2 H) 1.77 
- 1.95 (m, 3 H) 2.12 (s, 2 H) 2.56 - 2.76 (m, 21 H) 3.12 - 3.28 (m, 8 H) 4.82 (br. s., 11 H) 6.71 
(d, J=7.03 Hz, 3 H) 7.15 - 7.29 (m, 3 H) 8.18 (d, J=6.25 Hz, 3 H). 
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Figure 3-1 (A) Synthesis of Leu-LPV: (i) Boc-Leucine, DCC in DCM: 1h at 0°C; LPV, 
DMAP in DCM: 15min at RT and mixture stirred for 48h at RT. (ii) 60% TFA in DCM: 1 h 
at 0°C (B) Synthesis of His-Leu-LPV: (i) Boc-Histidine, DCC in DCM: 1h at 0°C; Leu-LPV, 
DCM, TEA: 30 min at RT and mixture stirred for 24h at RT. (ii) 60% TFA in DCM: 1 h at 
0°C 
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3.4. Methods 
3.4.1 Cell culture 
Human P-gp/MDR1 cDNA transfected MDCKII cells (MDCKII-MDR1; passages 5-
25) and human MRP2 cells (MDCKII-MRP2; passages 5-25), wild-type MDCKII cells 
(MDCK WT; passages 50-53) were generously provided by Drs. A. Schinkel and P. Borst 
(Netherlands Cancer Institute, Amsterdam, The Netherlands). Human derived colon carcinoma 
cells (Caco-2; passages 20-30) were obtained from ATCC (Manassas, VA, USA). All these 
cell lines were cultured in T75 flasks in DMEM containing high glucose and glutamine 
concentrations. The culture medium contained 10% FBS (heat-inactivated), 1% nonessential 
amino acids, 100 IU/ml streptomycin and 100 IU/ml penicillin. The pH of the medium was 
maintained at 7.4. Cells were maintained at 37ºC in an atmosphere containing 5% CO2 and 
90% relative humidity. The medium was replaced on alternate days until cells reached 80-90% 
confluency (5-7 days for MDCKII and 19-21 days for Caco-2 cells).  
3.4.2. Solubility studies in distilled deionized water (DDI) 
Aqueous solubility studies of LPV, Leu-LPV and His-Leu-LPV were performed 
according to a previously published protocol from our laboratory 89. Briefly, saturated solutions 
of LPV, Leu-LPV and His-Leu-LPV were freshly prepared in DDI in siliconized tubes and 
placed in a shaker bath for 24h at RT. At the end of 24h, tubes were centrifuged for 10min at 
10,000 rpm to separate the undissolved drug. Supernatants were carefully separated and 
filtered through 0.45 µm membrane filter (Nalgene syringe filter). Samples were further diluted 
appropriately and analyzed by HPLC. 
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3.4.3. Buffer stability studies 
The extent of chemical hydrolysis of Leu-LPV and His-Leu-LPV was assessed 
according to a previously published protocol from our laboratory 82. Degradation rate constants 
(k x 10-4) and half-life (t1/2) values were determined at pH 4, 5.5 and 7.4. Leu-LPV (50 µM) 
and His-Leu-LPV (50 µM) were dissolved in 1.5 mL DPBS in siliconized tubes and placed in 
a shaker bath maintained at 60 rpm at 37ºC. Aliquots (100µL) were withdrawn at 
predetermined time points for 24hr and stored at -80ºC until further analysis by HPLC. Prodrug 
concentrations were plotted against time to determine degradation rate constants at different 
pH values. 
3.4.4. Cytotoxicity studies 
Cytotoxicity of LPV, Leu-LPV and His-Leu-LPV was determined in MDCKII-WT 
cells (passage 52) with MTT based cytotoxicity assay kit (Promega Co., Madison, WI). Briefly, 
cells were seeded in 96 well tissue culture plates at a density of 20,000 cells per well and 
maintained overnight at 37ºC in an atmosphere of 5% CO2 and 90% relative humidity. The 
medium was aspirated the following day and replaced with 100 µL of serum free medium 
containing various concentrations of LPV, Leu-LPV and His-Leu-LPV (6.25-200 µM). After 
4hr incubation at 37ºC, 20 µL of MTT stock solution was added to each well. Cells were kept 
for incubation for 4h at 37ºC. Cell viability was assessed by measuring absorbance at 485 nm 
with a microplate reader (BioRad Hercules, CA, USA).  
3.4.5. Uptake studies 
For cellular uptake studies, cells were seeded at a density of 3 X 106 cells in 12 well 
culture plates and maintained until they achieved 80-90% confluency (6-7 days). The uptake 
assay was carried out according to previously published protocol from our laboratory 96. 
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Briefly, medium was aspirated and cell monolayers were washed three times with 2 mL of 
DPBS (pH 7.4) at 37ºC (each wash of 10 min). Studies were initiated by incubating cells with 
radioactive solutions in DPBS at 37ºC for 30min. Following incubations, radioactive solutions 
were immediately aspirated and plates were washed with ice-cold stop solution to arrest the 
uptake process. Lysis buffer (1mL, 0.1% Triton-X solution in 0.3% NaOH) was added to each 
well and plates were stored overnight at RT. Following day, 500 µL solution from each well 
were transferred to scintillation vials containing 3 mL of scintillation cocktail and assayed with 
a scintillation counter (Beckman Instruments Inc., Model LS-6500; Fullerton, CA, USA). The 
uptake rate was normalized to protein count, which was further quantified using a BioRad 
protein estimation kit (BioRad protein; Hercules, CA). For studies involving efflux inhibitors, 
cells were pre-incubated with 2µM GF 120918 (MDCK-MDR1) or 75µM MK 571 (MDCK-
MRP2) at 37ºC for 30 min prior to imitation of uptake studies. 
3.4.6. Transport studies 
Transepithelial transport studies were performed according to protocol published 
previously from our laboratory with minor modifications 82. Briefly, Transwell® inserts (0.4 
µm pore size, 12 mm) were coated with type 1 rat tail collagen (100 µg/cm2) and placed inside 
a vessel under ammonia vapor for 45 min to promote binding of collagen to the polyester 
membrane. Cells were seeded at a density of 250,000 cells per insert. Following confluency, 
medium was removed and cell monolayers were washed three times with DPBS at 37 ºC (each 
wash of 10 min). Cell monolayer integrity was evaluated by measuring transepithelial electric 
resistance (TEER) using EVOM (epithelial volt ohmmeter from World Precision Instruments, 
Sarasota, FL, USA), prior to initiation of transport studies. Cell monolayers exhibiting TEER 
values >250 Ω*cm2 were utilized for the transport studies. For A-B (absorptive direction) 
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permeability studies, 0.5 mL of test solution (25 µM) was added to the apical membrane of 12-
well Transwell® plates. At predetermined time points, 100 µL sample from basolateral 
chamber of each well was withdrawn and replaced with fresh DPBS in order to maintain sink 
conditions. Studies were carried out for a period of 3 h at 37ºC. Samples were stored at -80 ºC 
until further analysis using LCMS/MS. For studies involving efflux inhibitors, cells were pre-
incubated with 2µM GF 120918 (MDCK-MDR1) or 75µM MK 571 (MDCK-MRP2) at 37ºC 
for 30 min prior to initiation of transport studies. 
3.4.7. Caco-2 cell homogenate studies 
Cell homogenate studies were carried out according to protocol previously published 
from our laboratory. Briefly, confluent Caco-2 cells (passage 25) were washed three times with 
DPBS. Then cells were collected with a mechanical scrapper in two volumes of DPBS. 
Multipro variable speed homogenizer (DREMEL, Racine, WI) was used for cell 
homogenization. The homogenate was centrifuged at 12,500 rpm for 10min. The supernatant 
was collected and protein content was assessed using BioRad protein estimation kit. Suitable 
dilutions were made in DPBS (pH 7.4) to achieve a final protein concentration of 0.5 mg/mL. 
Aliquot (1 mL) of cell homogenate was incubated with His-Leu-LPV at 37ºC in a shaker bath 
(60 rpm) to achieve a final concentration of 40 ug/mL. At predetermined time points, 100 µL 
samples were collected and equal volumes of ice-cold acetonitrile:methanol (5:4) mixture was 
added to terminate enzymatic hydrolysis. Studies were carried out at pH 7.4 for a period of 4 
h. Samples were then stored at -80 ºC until further analysis by LCMS/MS.  
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3.5. Sample and data analysis 
3.5.1. Sample preparation for HPLC analysis 
Aqueous solubility and buffer stability studies were analyzed by an HPLC technique. 
Briefly, samples were freshly prepared in DDI or buffer with pH 4, 5.5 and 7.4 in siliconized 
tubes and placed in a shaker bath maintained at 60rpm for 24 h at 37ºC. Tubes were centrifuged 
for 10 min at 10,000 rpm. The supernatants were carefully separated and filtered through 
0.45µm membrane filter (Nalgene syringe filter). Further appropriate dilutions of the filtrate 
were made in acetonitrile (50%) and water (50%) containing 0.1% trifluoroacetic acid. 
Samples (20µL) were injected into HPLC for analysis. 
3.5.2. HPLC analysis 
Reverse phase HPLC was employed to analyze aqueous solubility and buffer stability 
of samples. The system comprised of a Waters 515 pump (Waters, Milford, MA, USA) with a 
C (18) Kinetex column (100 mm X 4.6 mm, 2.6 m; Phenomenex, Torrance, CA, USA) and a 
UV detector (Absorbance Detector Model UV-C, RAININ, Dynamax, Palo Alto, CA, USA, 
wavelength 210 nm). Acetonitrile:water (1:1) with 0.1% trifluoroacetic acid was selected as a 
mobile phase with 0.4 mL/min as flow rate. LPV, Leu-LPV and His-Leu-LPV eluted 
approximately at 13.62, 8.14 and 6.79 min respectively. 
3.5.3. Sample preparation for LCMS/MS analysis 
Transport and cell homogenate samples were analyzed utilizing a sensitive LCMS/MS 
technique according to a method previously published by our laboratory 89. Briefly, samples 
were subjected to liquid-liquid extraction with water saturated ethyl acetate (10% water) as 
extracting solvent. About 50 µL of amprenavir (2.5µM) was employed as internal standard 
(I.S.). Samples were extracted with 800 µL water saturated ethyl acetate by vigorously 
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vortexing for 2.5 min. Samples were centrifuged at 10,000 rpm for 7min and aliquots (600µL) 
were collected and dried under reduced pressure for 45 min. Samples were reconstituted in 100 
µL of acetonitrile (70%) and water (30%) containing 0.1% formic acid. The reconstituted 
samples (20µL) were injected into LCMS/MS for analysis.  
3.5.4. LCMS/MS analysis 
QTrap® 3200 LCMS/MS mass spectrometer (Applied Biosystems, Foster City, CA, 
USA) connected to Agilent 1100 Series quaternary pump (Agilent G1311A), vacuum degasser 
(Agilent G1379A) and autosampler (Agilent G1367A, Agilent Technology Inc. Palo Alto, CA, 
USA) was employed for sample analysis. Acetonitrile (70%) and water (30%) containing 0.1% 
formic acid was used as mobile phase at 0.3 mL/min. An XTerra1MS C18 column (50 mm X 
4.6 mm, 5.0 mm, Waters, Milford, MA, USA) was employed for analyte separation. 
Chromatograms were obtained over 5 min. LPV and amprenavir eluted at 3.05 and 2.28 min 
respectively. Leu–LPV and His-Leu-LPV eluted at 1.60 and 1.18 min respectively.  
Positive mode of electro spray ionization was employed and analytes of interest were 
detected in multiple-reaction monitoring (MRM) mode. Precursor and product ions generated 
for LPV and amprenavir were +629.30/155.10 and +506.20/245.20 respectively. 
Precursor/product ions for Leu-LPV and His-Leu-LPV were obtained at +742.30/155.10 and 
+879.40/155.10 respectively. Turbo ion spray setting and collision gas pressure were also 
optimized (IS Voltage: 5500V, temperature: 500 ºC, nebulizer gas: 60 psi, curtain gas: 60 psi). 
Other ion source parameters employed were declustering potential 66V, collision energy 60V, 
entrance potential 8V, and collision cell exit potential 4V. The peak areas for all components 
were integrated automatically using Analyst™ software. The lower limits of quantification 
were found to be 5 ng/mL for LPV and 15 ng/ml for Leu-LPV and His-Leu-LPV.  
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3.5.5. Permeability analysis 
Cumulative amounts of LPV, Leu-LPV and His-Leu-LPV generated during transport 
were plotted against time. Linear regression of the amount transported as a function of time 
generated the rate of transport (dM/dt). Ratio of transport rate to the cross sectional area (A) 
further yielded the steady state flux as shown in Eq. (1). 
Flux = dM/dt        Eq. (1) 
   A 
Transepithelial permeabilities were calculated by normalizing the steady state flux to the donor 
concentration (Cd) of the drug or prodrugs as shown in Eq. (2). 
Permeability = Flux     Eq. (2) 
   Cd 
 
3.5.6. Statistical analysis 
All experiments including uptake, transport, buffer and enzymatic stability were 
conducted at least in triplicate and results were expressed as mean ± S.D. Student t-test was 
employed to determine statistical significance between groups. A value of p ≤ 0.05 was 
considered to be statistically significant.  
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3.6. Results 
3.6.1. Solubility studies in distilled deionized water 
Aqueous solubility values of Leu-LPV and His-Leu-LPV were found to be 600 ± 42 
and 481 ± 82 µg/mL relative to 49 ± 3 µg/mL for LPV. The solubilities of Leu-LPV and His-
Leu-LPV were respectively 12 and 9.8 times higher relative to LPV. 
 
3.6.2. Buffer stability studies 
  Chemical hydrolysis of Leu-LPV and His-Leu-LPV was determined in DPBS adjusted 
to varied pH values i.e., 4, 5.5 and 7.4.  Degradation rate constants and half-lives of prodrugs 
at pH 4, 5.5 and 7.4 values are reported in Table 3-1. Degradation half-lives exhibited by Leu-
LPV and His-Leu-LPV at pH 4 were approximately 1.9 and 8.7 fold higher relative to pH 7.4.  
 Table 3-1 Leu-LPV and His-Leu-LPV degradation rate constants and half-lives at various 
pH values 
 
3.6.3. Cytotoxicity studies 
Cytotoxicity profiles of LPV, Leu-LPV and His-Leu-LPV were assessed in MDCK-
WT cells using MTT assay, prior to initiation of uptake and transport studies. Serum-free 
medium was employed to avoid interference of proteins with MTT reagents. Medium 
containing no test compounds and 0.1% Triton-X were selected as a negative and positive 
Prodrug  pH 4 pH 5.5 pH 7.4 
 k x 10-4 
(min) 
t1/2 (h) k x 10-4 (min) t1/2 (h) k x 10-4 (min) t1/2 (h) 
Leu-LPV 3.90±0.06 29.6±0.4 5.78±0.09 20.0±0.3 7.53±0.14 15.4±0.3 
His-Leu-LPV 2.92±0.03 39.6±0.5 6.21±0.15 18.6±0.5 25.5±2.4 4.6±0.5 
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control, respectively. Medium containing 2% and 10% methanol was also examined for 
cytotoxic effects. As depicted in Figure 3-2, medium containing 2% methanol did not exhibit 
any cytotoxicity effects while medium with 10% methanol showed significant cytotoxicity. 
Triton-X resulted in about 70% decrease in absorbance compared to negative control. LPV 
produced no cytotoxic effects in the range of 5-50 µM however, was cytotoxic at 100 and 200 
µM. Approximately 13 and 36% reduction in number of viable cells were observed at 100 and 
200 µM LPV concentration. Similarly, the prodrugs (Leu-LPV and His-Leu-LPV) were non-
toxic in the concentration range of 5-50 µM. Both prodrugs generated significant cytotoxicity 
at much higher concentrations. Leu-LPV and His-Leu-LPV reduced cell viability by 37% and 
33% at 200 µM concentrations.  
 
 
Figure 3-2 Cellular cytotoxicity studies of LPV, Leu-LPV and His-Leu-LPV in MDCK-WT 
cells after incubation for 4h. Data represent mean ± S.D (n= 8). **P<0.05 compared with the 
control group 
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3.6.4. Cellular uptake studies  
To study the interaction of LPV with P-gp and MRP2, [3H]-LPV uptake was carried 
out in MDCK-MDR1 and MDCK-MRP2 cells in presence of efflux inhibitors. As depicted in 
Figures 3-3 A and B, approximately 4.5 and 2.9-fold rise in LPV uptake was observed in the 
presence of GF 120918 (2µM) and MK-571(75 µM).  
To further confirm the extent of interaction and affinity of LPV, Leu-LPV and His-
Leu-LPV with P-gp and MRP-2, concentration dependent uptake studies were performed in 
MDCK-MDR1 and MDCK-MRP2 cells. Uptake of [3H]-LPV (0.5 µCi/mmol) was carried out 
in presence of increasing concentrations of unlabelled LPV, Leu-LPV and His-Leu-LPV. [3H]-
LPV uptake dramatically elevated with rise in unlabelled LPV concentrations in both MDCK-
MDR1 and MDCK-MRP2 cell lines indicating improved interactions of LPV with MDR1 and 
MRP2 efflux proteins. However, [3H]-LPV uptake remained unaltered with increasing Leu-
LPV and His-Leu-LPV concentrations (Figures 3-4 A, B and C) further signifying the ability 
of the prodrugs in circumventing the efflux proteins.  
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Figure 3-3 Cellular uptake studies of [3H]-LPV (1.5µM) (A) in absence and presence of 
GF 120918 (2 µM) in MDCK-MDR1 cells and (B) in absence and presence of MK 571 
(75 µM) in MDCK-MRP2 cells. Data represent mean ± S.D (n= 4). **P<0.05 compared 
with the control group 
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3.6.5. Transepithelial transport studies  
Transpeithelial studies of LPV, Leu-LPV and His-Leu-LPV were carried out in 
absorptive direction (A-B) in MDCK-MDR1 and MDCK-MRP2 cells. Results obtained from 
these studies are presented in Figure 3-5. A-B permeability rate of LPV drastically elevated in 
both MDCK-MDR1 and MDCK-MRP2 cell lines in the presence of efflux inhibitors. A-B 
permeability rates generated by LPV in the presence of GF120918 and MK571 were 3.4 ± 0.3 
x 10-6 cm/s and 3.1 ± 0.2 x 10-6 cm/s, respectively. Leu-LPV generated A-B permeability rates 
of 3.5 ± 0.4 x 10-6 cm/s and 3.3 ± 0.7 x 10-6 cm/s, a 2.3 and 2.2-fold increase in comparison to 
LPV, 1.6 ± 0.5 x 10-6 cm/s and 1.5 ± 0.3 x 10-6 cm/s. A-B permeability rates displayed by His-
Leu-LPV in MDCK-MDR1 and MDCK-MRP2 were 6.72 ± 0.67 x 10-6 cm/s and 6.10 ± 0.45 
Figure 3-4 Cellular uptake studies of [3H]-LPV (1.5µM) in presence of increasing 
concentrations of (A) cold LPV, (B) cold Leu-LPV and (C) cold His-Leu-LPV in MDCK-
MDR1 and MDCK-MRP2 cells. Data represent mean ± S.D (n= 4). **P<0.05 compared with 
the control group 
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x 10-6 cm/s. Approximately 4.3 and 4.1-fold enhancement in the A-B permeability rates were 
observed for His-Leu-LPV relative to LPV in MDCK-MDR1 and MDCK-MRP2 cells 
respectively. The significant improved permeability of His-Leu-LPV prodrug indicate its 
ability to circumvent efflux pumps and at the same time recognition and permeation through 
the influx transporters.  
 
 
3.6.6. Interaction with peptide/histidine transporter (PepT1 and PHT1)  
To study the interaction of LPV, Leu-LPV and His-Leu-LPV with PepT1 and PHT1 
influx transporters, uptake studies were performed in MDCK-MDR, MDCK-MRP2 and Caco-
2 cell lines. Glycylsarcosine (GlySar) and Histidine (His) were used as model substrates for 
peptide (PepT1) and histidine transporters (PHT1) respectively. Uptake of [3H]-GlySar (0.5 
Figure 3-5 A-B permeability of LPV, Leu-LPV, His-Leu-LPV and LPV in presence of 
GF120918 and MK571 across MDCK-MDR1 and MDCK-MRP2 cells respectively. Data 
represent mean ± S.D (n= 4). **P<0.05 compared with the control group 
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µCi/mmol) was performed in presence of cold GlySar, LPV, Leu-LPV and His-Leu-LPV to 
determine extent of prodrug interaction with peptide transporters (PepT1). Results obtained 
from this study demonstrating [3H]-GlySar uptake are depicted in Figure 3-6 A. 
Approximately 35% reduction was observed in uptake of His-Leu-LPV in all the cell lines in 
contrast to 75% reduction in presence of cold GlySar indicating that the PepT1 transporters are 
highly functional in these cell lines and improved affinity of His-Leu-LPV towards PepT1 
influx transporters. Furthermore, [3H]-His uptake (0.5 µCi/mmol) was performed in presence 
of cold His, LPV, Leu-LPV and His-Leu-LPV in MDCK--MDR, MDCK-MRP2 and Caco-2 
cell lines to determine prodrug interaction with peptide/histidine transporter (PHT1). [3H]-His 
uptake results have been demonstrated in Figure 3-6 B. Approximately 30% reduction was 
observed in uptake of His-Leu-LPV in all the cell lines in contrast to 90% reduction in presence 
of cold His indicating the functionality and improved interaction of His-Leu-LPV with PHT1 
influx transporters. 
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3.6.7. Caco-2 cell homogenate studies 
Enzymatic hydrolysis of prodrugs were also determined in Caco-2 cell homogenate at 
pH 7.4 for a period of 4h (Figure 3-8). As depicted in Figure 3-9, intact His-Leu-LPV, both 
intermediate amino acid prodrug (Leu-LPV) and regenerated parent drug (LPV) from His-Leu-
LPV were detected in homogenate samples. The degradation of His-Leu-LPV was found to be 
rapid in cell homogenates. At the end of 4h, approximately 6% of His-Leu-LPV was detected. 
Degradation rate constant and half-life of His-Leu-LPV were found to be 5.38 ± 0.13 x 10-3 
min-1 and 2.15 ± 0.06 h, respectively. Figure 3-7 depicts concentrations of regenerated LPV 
and Leu-LPV from His-Leu-LPV in Caco2 cell homogenates. Leu-LPV degradation rate 
Figure 3-6 Cellular uptake studies of [3H]-GlySar (17nM) (A) and [3H]-L-His (10.5nM) (B) 
in presence of cold GlySar/ cold L-His (10mM), LPV, Leu-LPV and His-Leu-LPV (25µM) 
in MDCK-MDR1, MDCK-MRP2 and Caco-2 cells. Data represent mean ± S.D (n= 4). 
**P<0.05 compared with the control group 
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constant and half-life values were also determined and observed to be 1.37 ± 0.07 x 10-3 min-1 
and 8.5 ± 0.4h, respectively (Figure 3-9). 
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Figure 3-7 Degradation profile (nmol/ml of drug vs time) for His-Leu-LPV in Caco-2 cell 
homogenate. Data represent mean ± S.D (n= 4). 
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Figure 3-8 Overlaid MRM chromatograms for His-Leu-LPV (red), Leu-LPV (green) and LPV (blue) 
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Figure 3-9 LCMS/MS (MRM mode) spectra of Leu-LPV and His-Leu-LPV in Caco-2 cell homogenate 
at various time points as indicated in the figure 
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 3.7. Conclusion 
Poor aqueous solubility and higher affinity towards drug efflux pumps and 
metabolizing enzymes (CYP3A4) pose a major challenge to LPV delivery. The present study 
demonstrates the potential of a prodrug approach to improve LPV absorption across P-gp and 
MRP2 overexpressing polarized membranes. Prodrugs, Leu-LPV and His-Leu-LPV, 
developed in this study were more water soluble relative to LPV. Moreover, these compounds 
possessed lower affinity towards P-gp and MRP2 relative to LPV indicating their true potential 
in circumventing efflux pumps. The higher affinity of LPV towards P-gp and MRP2 is evident 
from its improved permeation in presence of efflux pump inhibitors. His-Leu-LPV exhibited 
both PepT1 and PHT1 transporters mediated cellular uptake, which further substantiates 
improved interaction of His-Leu-LPV with the influx transporters. Thus there is tremendous 
potential of generating higher systemic as well brain concentrations of LPV through His-Leu-
LPV administration.  
In future studies, prodrug (a) competitive bidirectional transport in presence of PepT, 
and/or PHT substrates across blood-brain barrier (BBB), (b) metabolism in presence of esterase 
and protease inhibitor cocktails and human microsomes, (c) quantification of known CYP3A4 
LPV metabolites, (d) plasma protein binding, (e) chemical stability studies in buffers with 
adequate buffer capacity at different pHs and (f) oral absorption studies in rats will be reported. 
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PART II: NANOFORMULATIONS TO IMPROVE OCULAR DELIVERY OF 
CIDOFOVIR AND OCTREOTIDE 
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CHAPTER 4 
4. POLYMERIC NANOMICELLES FOR IMPROVED OCULAR DRUG DELIVERY 
 
4.1. Rationale 
The past decades have witnessed  significant progress in the development of nano-sized 
(1-200 nm) ocular drug delivery systems. Such increasing interest in nanomedicine may be 
attributed to the tremendous advances in nanotechnology, polymer chemistry and chemical 
engineering 97-98. However, additional research is required in the area of ocular drug delivery, 
particularly with regards to the delivery of hydrophobic compounds, nucleic acids and proteins, 
in order to improve their therapeutic outcomes and thus the quality of life for patients 99-100. 
Hydrophobic NSAIDs such as indomethacin, ibuprofen, and diclofenac, indicated for 
inflammatory disorders, are an excellent example to demonstrate the need for improved ocular 
delivery. Although, in-vitro studies have suggested their pharmacological effectiveness, 
studies involving animal models and patients generally fail to achieve sufficient therapeutic 
activity 101-102. Such failure is most likely due to insufficient retention and accumulation at the 
target site resulting in suboptimal therapeutic levels. Additionally, significant amounts of 
intravitreally administered drugs accumulate inside healthy ocular tissues and can potentially 
lead to serious side effects, discomfort and blurred vision 103-104. 
Several nanomedicines have been formulated and evaluated for ocular drug delivery 
over the years. The most relevant formulations are depicted in Figure 4-1. All of these have 
been designed keeping the following two key characteristics of nanomedicines in mind: (i) 
stable, efficient and reversible drug loading, as well as (ii) prolonged retention and circulation 
time. In the case of age-related macular degeneration (AMD), for instance, NSAIDs such as 
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indomethacin and ibuprofen are known to be extensively utilized to reduce inflammation and 
cystoid macular edema 105. However, because of their high hydrophobicity, both intravenous 
and intravitreal administrations are problematic and complicated. They are thus generally 
administered in combination with solublization enhancers, such as hydroxypropyl-β-
cyclodextrin, diethylene glycol monoethyl ether (Transcutol P), n-octenylsuccinate starch, α-
tocopheryl polyethylene glycol succinate, polysorbate 80 and tromethamine 106-109. 
      
 
FDA approved polymeric implants for posterior segment drug delivery include 
Vitrasert® (for CMV retinitis), Retisert® (for uveitis), Iluvien® (diabetic macular edema) and 
Ozurdex® (for macular edema associated with uveitis and diabetes). Vitrasert® and Retisert®, 
based on the same delivery platform but with Retisert® being slightly smaller in size, require 
sclerotomy at the pars plana region for implantation. On the other hand, Iluvien® and 
Ozurdex® are injected into the vitreous cavity via a 23-25 gauge needle. Since, Vitrasert®, 
Retisert® and Iluvien® are non-biodegradable, the drug-depleted devices need to be surgically 
Figure 4-1 Schematic depiction of the most relevant nanomedicine formulations for ocular delivery 
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removed or may accumulate in the vitreous cavity as in the case of Iluvien®. Taking frequent 
intravitreal implantation of these devices into consideration, many patients and insurance 
companies are taken aback by their price tags (USD $20,000 for Retisert® and $2,000 for 
Ozurdex®)110. Additionally, intravitreal administration of these implants requires skilled 
professional execution while carrying the risk of side effects potentially requiring patients to 
undergo cataract and/or glaucoma surgery as well as treatment with pressure lowering 
medications [11, 12]. Thus, exploring the feasibility of topical administration to deliver drugs 
to the posterior segment may drastically improve drug delivery in coming years, while 
minimizing costs and potential complications.  
In this chapter, we describe the clinical manifestation of cytomegalovirus (CMV) 
retinitis, challenges associated with current therapeutic regimen, targeted lipid ester prodrugs, 
basic principles for the preparation of commonly used polymeric micelles for ocular drug 
delivery and a combination of prodrug-nanomicellar approach for the treatment of CMV 
retinitis. Together, the insights obtained indicate that polymeric micelles are highly effective 
delivery systems for intraocular drug delivery, (i) facilitating the formulation and entrapment 
of highly hydrophobic drugs, (ii) aiding drug administration, (iii) enabling controlled drug 
release kinetics, (iv) enhancing therapeutic efficacy, (v) reducing side-effects and and (vi) 
improving the in-vivo stability.   
 
4.2. Cytomegalovirus (CMV) retinitis 
CMV retinitis is a disease caused by an enveloped ds-DNA virus, CMV belonging to 
the Herpesviridae family and occurs primarily in immunocompromised individuals. CMV 
retinitis is the most common opportunistic ocular infection in patients with AIDS with CD4 T 
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lymphocyte counts <50 cells per microliter 111. CMV retinitis typically initiates in the 
peripheral region of the retina and centrifugally progresses towards the posterior region 
ultimately leading to retinal necrosis and thus visual impairment. Other clinical manifestations 
involve dense, full-thickness areas, yellowish-white lesions, irregular granules at the border, 
retinal vasculitis and hemorrhage on the retinal surface (Figure 4-2) 112.  
 
4.3. Current therapeutic regimen and associated challenges 
Currently available therapies for CMV retinitis include ganciclovir (GCV), foscarnet, 
cidofovir (CDF) and valganciclovir 113. Most of these therapies are given by intravenous and/or 
intravitreal injections, which are associated with poor patient compliance and adverse side 
effects. An oral prodrug form of ganciclovir, valganciclovir (Valcyte®, Roche) has been 
approved for the treatment of CMV retinitis. Once-daily administration of valganciclovir 
(900mg) produced GCV systemic exposure equivalent to once-daily IV administration of GCV 
Figure 4-2 White wedged area, hemorrhage representing necrosis (left) and white sheathing 
along the blood-vessels (right) characteristics of CMV retinitis. Reprinted with permission 
from Keunen et al. 2, Copyright Massachusetts Medical Society 
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(5mg/kg) and 1.7 fold greater than oral GCV (1000mg) given thrice daily 114-115. However, 
local delivery of therapeutic agents including implants (Vitrasert®, Bausch and Lomb) to the 
ocular tissues have been found to be more effective compared to systemic therapy.  
Among these ART therapies, CDF (S-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine; HPMPC), an antiviral nucleoside phosphonate has 
demonstrated significant therapeutic activity against CMV and other herpesviruses 116. Unlike 
other nucleoside analogues such as acyclovir and GCV, CDF only needs two phosphorylation 
steps and is not phosphorylated by viral kinase i.e. is not dependent on viral-encoded enzymes 
in order to be converted to active diphosphate form. CDF undergoes phosphorylation to CDF-
monophosphate (CDF-MP) and CDF-diphosphate (CDF-DP) by pyrimidine nucleoside 
monophosphate and diphosphate kinases respectively 117. CDF-DP acts as a chain terminator 
of DNA synthesis and alternative substrate with respect to dCTP (deoxycytidine triphosphate) 
for DNA polymerase (Figure 4-3). The long half-life of the active diphosphate form and lower 
chances of viral resistance offers additional advantages to CDF therapeutically. Currently CDF 
is marketed only as an IV formulation with recommended dose of 5mg/kg once a week for two 
consecutive weeks followed by 5 mg/kg once every 2 weeks (maintenance phase) 118. 
However, the major limitation of CDF is severe renal toxicity119. Additionally, CDF is highly 
hydrophilic and a good substrate of efflux pump, MRP2 which leads to low bioavailability 120.  
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4.4. Challenges to ocular drug delivery 
Efficient drug delivery to the ocular tissues faces a number of challenges due to the 
dynamic anatomy and the blood-ocular barriers (including blood-aqueous and blood-retinal 
barrier). From a drug delivery perspective, the eye can be divided into four parts: (i) the pre-
corneal area (conjunctiva, eyelids); (ii) the cornea; (iii) the anterior segment (iris, ciliary body, 
lens) and (iv) the posterior segment (retina, vitreous cavity) 121.  
The tear drainage rate constant from the pre-corneal area is 1.45 min-1 which results in 500 to 
700 times greater drug loss from the ocular surface in comparison to the drug absorption rate 
Figure 4-3 Mechanism of action of cidofovir (HPMPC). Reproduced with permission 
from Clercq et al.6 
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into the anterior chamber 122. This process eventually leads to less than 5% of the topically 
applied dose reaching the intraocular tissues. Additionally, the complex anatomy of the tear 
film with its outer oily layer retarding water evaporation, further impedes drug absorption into 
the cornea and sclera 123. 
The cornea is an important route for drug absorption after topical application. It consists 
of five different layers, namely epithelium, Bowman’s membrane, stroma, Descemet’s 
membrane, and endothelium. The corneal epithelium plays a major role in limiting trans-
corneal drug absorption with a drug permeability rate of only 10-7-10-5 cm s-1 124. While small 
lipophilic drugs are passively transported via the transcellular pathway, hydrophilic drugs 
undergo restricted permeation through tight junctions via the paracellular pathway. The corneal 
stroma being hydrophilic, impedes transport of lipophilic drug molecules while hydrophilic 
molecules generally diffuse freely through the stroma. Overall, the efficacy of the trans-corneal 
route is limited by the relatively low absorption rate constants (1-5 x 10-3 min-1) 125-126, with a 
molecular weight cut-off of 400-600 Da also playing an important role in the corneal 
permeability of drug molecules 127. 
The high permeability of the human conjunctiva, on the other hand, can be attributed 
to its 17-fold larger surface area in comparison to the human corneal membrane. The larger 
paracellular spacing in conjunctival tissue (230 times greater than in the cornea cornea) 
facilitates passage of large hydrophilic molecules 128. These characteristics have established 
the importance of the conjunctival-scleral pathway for intraocular delivery of macromolecules 
including proteins, peptides and nucleic acids. The trans-scleral route may also be utilized for 
the delivery of large molecules to the retina and vitreous, if suitable drug-delivery systems are 
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employed. However, lymphatics and blood vessels present in the conjunctiva eliminate 
significant amounts of therapeutics via the systemic circulation 129.  
Similar to the corneal stroma, hydrophilic drugs permeate through scleral matrix pores 
readily in comparison to lipophilic drugs. The molecular radius and charge of the drug 
molecule also greatly control the permeability across the sclera. Positively charged molecules 
appear to permeate the sclera poorly presumably due to their binding with the negatively 
charged scleral matrix 130. Additionally, the blood ocular barriers contribute majorly, limiting 
drug entry into the posterior segment following systemic and periocular administration. The 
blood-aqueous barrier (BAB) is present in the anterior segment of the eye and restricts drug 
entry from the blood into the aqueous humor. However, the BAB is not considered a complete 
barrier because of the fenestrated capillaries present in the ciliary body stroma. These 
fenestrated vessels being the secondary source of plasma protein leakage to the iris also allow 
passage of small molecules to enter the iridial circulation 131. The blood-retinal barrier (BRB) 
present in the posterior segment is further divided into inner and outer BRB. The inner BRB is 
composed of tight junctions between retinal capillary endothelial cells and is anatomically 
similar to the blood-brain barrier (BBB). The outer BRB is formed by the tight junctions 
between retinal pigment epithelial (RPE) cells. The greater density of tight junctions and 
pericytes in comparison to the BBB as well as the presence of glial cells, render the inner BRB 
highly effective in limiting transport of drugs from the blood into the retina 132-133.  
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4.5. Lipid ester prodrug approach 
Prodrugs have been categorized in various classes which include carrier linked vs 
bioprecursor, site of conversion/metabolism (intracellularly vs extracellularly) and mixed 
prodrugs (prodrugs belonging to multiple classes) 134-135. Lipid prodrugs, a type of carrier 
linked prodrugs, are typically designed to elevate the lipophilic characteristics of hydrophilic 
drugs thereby promoting passive diffusion (Figure 4-4). Hydrophilic drugs usually generate 
poor cellular transport due to high polarity and low passive permeability. Transport of these 
agents may be enhanced by masking the ionizable or polar groups 135-136. However, it is 
extremely important to maintain a balance between the lipophilic and hydrophilic properties 
in order to generate optimal transcellular diffusion and aqueous solubility 136. The type of the 
linkages that can be selected for synthesizing prodrugs mainly depends on the nature of 
functional groups in the parent drug structure. 
Figure 4-4 Basic cellular uptake mechanism of two types of lipid linked prodrugs 
extensively employed to improve absorption of hydrophilic drugs 
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Hydrophilic drugs containing carboxylic acid or hydroxyl groups may be formulated 
in the form of ester prodrugs by covalently linking suitable pro-moieties. An appropriate 
geometry and size of the alkyl carbon chain may be optimized to produce stable lipophilic 
prodrugs, in vivo. Such prodrugs can generate higher cellular permeation relative to 
unmodified parent drug due to improved interaction with absorptive membranes. Following 
cellular entry, these compounds may undergo enzymatic degradation by esterase class of 
enzymes to regenerate parent drug and pro-moiety 137. An important advantage of generating 
ester prodrugs is the ubiquitous expression of esterase class of enzymes in humans. Hence, 
prodrugs can be designed such that these compounds are cleaved in blood, liver and other 
intended target tissues. A careful selection of pro-moiety is highly important so as to render 
the process of prodrug development more feasible. Ideal properties of pro-moiety include non-
immunogenicity, optimal stability at physiological temperature and biological conditions, 
degradation to non-toxic and inactive metabolites, ease of synthesis and cost effectiveness 7, 9, 
138. Despite potential advantages, ester prodrugs are highly susceptible to enzymatic hydrolysis 
and may generally yield lower half-lives in vivo. In such conditions, carbamate ester prodrugs 
may be preferred over carboxyl ester prodrugs to impart higher in vivo stability and longer 
half-lives 7. 
Amide prodrugs are also generally employed to improve drug absorption due to higher 
stability relative to ester prodrugs. However, such prodrugs are commonly used for improving 
tissue specificity and minimizing dose-related toxicities. Some of the amide prodrugs have 
been evaluated for their potential to improve drug accumulation and efficacy in target tissues 
139-140. Furthermore, disulfide, oximes, imines and thioether linkages have also been explored 
for prodrug development 7-8, 141-143. Various types of linkages that can be produced depending 
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on the presence of a specific functional group in the parent drug structure have been extensively 
discussed previously 8, 135. However, considerable attention should be paid to prodrug design 
in early development phases as these compounds can significantly modulate the 
pharmacokinetic, toxicokinetic and efficacy profiles of a parent drug.  
Recently, transporter targeted lipid prodrug design has emerged as an interesting 
strategy to improve drug absorption and efficacy 34, 144-149. In this approach, prodrugs are 
produced by covalently linking lipid raft as well as a membrane transporter or receptor 
targeting moiety (Figure 1-1). Lipid rafts would impart lipophilicity whereas targeting moiety 
may enhance site specificity and selectivity. Such prodrugs generate significantly higher 
cellular accumulation due to synergistic effects of lipid rafts and transporter or receptor 
targeting pro-moieties. The presence of lipid may dramatically increases prodrug interaction 
by facilitating docking of the targeting pro-moiety to the binding domain of membrane 
transporter or receptor 34. Subsequently, prodrugs are rapidly translocated across cell 
membrane and enzymatically cleaved in cytoplasm to yield the parent drug. Such strategy may 
be employed to improve tissue absorption and specificity of various hydrophilic therapeutic 
agents such as nucleosides, nucleotides, genes, siRNA, oligonucleotides, peptides, proteins and 
other macromolecules. 
4.6. Targeted lipid ester prodrugs 
Membrane transporter or receptor targeted lipid prodrugs presents an innovative 
approach to improve drug delivery and specificity. Cumulative effects of high passive 
diffusion, transporter recognition and reduced efflux by targeted lipophilic prodrugs may 
significantly improve drug efficacy and overcome development of resistance. Vadlapudi et al. 
have developed a series of sodium dependent multivitamin transporter (SMVT) targeted and 
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non-targeted lipid prodrugs (Figure 4-5) of acyclovir 144. These include biotin-ricinoleic acid-
acyclovir, biotin-12-hydroxy stearic acid-acyclovir, ricinoleic acid-acyclovir and 12-hydroxy 
stearic acid-acyclovir. Ricinoleic acid and 12-hydroxy stearic acid were employed as lipid 
rafts. Biotin was selected to target SMVT. B-R-acyclovir and R-acyclovir have generated 
about 10 and 4-fold higher cellular uptake in MDCK-MDR1 cells relative to parent drug. 
Interestingly, biotin-acyclovir has generated about 6-fold higher cellular accumulation relative 
to unmodified acyclovir. Based on these results, it is apparent that the incorporation of lipid 
raft as well as transporter targeting moiety in the prodrug construct (B-R-acyclovir) can 
significantly improve cellular accumulation relative to parent drug (acyclovir), lipid prodrug 
(R-acyclovir) and transporter targeted prodrug (B-acyclovir). Importantly, cellular 
accumulation of B-R-acyclovir and B-12HS-acyclovir was significantly diminished in the 
presence of unlabeled biotin, a potent substrate of SMVT 96, 150-154. Considerable uptake 
inhibition clearly indicates that these prodrugs possess higher affinity towards SMVT. 
Moreover, the half-maximal inhibitory concentration (IC50) values exhibited by B-R-acyclovir 
(8.04 ± 0.07 µM) and B-12HS-acyclovir (8.17 ± 0.09 µM) were significantly lower relative to 
B-acyclovir (14.84 ± 0.10 µM). This result further supports the contributory role of lipid raft 
in generating higher and tighter prodrug binding with SMVT. Similarly, B-R-acyclovir and B-
12HS-acyclovir produced about 10 and 8-fold higher cellular uptake relative to unmodified 
acyclovir in human Caco2 cells.  
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Vadlapudi et al. have also investigated the potential of B-R-acyclovir and B-12HS-
acyclovir to improve corneal absorption of acyclovir 34, since SMVT is reported to be highly 
expressed on the apical surface of corneal epithelial cells 150, 155. B-R-acyclovir and B-12HS-
Figure 4-5 Structure of acyclovir (A), B-acyclovir (B), 12-HS-acyclovir (C), R-acyclovir (D), 
B-12HS-acyclovir (E) and B-R-acyclovir (F). Modifications with lipid rafts and biotin are 
shown with red and blue color, respectively 
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acyclovir have displayed about 13-fold higher uptake relative to acyclovir in human corneal 
epithelial cells (HCEC). Moreover, transepithelial transport of [3H]-biotin was significantly 
abolished in the presence of both prodrugs confirming SMVT involvement in the prodrug 
translocation across freshly excised rabbit cornea. Docking analysis revealed superior binding 
affinity towards SMVT for B-R-acyclovir and B-12HS-acyclovir compared to B-acyclovir. 
Docking scores for B-R-acyclovir, B-12HS-acyclovir and B-acyclovir were -7.5, -7.9 and -6.6, 
respectively.  
Biotin-lipid prodrugs also possessed superior antiviral activities against herpes simplex 
viruses (HSV-1 and HSV-2) and Epstein Barr virus (EBV) relative to acyclovir itself. B-12HS-
acyclovir (EC50 = <0.096 µM) has generated 36 and 62-fold higher antiviral potency relative 
to unmodified acyclovir (EC50 = 3.43 and 5.98 µM) against HSV-1 and HSV-2 viruses, 
respectively. B-R-acyclovir (EC50 = 0.27 µM) has produced 22-fold higher antiviral activity 
against HSV-2 relative to parent drug (EC50 = 5.98 µM). Moreover, this prodrug (EC50 = 12.4 
µM) has demonstrated about 6-fold higher antiviral activity against EBV relative to acyclovir 
(EC50 = 2.1 µM). However, antiviral efficacy of B-R-acyclovir (EC50 = 70 µM) and B-12HS-
acyclovir (EC50 = >300 µM) against human cytomegalovirus (HCMV) was observed to be 
significantly lower relative to ganciclovir (EC50 = 0.21 µM). Importantly, B-R-acyclovir and 
B-12HS-acyclovir were found to be highly selective and generated negligible cell cytotoxicity 
as demonstrated by neutral red dye uptake and CellTiter Glo (Toxicity) assays. These results 
clearly indicate the feasibility of using SMVT targeted lipid prodrugs for the treatment of 
ocular infections such as herpes keratitis. Investigators also mentioned that these compounds 
are currently being examined for antiviral efficacy in virus infected animal models by 
NIH/NIAID.  
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Recently, Gokulgandhi et al. have designed and developed a series of transporter 
targeted and non-targeted lipid prodrugs to improve absorption of cidofovir in ocular tissues 
145. Prodrugs synthesized were C6-cidofovir, C12-cidofovir, biotin-C2-cidofovir, biotin-C6-
cidofovir and biotion-C12-cidofovir (Figure 4-6), where n denotes number of carbons in lipid 
chain. Prodrugs were highly lipophilic relative to cidofovir. Significant enhancement in the 
lipophilicity may improve prodrug diffusion in ocular tissues relative to cidofovir upon topical 
or systemic administration. [3H]-biotin uptake was diminished significantly with increase in 
lipid carbon chain length in prodrug structure. B-C12-cidofovir has produced 73% inhibition 
in [3H]-biotin uptake rate relative to 50% by B-C2-cidofovir. Moreover, affinity of B-C12-
cidofovir (IC50 = 2.9 µM) towards SMVT was significantly higher compared to B-C2-cidofovir 
(IC50 = 31.4 µM). B-C12-cidofovir reduced [3H]-biotin transport (70%) across MDCK–MDR1 
cells relative to B-C2-cidofovir (44%). This study indicates that substrate affinity of prodrugs 
towards SMVT increase significantly with rise in lipid carbon chain length. Importantly, B-
C2-cidofovir (3-fold), B-C6-cidofovir (5-fold) and B-C12-cidofovir (10-fold) prodrugs were 
observed to partition into the retina–choroid tissue at significantly higher levels relative to 
cidofovir. This result indicates that intravitreal injection of SMVT targeted lipid prodrugs may 
be a viable approach to treat infections affecting posterior segment tissues of the eye. 
Antiviral efficacy of cidofovir and prodrugs have also been investigated against 
HCMV, HSV-1 and 2, VZV, EBV, BK and JC viruses, Vaccina (VACV) and Cow pox viruses 
(CXPV) 156. B-C12-cidofovir has displayed superior antiviral efficacy against HCMV (EC50 = 
0.57 vs 1.24 µM), HSV-2 (EC50 = 2.16 vs 54.41 µM) and BK (EC50 = 13.8 vs 28.6 µM) viruses 
relative to parent drug. EC50 values generated by this prodrug were approximately 2 to 25-fold 
lower relative to cidofovir. B-C6-cidofovir has displayed excellent antiviral activity against 
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HCMV (EC50 = 1.03 vs 1.24 µM) and HSV-2 (EC50 = 12.16 vs 54.41 µM) relative to cidofovir. 
Interestingly, C12-cidofovir has generated about 3 to 30-fold higher antiviral efficacies against 
HSV-2 (EC50 = 2.09 vs 54.41 µM), BK (EC50 = 1.4 vs 28.6 µM), JC (EC50 = 0.23 vs 6.61 µM), 
VACV (EC50 = 1.5 vs 9.08 µM) and CXPV (EC50 = 1.44 vs 4.25 µM) viruses relative to 
unmodified cidofovir. Therefore, it appears that biotin lipid prodrug approach may markedly 
improve delivery as well as efficacy of antiviral drugs. Since, SMVT is highly expressed in 
intestinal epithelial cells 151, 157-158, lipid prodrugs targeted toward this influx transporter can be 
explored to improve oral absorption of acyclovir and ganciclovir.  
 
 
 
 
 
 
 
 
 
 
71 
 
 
4.7. Polymeric micelles 
The physicochemical nature of nano-sized micelles also termed as “nanomicelles” 
consisting of a hydrophobic core and a hydrophilic shell, renders these spherical vesicles 
Figure 4-6 Structure of C6-cidofovir (A), C12-cidofovir (B), B-C2-cidofovir (C), B-C6-
cidofovir (D) and B-C12-cidofovir (E). Modifications with lipid rafts and biotin are shown 
with red and blue color, respectively 
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highly acceptable for passive drug delivery of hydrophobic compounds. Polymeric micelles 
(10-200 nm) are based on amphiphilic molecules or block copolymers which can generally 
self-assemble into organized core-shell/supramolecular structures in aqueous media at 
concentrations exceeding their critical micellar concentrations (CMC) 159. On the other hand, 
low-molecular weight surfactant-based micelles exhibit higher CMC in contrast to polymeric 
micelles, leading to diminished stability and potential side effects. The potential of polymeric 
micelles to solubilize and stabilize hydrophobic compounds leads to their prolonged retention 
thereby improving therapeutic outcomes 160. Nevertheless, micelle-based nanomedicines suffer 
from a myriad of problems when employed in in vivo systems. Dilution in the blood stream as 
well as interactions with blood components (including plasma proteins such as albumin, 
fibrinogen, prothrombin and gamma globulins) lead to their premature disintegration in the 
systemic circulation. This substantiates the primary reason for the limited improvements in 
therapeutic efficacy of micellar nanomedicines in clinical trials when administered 
systemically 161-162, while such issues would be minimal for topical ocular administration.  
4.7.1. Principles of micelle formation 
The polymeric units self-assemble into a nanoscale aggregates (10-200 nm), known as 
micelles having a hydrophobic core and a hydrophilic corona. Such self-assembly is favored 
by a thermodynamic process. The hydrophilic chains cover the hydrophobic core to avoid their 
direct contact with water and thus reduce the interfacial free energy of the polymer-water 
system. Micellar formation confides upon the reduction of the interfacial free energy 163-164. 
The degree of self-aggregation generally depends on the polymer chain concentration, the 
properties of the drug or any targeting agents, and the mass and composition of the copolymer 
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backbone 165. Depending upon the molecular weight of the block copolymers, micelles can 
have different shapes including spherical, cylindrical and star-shaped structures 166-167.  
4.7.2. Critical micelle concentration (CMC): a key factor in micellization 
The minimum polymer concentration required to form micelles is termed as CMC. 
Below the CMC, insufficient numbers of polymeric chains are uniformly distributed in the 
solution as monomers168. With an increase in the concentration, more polymeric chains are 
absorbed at the interface. The concentration, at which the interface becomes saturated with 
polymeric chains is known as the CMC. Above this point, an increase in the polymer 
concentration in solution results in the formation of micelles 169-170. Polymeric micelles (10-6–
10-7 M) usually exhibit CMC values 1000 times lower than that of low-molecular-weight 
surfactant based micelles (10-3–10-4 M), with a low CMC value indicating increased stability 
of the micellar structure in an aqueous solution 171-172. For topically administered micellar 
ophthalmic formulations, the CMC is a critical factor. It regulates the chances of premature 
drug release from the formulation due to constant tear dilution and nasolacrimal drainage173. 
Dispersity (D), also known as polydispersity index (PDI), is another important factor that can 
influence the shape, stability and overall performance of the micellar formulation174. The 
kinetics of copolymers which exist between the micellar and non-micellar state are also 
influenced by the dispersity of the polymers. Therefore, block copolymers with monodisperse 
core-shell structures having a low dispersity (D<1.2) are preferred for the development of 
controlled release systems 175-176.  
4.7.3. Polymeric micelle structures 
The preparation of polymeric micelles can be divided into three categories namely (i) 
polymer–drug conjugates, (ii) drug-encapsulated carriers and (iii) polyion complex micelles.   
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4.7.3.1. Polymer–drug conjugates 
Micelle forming polymer-drug conjugates are developed through hydrolysable 
chemical bonds between the functional group(s) of the polymeric backbone and the drug. To 
date, poly(ethylene oxide)-b-poly(ester) and poly(ethylene oxide)-b-poly(amino acid) block 
copolymer based conjugates have been extensively studied for effective drug delivery 
applications. Thes polymers may have several functional groups providing various sites for the 
conjugation of a number of drug molecules to one polymeric chain allowing efficient delivery 
of therpeutic doses. 177-181.  
4.7.3.2. Drug-encapsulated carriers  
The solublization and stable encapsulation of drug into polymeric micelles can  
primarily be achieved by chemical and physical methods. Chemical methods involve covalent 
core cross-linking of the drug with the polymers consisting of side-chain or end-group-
functionalized block copolymers. An important factor to be considered using chemical 
methods is that the reactive groups of the polymers should be sufficiently hydrophobic or low 
in number so that they do not interfere with the formation of monodisperse micelles182. The 
most commonly employed methods for preparing core cross-linked polymeric micelles are: (i) 
radical polymerization, used for micelles containing polymerizable groups in their core; (ii) 
addition of bifunctional crosslinkers, used for micelles containing reactive groups in their core; 
and (iii) disulphide bridges, used for micelles containing thiol groups. The last method allows 
for stimuli-responsive disintegration and drug release. Although chemical crosslinking allows 
significant improvements in circulation kinetics, biodistribution and target site accumulation 
of micelles, the series of chemical reactions involved may sometimes be challenging and 
complicated. On the other hand, physical methods including (i) direct dissolution, (ii) dialysis, 
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(iii) oil-in-water emulsion, (iv) solvent evaporation, (v) co-solvent evaporation and (vi) freeze-
drying methods (Figure 4-7) are much simpler and practical183. 
 
4.7.3.2.1. Direct dissolution method 
The direct dissolution method is the simplest technique for the preparation of drug-
loaded polymeric micelles. Copolymers along with drugs are mixed in water at or above the 
CMC to self-assemble into drug-loaded micelles184. However, this technique is associated with 
Figure 4-7 Physical methods of drug encapsulation into polymeric micelles: (A) direct 
dissolution; (B) dialysis; (C) oil-in-water emulsion; (D) solvent evaporation; (E) co-solvent 
evaporation; (F) freeze-drying 
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low drug-loading which can be enhanced by increasing the temperature of the system before 
the addition of the copolymer. Preparation of a thin film of drug before the addition of the 
polymer into the system can also result in higher drug loading (Figure 4-7 A) 185. 
4.7.3.2.2. Dialysis method 
The drug along with the block copolymer are dissolved in a water-miscible organic 
solvent (such as N,N-dimethylformamide) and the resultant solution is dialysed against water 
186-190 (Figure 4-7 B). During the dialysis process, the organic solvent is replaced by water 
which induces self-association of block copolymers and the entrapment of drug. The 
semipermeable membrane of the dialysis bag keeps the drug encapsulated polymeric micelles 
inside191. At the same time unloaded or free drug remains outside the dialysis bag. However, 
this method is only suitable for lab scale production, while incomplete removal of the free drug 
from the polymeric assemblies is another drawback. Alternatively, tangential flow filtration 
(TFF) is a fast and simple method that can be used for scalable manufacturing processes of 
polymeric micelles 192. 
4.7.3.2.3. Oil-in-water emulsion method 
The drug is dissolved in a water-immiscible organic solvent (such as chloroform or 
methylene chloride), followed by addition of this organic to the aqueous phase under vigorous 
stirring. The polymer may be dissolved in either the organic or the aqueous phase and the 
organic solvent is then removed by evaporation (Figure 4-7 C) 193-195. 
4.7.3.2.4. Solvent evaporation method 
Drug and polymer are dissolved in a volatile organic solvent. A thin film of 
drug/polymer is formed at the bottom of the flask after the evaporation of the organic solvent. 
This film is then reconstituted in an aqueous phase by vigorous shaking (Figure 4-7 D). This 
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method can be applied for micelle-forming block copolymers having high hydrophilic 
lipophilic balance (HLB) values so that the polymer film can be easily reconstituted in an 
aqueous medium 196-198.  
4.7.3.2.5. Co-solvent evaporation method 
Drug and polymer are dissolved in a volatile water-miscible organic solvent (co-
solvent) followed by addition of the aqueous phase (non-solvent for the core-forming block) 
which triggers the formation of micelles and drug entrapment. The organic co-solvent is 
evaporated at the end resulting in drug loaded polymeric micelles (Figure 4-7 E) 199-202.  
4.7.3.2.6. Freeze-drying method 
This method is applicable for freeze-dryable organic solvents such as tert-butanol 
which can dissolve the polymer and the drug. The drug/polymer solution is then mixed with 
water, freeze-dried and reconstituted with isotonic aqueous media. This method is suitable for 
large scale production. However, it is applicable only to block copolymers and drugs that can 
be solubilized in tert-butanol (Figure 4-7 F) 203. 
4.7.3.3. Polyion complex micelles 
Electrostatic interactions between oppositely charged polymer/drug combinations 
result in polyion complex micelles. This method is suitable for different therapeutic moieties 
that carry charge including peptides and DNA. Upon neutralization of the charge, the core-
forming segment of the block copolymer can induce self-assembly of the polyion complex and 
further stabilization of the micelle 204-207. 
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4.8. Ocular delivery pathways of micelles  
After topical application of an eye drop, a drug is anticipated to follow either the corneal 
or the conjunctival-scleral pathway to reach posterior segment tissues 208. The hydrophilic 
stroma which constitutes 85-90% of the cornea, acts as a rate limiting barrier for topically 
applied hydrophobic drugs 209. Such limitation can be overcome by encapsulating hydrophobic 
drugs into the lipophilic cores of highly water soluble polymeric micelles. Polymeric micelles, 
being extremely small, can penetrate through the cornea and/or the alternative conjunctival-
scleral pathway after topical application. The higher conjunctival-scleral surface area allows 
lateral diffusion of such polymeric micelles to reach the posterior segment of the eye 210. Nano-
sized micelles with their hydrophilic corona assist in scleral transport of the micellar-drug 
construct through the aqueous pores/channels. In addition, the scleral pathway also minimizes 
the chances of drug washout into the systemic circulation by the conjunctival blood circulation 
and lymphatics. From the posterior segment, the polymeric micelles may be further engulfed 
by RPE cells by endocytosis to generate therapeutic concentrations in posterior ocular tissues 
211-213. Such tissue absorption and cellular uptake depend on the surface charge and size of the 
micelles 214. Figure 4-8 shows a schematic illustration of the penetration of a polymeric 
micellar formulation applied in the form of a topi  cal eye drop to the posterior ocular tissues.  
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4.9. Drug release from polymeric micelles 
Drug release from polymeric micelles mainly depends upon (i) the design and method 
used for their preparation; (ii) the structure of the micelle-forming block copolymer and the 
drug; (iii) their physicochemical properties; and (iv) the localization of the drug in the 
polymeric micelles. Figure 4-9 shows various modes of drug release from polymeric micelles. 
Drug release from polymer-drug conjugates generally follows two mechanisms, (i) 
dissociation of micelles followed by drug cleavage from the polymeric unimers or (ii) drug 
cleavage inside the micellar structure followed by diffusion out of the carrier215 (Figure 4-9 
A). Drug release from drug-loaded micellar carriers is usually preceded by diffusion (Figure 
4-9 B), whereas drug release from polyion complex micelles is triggered via ion exchange in 
physiological media Figure 4-9 C). 
Figure 4-8 Schematic representation of polymeric micelles reaching the posterior ocular tissues via the 
transcleral pathway after topical application 
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Figure 4-9 Modes of drug release from polymeric micelles. (A) Drug release from block 
copolymer-drug conjugates, (B) Drug release from drug encapsulated micellar carriers and 
(C) Drug release from polyion complex micelles 
  
Apart from these basic drug release mechanisms, instant, sustained, pulsed or delayed 
drug release can be achieved by modifying the chemical structure of the micelle-forming block 
copolymers which will ultimately modify the physicochemical properties of the core/shell 
forming blocks. For example, sustained or delayed drug release from the carrier can be 
achieved by enhancing the hydrophobicity and rigidity of the micellar core which limits the 
movement of water and free ions to the micellar core in micelle-forming drug conjugates and 
polyion complex micelles 216-217.  
A lower rate of micellar dissociation, the diffusion of drug and the overall drug release 
from micellar carriers can also be achieved via crosslinking of the micellar core structure and 
the induction of strong hydrophobic interactions or hydrogen bonds between the core-forming 
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blocks and the drug 218-220. The incorporation of hydrophilic or stimuli responsive groups to 
the core structure may be another avenue to provide an instant or pulsed mode of drug delivery 
219, 221-224. 
4.10. Potential polymeric micellar formulations for clinical translation  
Various polymeric micellar formulations have been patented to date exhibiting great 
potential for proof-of-concept efficacy and safety as novel ophthalmic micellar formulations. 
However, for successful clinical translation, a few critical steps are necessary. Obtaining 
preclinical proof of efficacy and pharmacokinetic data in various animal models is a 
prerequisite before going into clinical trials225. Besides the therapeutic response, systemic 
exposure and bio distribution in animal models should be reported. Direct head-to-head 
comparisons of the therapeutic efficacy of various related formulations are strongly 
recommended. In addition, in vitro and in vivo safety and tolerability profiles should be 
generated to determining a safe dose range for clinical evaluation. A thorough characterization 
including impurity profiling and methods for upscaling production is imperative for successful 
clinical translation. Table 4-1 lists recent patent inventions related to polymeric micellar 
formulations for effective ocular drug delivery with most of these still being under preclinical 
development. 
 
Table 4-1 Summary of recent patented polymeric micelle formulations for ophthalmic 
applications currently under preclinical evaluation 
Patent number Year Formulation characteristics 
US8980839 B2 2015 Aqueous nanomicellar ophthalmic solution comprising cyclosporine, 
a polyoxyl lipid or fatty acid and a polyalkoxylated alcohol 
WO2015041520 A1 2015 Peptide-based self-assembling micelles 
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Patent number Year Formulation characteristics 
US 9017725 B2 2015 Nanomicelles consisting of dexamethasone, vitamin E TPGS and 
octoxynol-40. 
CN104644550 A 2015 A curcumin micelle drops, comprising curcumin, chitosan micelle 
drug carriers, surface active agents, surfactants and pharmaceutical 
purified water. 
US 8697098 B2 2014 Prolamine protein conjugated to a polymer, such as a polyethylene 
glycol (PEG) chain, with conjugates used to prepare micelle 
assemblies. 
US8470371 B2 
 
2013 A polymeric micellar aggregate having a mean particle size between 
20 and 500 nm formed from an amphiphilic carbohydrate polymer. 
US 20120225834 A1 
 
2012 Ocular iontophoresis consisting of micelles comprising one or more 
charged surfactants and one or more bioactive agents. 
US 20120294945 A1 2012 Micelle consisting of hyaluronic acid and a core region comprising a 
water-insoluble peptide with a terminal amine group, wherein the 
water-insoluble peptide is bound to hyaluronic acid or its 
pharmaceutically acceptable salt. 
WO2010144194 2010 Mixed nanomicellar formulations (vitamin E, TPGS, octoxynol-40) 
of water insoluble drugs. 
WO 2011041377 A1 2010 Ocular iontophoresis of charged nanomicelles consisting of 
alkyltrimethylammonium halide, alkyldimethylammonium halide, 
alkylmethylammonium halide, alkylethyldimethylammonium halide, 
alkyldimethylbenzylammonium halide, alkylpyridinium halide, and 
alkylimidazolium halide, or a mixture of two or more. 
WO2008004978 A1 
 
2008 A block copolymer comprising at least a first block and a second 
block, wherein the first block comprises a range of temperature-
sensitive monomeric units, a range of hydrophilic monomeric units 
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Patent number Year Formulation characteristics 
and a range of targeting monomeric units. The second block 
comprises a range of hydrophobic monomeric units and at least one 
pH-sensitive moiety. 
WO2008017839 A1 
 
2008 Polymeric micellar clusters formed from amphiphilic carbohydrate 
polymer. 
US 20060110356 A1 2006 Micelles with a hydrophilic polymer chain of polyoxyethylene or 
polyethylene glycol and a hydrophobic polymer chain of polylactone. 
EP1609465 A1 
 
 
 
2005 Polymer micelle of a block copolymer wherein the hydrophilic 
polymer chain is polyoxyethylene or polyethylene glycol. The charged 
polymer chain is a polyamine, a polycarboxylic acid or a polypeptide. 
CA 2520525 A1 2004 Polymer micelle of a block copolymer comprising a hydrophilic 
polymer chain (polyoxyethylene or polyethylene glycol) and charged 
polymer chain as a core (polypeptide) 
US6579519 B2 
 
 
2003 Micelle solution of block random copolymers of the general formula 
(X+Y+Z-)m, wherein X is a monomer selected from the vinyl group 
of compounds, Y is a monomer which will provide thermo-sensitivity 
of the co-polymer having a general formula R1-R2N-(C═O)-
CH═CH2. Z is a monomer selected from acrylate based monomers 
which will provide mucoadhesiveness and pH-sensitivity. 
US5955509 A 
 
1999 Poly(vinyl N-heterocycle)-block-poly(alkylene oxide) copolymer 
based micelles 
US 5766580 A 1998 Micelle comprising ethylene oxide-propylene oxide-ethylene oxide 
block copolymer. 
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4.11. Nanomicelles for targeted lipid ester prodrug delivery 
Various formulation strategies including polymeric nanoparticles, liposomes, and 
dendrimers have been developed to improve ocular concentrations of therapeutic agents. 
However, the majority of these formulations are administered via intracameral, intravitreal and 
periocular injections to overcome the ocular barriers with frequent injections generally 
required which may result in adverse effects226. Therefore, formulation strategies that are 
capable of delivering therapeutic agents to the back of the eye after topical application can be 
highly effective in improving drug efficacy.  
Additionally, improving the permeability of hydrophilic agents employing lipid esters 
and targeting the overexpressed SMVT transporters, has allowed such transporter targeted 
prodrug approaches to be highly effective in improving permeability and efficacy of 
hydrophilic therapeutic agents such as CDF. 
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Figure 4-10 Hypothetical mechanisms involved in the transport of B-C12-cCDF prodrug-
loaded nanomicelles to improve retinal targetibility and bioavailability, simultaneously 
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In this approach (Figure 4-10), we have utilized a highly effective prodrug of CDF, B-
C12-cCDF that was developed by Gokulgandhi et al. and manufactured in contract with SRI 
International (Menlo Park, California). We hypothesized that the prodrug would generate 
improved permeability across ocular barriers in comparison to CDF. The biotin moiety coupled 
to CDF will allow improved binding and translocation via SMVT transporters simultaneously 
evading efflux pumps. However, the twelve-carbon chain moiety imparts lipophilicity to the 
prodrug, which renders it improper for topical application. Hence, we propose to develop a 
topical aqueous nanomicellar formulation of the lipophilic B-C12-cCDF prodrug. This 
nanomicellar formulation will allow signficiant entrapment of the lipophilic prodrug into its 
core. We hypothesize that these nanomicelles being significantly smaller in size (20-80nm) 
will effectively permeate through the conjunctival scleral pathway and generate improved 
retinal CDF concentrations over a period for the treatment of CMV retinitis.  
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CHAPTER 5 
5. TOPICAL FORMULATION OF SELF-ASSEMBLED ANTIVIRAL PRODRUG 
NANOMICELLES FOR TARGETED RETINAL DELIVERY 
5.1. Rationale  
Cidofovir and its cyclic analogues (cCDF) are indicated in the treatment of 
cytomegalovirus retinitis (CMV, an infection of retina in the eye in AIDS patients) 113, 227. 
However, the biological activity of this compound is dependent on its intracellular 
accumulation which is hindered by the reticuloendothelial system (RES) as well as various 
efflux pumps expressed on the corneal and retinal epithelia 228-229. Self-assembled polymeric 
nanomicelles have emerged as one of the promising nanocarrier systems 182, 230. Enhanced 
aqueous solubility, prolonged circulation time, improved drug bioavailability, reduced toxicity 
and evasion from RES and efflux pumps render these polymeric nanomicelles superior to other 
delivery systems 231-232. The ability to precisely control the chemical composition, molecular 
weight and size of these polymeric nanomicelles furnishes additional advantages 233-234. 
Moreover, slow drug release from these polymeric nanomicelles over a long time period may 
limit frequent dosing into ocular tissues 183, 235-236.  
Remarkably, in contrast to numerous examples of successful delivery of therapeutic 
agents to ocular tissues with nanocarrier systems 237-239, the development of polymeric 
nanomicelles for back of the eye delivery has rarely been addressed. However, such a 
nanomicellar approach may be desirable 240, for instance, in case of a drug such as cidofovir 
which has lower bioavailability in human ocular tissues following intravenous and/or 
intravitreal administration 113, 241. 
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Earlier, we reported on the transporter targeted lipid prodrug of cyclic cidofovir (B-
C12-cCDF). This was achieved by conjugating a lipid chain (C-12) and a targeting moiety 
(biotin) to cCDF. The concept was based on enhanced lipophilicity and melanin-binding in the 
retina owing to the lipid raft. Better retinal targetability was achieved by conjugating biotin 
which specifically targets sodium dependent vitamin transporters highly expressed in the 
retina. By selecting a suitable lipid raft and targeting moiety, it was possible to achieve higher 
bioavailability in the retina and lower the viral load 145, 242. Antiviral studies conducted under 
the contract of the National Institute of Allergy and Infectious Diseases (NIAID) reported that 
B-C12-cCDF exhibited 2 to 25-fold reduction in EC50 value against HCMV (0.57 μM), HSV-
2 (2.16 μM) and BK virus (13.8 μM) relative to the parent drug CDF. 
Although we were able to prove that this approach works, the low aqueous solubility 
of B-C12-cCDF and possibility of getting detected by the RES 243-245 and efflux pumps 246-247 
rendered lower drug concentrations in human ocular tissues. Taking all previous results 
together, further work led to the development of a self-assembled topical nanomicellar 
formulation of the transporter targeted lipid prodrug of cCDF.  
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5.2. Objective  
(i) In this study, we have developed polymeric nanomicelles based on a blend of polymers, 
polyoxyethylene hydrogenated castor oil 40 (HCO-40) and octoxynol 40 (OC-40) for the 
intracellular targeted delivery of B-C12-cCDF to the retina. B-C12-cCDF was manufactured 
in contract with SRI International. Utilization of such a blend of polymers by our laboratory in 
the past has resulted into highly stable and water soluble self-aggregating nanomicellar 
formulations 248-249. This formulation has recently completed Phase 3 clinical trials and has 
shown promising results for the treatment of dry eye disease (NCT02254265).  
(ii) Physicochemical properties, in vitro release and drug loading capacities of polymeric 
nanomicelles of B-C12-cCDF were evaluated utilizing dynamic light scattering (DLS), 
transmission electron microscopy (TEM) and ultra-fast liquid chromatography (UFLC).  
(iii) The cytotoxicity of prodrug loaded nanomicelles was studied in HRPE (human retinal 
pigment epithelial, D407), HCE-T (human corneal epithelial) and CCL 20.2 (human 
conjunctival epithelial) cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and lactate dehydrogenase (LDH) assays.  
(iv)The uptake behavior and permeability of B-C12-cCDF-loaded nanomicelles were 
demonstrated in D407 and HCE-T cells using confocal laser scanning microscopy (CLSM) 
and flow cytometry (FCM).   
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5.3. Experimental Section 
5.3.1. Materials 
B-C12-cCDF was obtained from SRI Chemical Synthesis Program (SRI International, 
Menlo Park, CA). Hydrogenated castor oil-40 (HCO-40) of pharmaceutical grade was 
procured from Barnet Products, USA and octoxynol-40 (OC-40 or Igepal CA-897) was 
purchased from Rhodia Inc., New Jersey, USA. Povidone (PVP)-K90 (lot #56943447G0) was 
obtained from BASF AG (Ludwigshafen, Germany). For buffer and formulation preparation 
double distilled deionized (DI) water was utilized. HPLC grade DMSO and methanol were 
purchased from Fisher Scientific Co. (Pittsburgh, PA, USA). TrypLETM Express Stable trypsin 
solution, Dulbecco’s modified Eagle’s medium (DMEM) were received from Invitrogen 
(Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Atlanta Biologics 
(Lawrenceville, GA, USA). All other chemicals were of analytical reagent grade procured from 
Thermo Fischer Scientific or Sigma Aldrich and were utilized without any further purification. 
5.3.2. Cell culture 
  Cell lines D407 and HCE-T transfected with a recombinant SV40-adenovirus vector 
were kindly provided by Dr. Richard Hunt (University of South Carolina, Columbia, SC, USA) 
and Dr. Araki-Sasaki (Kinki Central Hospital, Japan) respectively. Mouse macrophage RAW 
264.7 cell line and human conjunctival cell line CCL 20.2 were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA). All cell lines were cultured in T75 flasks in 
DMEM medium containing high glucose and glutamine concentrations. The culture medium 
contained 10% FBS (heat-inactivated), 1% nonessential amino acids, 100 IU/ml streptomycin 
and 100 IU/ml penicillin. The pH of the medium was maintained at 7.4. Cells were maintained 
at 37 ºC in an atmosphere containing 5% CO2 and 90% relative humidity. The medium was 
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replaced on alternate days until cells reached 80-90% confluency (5-7 days for D407, CCL 
20.2 and 19-21 days for HCE-T cells).  
5.3.3. Synthesis of B-C12-cCDF prodrug 
  B-C12-cCDF was synthesized by the SRI Chemical Synthesis Program. Briefly, in a 
flask, CDF (1 equiv), 20 mL of anhydrous N,N-Dimethylformamide (DMF), and 2.1 mL of 
dry N,N-diisopropylethylamine (DIPEA) were added. The reaction vessel was warmed by a 
heat gun to facilitate the dissolution of the CDF–DIPEA salt. The solvent was removed under 
vacuum. The residue, 20 mL of anhydrous DMF, DIPEA (5 equiv), the biotin-conjugated lipid 
(1.5 equiv) in anhydrous DMF, and benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium 
hexafluorophosphate PyBOP (2.1 equiv) were added, and the reaction mixture was stirred 
under nitrogen at 45 °C for 48–60 h. The reaction mixture was monitored by 31P NMR, and 
additional portions of PyBOP were added as necessary. After completion of the reaction, the 
solvent was removed under vacuum, and the brownish-red residue was purified by repetitive 
silica gel column chromatography. The product was obtained by a combination of 
dichloromethane and methanol as the eluent. 
5.3.4. Experimental Design 
In order to screen the weight percent of polymers, effects of formulation variables on 
B-C12-cCDF loading, micellar size and polydispersity index (PDI) were evaluated based on a 
statistical design of experimental (DOE) protocol. Student version of JMP® 10.0 software 
(SAS institute, USA) was applied to develop the experimental design and analyze the data. 
Five independent (X1, X2, X3, X4 and X5) and three dependent variables (Y1, Y2, and Y3) 
were identified. Independent variables X1 through X5 included HCO-40 (wt. %), OC-40 (wt. 
%), sonication time (min), pH and buffer concentrations (molarity, M), respectively. 
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Dependent variables Y1, Y2 and Y3 represented the percent drug loading (% w/w), micellar 
size (nm) and polydispersity index, respectively. The “screening design” in JMP was selected 
to create the design. A Plackett-Burman design with twelve runs was selected from the “design 
list” (Table 5-1) and two center points were included. This arrangement resulted in 14 
experiments. Coded values −1, 0, +1 were assigned to the weight percent levels for two 
polymers. 
5.3.5. Preparation of polymeric nanomicelles 
 Nanomicellar formulations of B-C12-cCDF were prepared following solvent 
evaporation and film rehydration as described previously248. Briefly, the experimental 
procedure was divided into two steps (i) formulation preparation and (ii) rehydration.  
(i) Formulation preparation: B-C12-cCDF was accurately weighed out and dissolved 
in ethanol and dichloromethane (DCM) mixture (10:1). Then HCO-40 and OC-40, were 
weighed out and dissolved separately in ethanol. This solution was stirred and the mixture 
generated a homogenous solution. The calculated volume of B-C12-cCDF solution was added 
drop by drop to this solution. The solvent was evaporated under high-speed vacuum (Genevac, 
Ipswich, Suffolk, UK) overnight (∼10 h) to obtain a solid thin film.  
(ii) Rehydration: The resultant solid thin film was rehydrated in 10 mL of water, and 
the volume was made up with 2× phosphate/ citrate buffer solution containing 1.2% of PVP 
K90 (BASF SE, Ludwigshafen, Germany) with varying pH values. PVP was added to increase 
the viscosity and hence retention of the formulation. The solution was sonicated for an 
appropriate amount of time. Finally, the formulation was filtered with a 0.2 μm nylon 
membrane syringe filter (Tisch Scientific, USA) to remove unentrapped drug aggregates and 
other foreign particulates. 
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5.3.6. Characterization 
Hydrodynamic diameter and polydispersity index (PDI) of nanomicelles were 
determined in aqueous solution with a Zeta Sizer (Zetasizer Nano ZS, Malvern Instruments 
Ltd, Worcestershire, UK) at RT. Briefly, 1 ml of nanomicellar solution (2 mg/mL) was placed 
into a glass cuvette. The samples were measured at a scattering angle of 173 º and 25 ºC. 
Average values were calculated from three replicate measurements of each sample. The 
morphology of polymeric nanomicelles was examined with TEM. Typically, a drop of 
nanomicellar solution was placed on a copper grid. A layer of nitrocellulose and carbon in the 
evaporator was applied and stained with 1% uranyl formate.  Measurements were performed 
with JEM 1200 EX II TEM at an acceleration voltage of 100 kV.  
5.3.7. Critical micellar concentration (CMC) 
CMC was determined with iodine as a probe. The polymer concentrations ranged from 
3.5 to 1.63 x 10-9 wt. %, and the iodine solution was adjusted to a ratio of 0.5:1 (I2: KI). The 
absorbance of hydrophobic iodine, I2, entrapped in the core of polymeric nanomicelles was 
recorded with a Beckman Coulter (DDX 880). The emission spectrum was recorded from 286 
nm to 460 nm at an excitation wavelength of 279 nm. From the iodine emission spectrum, the 
intensity ratio (I460/I286) was analyzed as a function of polymer concentration. The CMC 
value was determined at a cross-point by extrapolating the intensity ratio at the polymer 
concentration regions.  
5.3.8. 1H-NMR spectroscopy 
To perform 1H-NMR spectroscopy, B-C12-cCDF was dissolved in d6-DMSO. HCO-
40, OC-40, Blank and B-C12-cCDF-loaded nanomicelles were prepared in D2O for NMR 
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analysis. Spectra were recorded with Varian-400 NMR instrument. NMR data was processed 
using VNMRJ or ACD labs software.   
5.3.9. Entrapment and loading efficiency 
The total amount of prodrug entrapped in the formulation was determined by reversed-
phase UFLC (RP-UFLC). Ten milliliters of each micellar formulation was collected and 
centrifuged at 10,000 rpm for 10 min at 4 ºC. One milliliter of supernatant was carefully 
collected from each centrifuge tube and transferred into fresh vials and lyophilized to obtain a 
solid pellet. Five hundred microliter of DCM was added to each vial in order to reverse the 
polymeric nanomicelles and release the prodrug into the surrounding organic solvent. This 
DCM solution was evaporated under speed vacuum (Genevac Technologies VC3000D, USA) 
to obtain a solid pellet of reversed micelles. Further, this solid pellet was appropriately diluted 
in UFLC mobile phase and the amount of prodrug present in the samples was determined. The 
percent entrapment and loading efficiency of prodrug (B-C12-cCDF) were calculated 
according to the following formula: 
Percent entrapment = (mass of B-C12-cCDF in nanomicelles)/ (mass of B-C12-cCDF 
added in formulation) x 100                           [Eq. 3] 
Loading efficiency = (mass of B-C12-cCDF in nanomicelles)/ (mass of B-C12-cCDF 
added + mass of polymers used) x 100          [Eq. 4] 
5.3.10. In vitro cytotoxicity assay 
Cytotoxicity of B-C12-cCDF-free nanomicelles or B-C12-cCDF-loaded nanomicelles 
against D407, HCE-T and CCL 20.2 cells were assessed in vitro by MTT and LDH assays. All 
three cell lines were seeded into a 96-well plate at a density of 1x104 cells/well in 100 µL 
95 
complete DMEM solution containing 10% FBS. Cells were cultured for 1 day at 37 ºC in 5% 
CO2 atmosphere. B-C12-cCDF, B-C12-cCDF-free nanomicelles or B-C12-cCDF-loaded 
nanomicelles were prepared in serum free medium and filtered with 0.22 µm nylon membrane 
filters under a laminar flow hood. B-C12-cCDF being poorly water soluble was prepared in 
serum free medium by adding 2-3 drops of DCM. Afterwards, cells were incubated with B-
C12-cCDF, B-C12-cCDF-free nanomicelles or B-C12-cCDF-loaded nanomicelles for 24 h at 
37 ºC. The concentration of B-C12-cCDF-free nanomicelles (HCO-40/OC-40) ranged from 
0.24 to 7.0 mg/mL. B-C12-cCDF-loaded nanomicelles with final B-C12-cCDF-concentrations 
from 13.95 g/mL to 400 µg/mL were employed. After 24 h of incubation, MTT stock solution 
(5 mg/mL in potassium phosphate buffer, PBS 20 µL) was added to each well and incubated 
for 2.5 h. The absorbance was measured with a microplate reader (BioRad Hercules, CA, USA) 
at 485 nm. Cell viability was expressed according to the following formula:  
Cell viability (%) = (Abs of sample- Abs of negative control)/ (Abs of positive control- 
Abs of negative control) * 100               [Eq. 5] 
5.3.11. LDH assay 
D407, HCE-T and CCL 20.2 cells were seeded into a 96-well plate at a density of 1x104 
cells/well in 100 µL of complete DMEM containing 10% FBS. Cells were cultured for 1 day 
at 37 ºC in 5% CO2 atmosphere. CDF, B-C12-cCDF, B-C12-cCDF-free nanomicelles or B-
C12-cCDF-loaded nanomicelles solutions were prepared as described previously. After 24 h 
of incubation, plates were centrifuged at 250 x g for 10 min and the supernatant was collected 
from each well. LDH released into the cell supernatant was quantified with a LDH assay kit 
(Takara Bio Inc., Japan). The absorbance of the solution was measured using a microplate 
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reader (BioRad Hercules, CA, USA) at 490 nm. LDH release was expressed according to the 
following formula: 
LDH release (%) = (Abs of sample- Abs of negative control)/ (Abs of positive control- 
Abs of negative control) * 100               [Eq. 6] 
5.3.12. In vitro biocompatibility studies 
  RAW-264.7 cells were seeded into a 96-well plate at a density of 1x104 cells/well in 
100 µL of complete DMEM containing 10% FBS. Cells were cultured for 1 day at 37 ºC in 
5% CO2 atmosphere. CDF, B-C12-cCDF, B-C12-cCDF-free nanomicelles or B-C12-cCDF-
loaded nanomicelles solutions were prepared as described previously. After 24 h of incubation, 
plates were centrifuged at 250 x g for 10 min and the supernatants were analyzed for the 
presence of cytokines i.e., Tumor necrosis factor- α (TNF-α), Interleukin 6 (IL-6) and 
Interleukin-1β (IL-1β). Lipopolysaccharide (LPS) served as positive control whereas cells 
without any treatment were considered as negative control. Cytokine levels (in pg/mL) were 
measured by ELISA according to manufacturer’s (e-Biosciences, San Diego, CA) protocol. 
Standard calibration curves for TNF-α, IL-6 and IL-1β were prepared in the concentration 
range of 10-750 pg/mL, 5-500 pg/mL and 10-500 pg/mL, respectively. 
5.3.13. In vitro release of B-C12-cCDF from B-C12-cCDF-loaded nanomicelles 
A fixed volume (1 mg/mL) of B-C12-cCDF-loaded nanomicelles was transferred to a 
membrane tubing (MWCO 2000 Da, Spectrum labs, CA, USA). The tubing was subsequently 
immersed in 5 mL PBST (PBS with 0.002 wt. % Tween 20, pH 7.4) or STF (Composition: 2 
g NaHCO3, 6.7 g NaCl, 0.08 g CaCl2·2H2O, and deionized water was added up to 1 L, Tween-
80 (0.5 wt. %)) solution in a shaking water bath fixed at 60 rpm and 37 ºC to maintain sink 
condition. At predetermined time points, the entire 5 mL of external buffer were withdrawn 
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and replaced with 5 mL of fresh buffer solution to maintain sink condition. The amount of 
prodrug released was determined by RP-UFLC as described below.  
5.3.14. Drug Release Mechanism 
Drug release parameters were calculated by the following mathematical models: zero 
order (Eq. 7), first order (Eq. 8), Higuchi (Eq. 9), and Korsmeyer-Peppas (Eq. 10). Release 
data were fitted into the model equations in order to identify the release mechanism of drug 
release from formulations. 
Zero‐order equation: Qt = Q0 + K0t                [Eq. 7] 
First‐order equation: logQt = logQ0 + K1t/2:303                [Eq. 8] 
Higuchi equation: Qt = Kht
1/2                [Eq. 9] 
Korsmeyer‐Peppas equation: Qt/Q∞ = Kptn                [Eq. 10] 
5.3.15. FITC labeling of CDF and B-C12-cCDF 
Fluorescein isothiocyanate (FITC, Life Technologies, Eugene, OR, USA) was freshly 
dissolved in DMSO (1 mg/ml) and added to 2 mg/ml of CDF and B-C12-cCDF in 50 mM PBS 
(final pH 7.6). The final concentration of FITC was 15 µg/ml. The calculated molar ratio of 
FITC to CDF/B-C12-cCDF was 0.10. After incubation for 16 h in the dark at 4 °C, 50 mM 
NH4Cl was added to inactivate the residual FITC. The solution was stored in the dark for an 
additional 2 h at 4 °C, and stored in aliquots at -20 °C.  
5.3.16. Evaluation of cellular uptake by FCM 
D407 and HCE-T cells were seeded into 12-well plates at a density of 2.5x104 cells/well 
in 24 mL complete DMEM containing 10% FBS, and maintained until they achieved 80-90% 
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confluency (6-7 days) at 37 ºC in 5% CO2 atmosphere. Afterwards, cells were incubated with 
FITC-tagged CDF, B-C12-cCDF, B-C12-cCDF-free nanomicelles or B-C12-cCDF-loaded 
nanomicelles at a final CDF or B-C12-cCDF concentration of 50 µg/mL in serum free medium 
for predetermined time points at 37 ºC. At each time point, the culture medium was removed 
and cells were washed twice with DPBS to remove the various treatment groups that were not 
ingested by the cells. Cells were detached with trypsin for 10 min, and then centrifuged at 1550 
rpm for 10 min to obtain a solid pellet. The solid cell pellet was washed twice with DPBS. 
After removal of the supernatant, the cells were resuspended in 500 µL of 4% (w/v) 
paraformaldehyde aqueous solution and stored at 4 ºC. The mean fluorescence intensity of 
FITC-tagged CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles in cells were 
analyzed by FCM (Becton Dickinson, Franklin Lakes, NJ, USA) with an excitation wavelength 
of 490 nm for comparative studies.   
5.3.17. CLSM observation for cellular distribution 
D407 and HCE-T cells were seeded on Nunc Lab-Tek® 8 chambered #1.0 borosilicate 
cover glass system (Thermo Fisher Scientific, Waltham, MA, USA) at a density of 1x104 
cells/well in 2 mL of complete DMEM containing 10% FBS and cultured for 1 day at 37 °C in 
5% CO2 atmosphere. FITC-tagged CDF, B-C12-cCDF, B-C12-cCDF-free nanomicelles or B-
C12-cCDF-loaded nanomicelles were added at a final concentration of 15µg/mL, followed by 
incubation for 2, 12 and 24 h. At each predetermined time point, the culture medium was 
removed and cells were washed with DPBS (3 x 5 min) to remove the various treatment groups 
not ingested by cells. Two hundred microliter of cold 4% buffered paraformaldehyde was 
added to each well to fix the cells and incubated for 10 min at 37 °C. The slides were rinsed 
with DPBS (3 x 5 min). Finally, the cells were stained with Vectashield Antifade Mounting 
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Medium with DAPI and stored at 4 °C until examined by CLSM (Leica TCS SP5, Wetzlar, 
Germany). 
5.3.18. Evaluation of cellular transport by FCM 
Transwell diffusion chambers (pore-size, 0.4 µm) were utilized for determining in vitro 
permeability of CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles. D407 cells were 
seeded into 12-well plates (bottom chamber) at a density of 2.5x104 cells/well in 24 mL 
complete DMEM containing 10% FBS, and maintained until they achieved confluency and 
developed completely (9-10 days) at 37 ºC in 5% CO2 atmosphere.  Similarly, HCE-T cells 
were seeded at a density of 1.25x104 cells/inserts (collagen coated, top chamber) until 
confluency and complete development. Afterwards, the transport experiment was initiated by 
incubating the HCE-T cells (top chamber) with FITC-tagged CDF, B-C12-cCDF, B-C12-
cCDF-free nanomicelles or B-C12-cCDF-loaded nanomicelles at a final CDF or B-C12-cCDF 
concentration of 50 µg/mL in serum free medium for predetermined time points at 37 ºC. At 
each time point, the culture medium was removed and the D407 cells (bottom chamber) were 
washed twice with DPBS to remove the various treatment groups that were not ingested by the 
cells. The D407 cells were detached using trypsin for 10 min, and then were processed as 
mentioned in section illustrating the cell uptake of nanomicelles. The mean fluorescence 
intensity of FITC-tagged CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles in cells 
were analyzed by FCM (Becton Dickinson, Franklin Lakes, NJ, USA) with an excitation 
wavelength of 490 nm for comparative studies. 
5.3.19. Sample and data analysis 
RP-UFLC was employed to analyze in vitro release samples. The system comprised of 
Waters 515 pump (Waters, Milford, MA, USA) connected to C (18) Kinetex column (100 mm 
100 
X 4.6 mm, 2.6 m; Phenomenex, Torrance, CA, USA) and a UV detector (Absorbance Detector 
Model UV-C, RAININ, Dynamax, Palo Alto, CA, USA, wavelength 280 nm). 
Acetonitrile:water (4:1) with 0.1% trifluoroacetic acid was selected as a mobile phase with a 
flow rate of 0.4 mL/min. B-C12-cCDF eluted approximately at 2.61 min. All experiments were 
conducted at least in triplicate and results were expressed as mean ± S.D. Student t-test was 
employed to determine statistical significance between groups. A value of p ≤ 0.05 was 
considered to be statistically significant. 
 
5.4. Results and Discussion 
5.4.1. Formulation Optimization 
In this study we selected the Plackett-Burman design to screen essential independent 
variables for outcomes such as loading efficiency, micellar size and PDI. The results for 
dependent variables (Y1, Y2 and Y3) from 14 sets of formulations with two center points were 
subjected to data analysis with the Plackett Burman-Fit Least square analysis via JMP® 10.0 
software. Analysis was performed to identify the most pertinent variables for each dependent 
variable. For data analysis, the main effects of one- and two factor interactions were considered 
because higher order interactions are less significant. The parameters that showcased the most 
significant outcomes were selected and processed with a standard least square regression 
model to fit those parameters. The summary for fit model for loading efficiency, micellar size 
and PDI are presented in Table 5-1. Further, analysis of variance (ANOVA) for loading 
efficiency, size and PDI exhibited a non-significant effect with a F ratio (probability > F) of 
0.0819, 0.2167 and 0.2997, respectively.  
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Table 5-1 Experimental design with independent and dependent variables 
Pattern HCO-40 
(wt. %) 
OC-40 
(wt. %) 
Sonicatio
n time 
(mins) 
pH Buffer 
(M) 
%Entrapmen
t efficiency 
Loading 
efficiency 
(%) 
Size 
(nm) 
PDI 
−+++− 0.5 2 5 7.2 0.01 22.85 1.69 17.33 0.63 
++−−− 4.5 2 0 5.5 0.01 61.16 1.83 15.99 0.13 
00000 2.5 1.005 2.5 6.35 0.055 90.94 4.64 17.73 0.2 
+−−−+ 4.5 0.01 0 5.5 0.1 82.75 3.51 16.61 0.06 
+−+++ 4.5 0.01 5 7.2 0.1 87.57 3.72 16.51 0.06 
+++−− 4.5 2 5 5.5 0.01 89.79 2.68 15.47 0.15 
−+−−+ 0.5 2 0 5.5 0.1 62.84 4.65 12.77 0.47 
−−−+− 0.5 0.01 0 7.2 0.01 10.58 2.98 19.26 0.23 
−−+−− 0.5 0.01 5 5.5 0.01 21.62 6.09 21.45 0.31 
−+−++ 0.5 2 0 7.2 0.1 44.39 3.29 17.74 0.46 
+−−+− 4.5 0.01 0 7.2 0.01 69.41 2.95 16.56 0.08 
00000 2.5 1.005 2.5 6.35 0.055 87.03 4.70 16.22 0.21 
+++++ 4.5 2 5 7.2 0.1 75.87 2.26 15.18 0.11 
−−+−+ 0.5 0.01 5 5.5 0.1 15.97 4.50 19.8 0.22 
 
5.4.2. Master formula (Prediction Equation) 
The fit model developed by the following polynomial equations for the output are 
loading efficiency (Eq. 11), micellar size (Eq. 12) and PDI (Eq. 13): 
Y1 = Y1= 4.585 + 1.385*X1+ (-1.3375*X2) + 0.2625*X3 + (-0.7125*X4) + (-1.8575*X5) + X1*[X1*(-
1.07)] + X1*[X2*(-0.9875)] + X1*[(X3)*1.8775] + X1*[X4*0.0675] + X1*[X5*(-1.1925)] + X2*[X2*0] + 
X2*[X3*(-0.245)] + X2*[X4*2.525] +X2*[X5*0]+ X3*[X3*0] + X3*[X4*0] + X3*[X5*0] + X4*[X4*0 ] + 
X4*[X5*0] + X5*[X5*0]                 [Eq. 11] 
Y2= 15.77 + (-0.776)*X1+ (-1.675*X2) - 0.5833*X3 + (-0.0366*X4) + (0.4058*X5) + 
X1*[X1*(1.2858)] + X1*[X2*(1.1166)] + X1*[(X3)*0.2366] + X1*[X4*(-0.06891)] + X2*[X2*0] + X2*[X3*(-
0.1841)] + X2*[X4*0.4833] +X2*[X5*0]+ X3*[X3*0] + X3*[X4*0] + X3*[X5*0] + X4*[X4*0 ] + X4*[X5*0] 
+ X5*[X5*0]                          [Eq. 12] 
Y3= 0.155 + (-0.1617)*X1+ 0.1029*X2 + 0.00256*X3 + (-0.0209*X4) + (0.0399*X5) + 
X1*[X1*(0.08808)] + X1*[X2*(-0.0387)] + X1*[(X3)*(-0.0234)] + X1*[X4*(0.01851)] + X1*[X5*(-0.0007)] 
+ X2*[X2*0] + X2*[X3*(0.0173)] + X2*[X4*(-0.0416] +X2*[X5*0]+ X3*[X3*0] + X3*[X4*0] + X3*[X5*0] 
+ X4*[X4*0 ] + X4*[X5*0] + X5*[X5*0]       [Eq. 13] 
where, X1= [HCO-40 (wt. %)-2.5]/2, X2= [OC-40 (wt. %)-1.005]/0.995, X3= 
[Sonication time (mins)-2.5]/2.5, X4= (pH-6.35)/0.85 and X5= [Buffer (M)-0.055]/0.046  
Since the polynomial equations for Y1, Y2 and Y3 fit well with R2 = 0.999, 0.993 and 0.987 
respectively, these were used for the optimization process. Therefore, the obtained polynomial 
equations for loading efficiency (Y1), micellar size (Y2) and polydispersity index (Y3) of input 
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variables were selected to determine the optimal formula with high loading, small size and 
narrow PDI.  
A Pareto chart was developed for each individual outcome to determine which factors 
and interactions were relevant. These charts were developed using the absolute value obtained 
from half the value of the main effects. The bars in the chart that extend past the line indicate 
values reaching statistical significance (α = 0.05). In the case of loading efficiency, individual 
variables i.e., HCO-40, OC-40 and buffer; two factor-interactions such as OC-40*pH; HCO-
40*sonication time and HCO-40*buffer were observed to pass the line indicating their 
statistically significant effect on loading efficiency (Figures 5-1). However, for micellar size 
and PDI interactions between the input factors did not cross the line and were thus insignificant 
(Figure 5-2 and 5-3). These results indicate that only drug loading was dependent on HCO-40, 
OC-40, buffer concentration and two factor interactions (OC-40*pH; HCO-40*sonication 
time; and HCO40*Buffer).      
A prediction profiler for loading efficiency, micellar size and PDI was also developed 
(Figure 5-4). This helps to determine the levels of input variables to be adjusted in a 
combination where the outcome can be predicted. The input variables HCO-40 (2.5 wt. %), 
OC-40 (1.005 wt. %), sonication time (2.5 min), pH (6.35) and buffer concentration (0.055 M) 
resulted in high loading efficiency (4.3 ± 0.5 %), which is evident from the results. The 
prediction profiler and experimental results are in excellent agreement. Therefore, the 
combination of variables at the above mentioned levels appeared to be the optimal formulation. 
Also, to determine the effects of input variables on the loading efficiency we developed a 
contour plot (data not shown) and surface profiles with actual data points (Figures 5-5, 5-6 and 
5-7). Contour plots are a three dimensional representation for the outcome where the input 
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variables are adjusted. From the contour plot one can estimate the levels of input variables and 
determine the outcome (present on the surface of the box). The shaded region in the contour 
plot indicates the lower drug loading region. In contrast, the unshaded region represents the 
higher loading zone. As variables are set at HCO-40 (2.5 wt. %), OC-40 (1.005 wt. %), 
sonication time (2.5 min), pH (6.35) and buffer concentration (0.055 M), a high loading 
efficiency can be predicted. Experimental design results and our experimental outcomes 
suggest that the polymer combination and manufacturing processes kept at a certain level, can 
yield higher drug loading, small size and narrow PDI. Our experimental results validate the 
predicted outcome. Taking input levels at adjusted levels, the loading efficiency was predicted 
to be 4.585 %. We prepared nanomicellar formulation following the procedure described 
previously and the loading efficiency was determined according to the RP-UFLC method. 
Results confirmed the average percent drug loading into the nanomicellar formulation to be 
4.6 ± 1.8, which is in agreement with the DOE. 
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Figure 5-1 Pareto chart for loading efficiency. * next to p-value 
represents significant term 
Figure 5-2 Pareto chart for PDI 
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Figure 5-3 Pareto chart for size 
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Figure 5-4 Prediction profiler for loading efficiency, size and PDI of B-C12-cCDF-loaded 
nanomicellar formulation 
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Figure 5-6 Response surface of loading efficiency. B-C12-cCDF-loaded nanomicelles 
loading efficiency is plotted as a function of HCO-40 and OC-40 amounts between -1 and 
+1 
Figure 5-5 Response surface of size. B-C12-cCDF-loaded nanomicelles size is 
plotted as a function of HCO-40 and OC-40 amounts between -1 and +1 
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5.4.3. Entrapment and loading efficiency 
B-C12-cCDF entrapment and loading into the polymeric nanomicelles were 
determined using RP-UFLC. A combination of different wt. % of polymers displayed a range 
of entrapment and loading efficiencies, which are summarized in Table 5-1. Among the various 
formulations developed, F3 exhibited the highest entrapment efficiency with optimal drug 
loading. Formulation F3 was therefore further characterized for size, PDI and surface 
morphology. 
Figure 5-7 Response surface of PDI. B-C12-cCDF-loaded nanomicelles PDI is plotted as a 
function of HCO-40 and OC-40 amounts between -1 and +1 
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5.4.4. Characterization 
Amphiphilic polymers tend to form core-shell structural nanomicelles in water. Herein, 
nanomicelles of HCO-40 and OC-40 were prepared by the solvent evaporation and film 
rehydration method. The micellar size is an important parameter for ocular drug delivery 
because small sized nanocarriers (<1000 nm) are highly effective in maintaining a low-level 
of RES uptake and minimal renal excretion 250. Moreover, topically applied therapeutic agents 
following conjunctival/scleral pathway penetrate ocular tissues by passive diffusion through 
scleral aqueous channels/pores (ranging from 30 to 300 nm in size) 251-252. DLS measurements 
exhibited nanomicelle formation with HCO-40/OC-40 within a size range of 10-30 nm and a 
PDI of 0.05-0.46. B-C12-cCDF-loaded nanomicelles were slightly smaller than B-C12-cCDF-
free nanomicelles. B-C12-cCDF-free nanomicelles (HCO-40:OC-40; 2.5:1.0) and B-C12-
cCDF-loaded nanomicelles showed an average size of 19.0 ± 0.5 nm and 17.73 ± 0.3 nm 
respectively (Figures. 5-8 A and B). The smaller size of B-C12-cCDF-loaded nanomicelles 
could be attributed to the strong hydrophobic interactions of the hydrophobic prodrug with the 
hydrophobic chains of the polymers. Additionally, the size and surface morphology of B-C12-
cCDF-loaded nanomicelles were also measured and observed by TEM. As shown in Figure 5-
8 C, the TEM microscopic image confirmed that polymeric nanomicelles were spherical in 
shape in aqueous medium with an average diameter close to the result of the DLS 
measurement. Surface morphology revealed smooth architecture without any nanomicellar 
aggregation. The size distribution of B-C12-cCDF-loaded nanomicelles and TEM microscopic 
images are depicted in Figures 5-8 A, B and C. 
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One of the objectives of this study was to achieve a clear aqueous solution of B-C12-
cCDF. The optical clarity of the formulation was compared with DI water as blank. As shown 
in Figure 5-8 D, the formulation clarity is similar to water with no suspended particulate matter 
in it due to extremely small size of these polymeric nanomicelles.  
5.4.5. CMC 
CMC is a critical factor which regulates the premature release of topically applied 
therapeutic agents.250 Such premature release of drug molecules is due to the presence of 
several static and dynamic ocular barriers. Tear dilution is one such barrier which contributes 
majorly to the loss of topically applied drugs 247. Out of the total dose applied topically, only 
less than 10% of the formulation is available for absorption. The instilled formulation replaces 
Figure 5-8 The size distribution of  (A) B-C12-cCDF-free nanomicelles and (B) B-C12-cCDF-
loaded nanomicelles; (C) TEM micrograph of B-C12-CDF-loaded nanomicelles; (D) B-C12-cCDF-
loaded nanomicellar formulation compared with DI water 
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the lacrimal fluid in precorneal pocket and occupies the desired space. The precorneal pocket 
can hold up to 10 µL of tear volume and the tear turnover rate is approximately 0.7 µL/min. 
Once a formulation is dropped in the cul de sac, it gets continuously diluted by the presence of 
tears. This may result in disruption of nanocarriers in contact with ocular membranes leading 
to drug release at the application site itself 253-254. Low CMC of the formulation is desired to 
prevent the disruption of nanocarriers including nanomicelles by tear dilution 255. In order to 
achieve reduced CMC of polymeric nanomicelles, blends of non-ionic surfactants were applied 
herein. The CMC of HCO-40/OC-40 polymeric nanomicelle was determined to be 0.033 wt. 
% measured by fluorescence spectrophotometry with iodine as the probe (Figure 5-9). A low 
CMC is an indicator of stable formulation.  
 
 
 
 
Figure 5-9 Fluorescence intensity ratios of iodine excitation bands (I460 nm/I286 nm) as a function 
of the concentration of HCO-40 and OC-40 aqueous solutions 
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5.4.6. 1H-NMR spectroscopy of B-C12-cCDF-loaded nanomicelles 
Process of nanomicelle formation and B-C12-cCDF encapsulation in nanomicelle core 
were studied with proton NMR spectroscopy. Separate 1H-NMR spectra for HCO-40, OC-40 
and blank and B-C12-cCDF-loaded nanomicelles were recorded and compared. Sharp 1H-
NMR signals from oxyethylene (-CH2-CH2-O) protons (δ=3.8 ppm) and weak signals from 
methyl (δ=0.9 ppm) and methylene (δ=1.3 ppm) protons of the hydrophobic chain for HCO-
40 were recorded (Figure 5-10). Similarly, for OC-40, sharp signals from oxyethylene protons 
and weak signals from methyl and methylene protons were recorded (Figure 5-11). In addition, 
aromatic protons (δ=7.3 ppm) on phenyl ring were recorded for OC-40. There was no 
significant difference observed in the spectra for blank and B-C12-cCDF-loaded nanomicelles 
(Figures 5-12 and 5-13). Since, the hydrophobic core of the nanomicelle lacks accessibility to 
polar solvents, no characteristic peaks from B-C12-cCDF were observed in B-C12-cCDF-
loaded nanomicelles implying that the drug was molecularly dispersed in the nanomicellar 
core. D2O peaks (δ=4.8 ppm) were recorded in all the cases except B-C12-cCDF which is in 
CDCl3 (Figures 5-14 & 5-15). 
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Figure 5-10 1H-NMR spectra for HCO-40 in D20 
Figure 5-11 1H-NMR spectra for OC-40 in D20 
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Figure 5-12 1H-NMR spectra for Blank nanomicelles in D20 
Figure 5-13 1H-NMR spectra for B-C12-cCDF-loaded nanomicelles in D20 
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Figure 5-14 1H-NMR spectra for B-C12-cCDF in d6-DMSO 
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5.4.7. In vitro B-C12-cCDF release 
  To investigate the prodrug release behavior from polymeric nanomicelles, we 
performed B-C12-cCDF release experiments with B-C12-cCDF-loaded nanomicelles in both 
PBST and STF at 37°C. As shown in Figure 5-16, a sustained release of B-C12-cCDF from 
the core of polymeric nanomicelles over a period of >1 month was achieved without any 
significant burst release. In presence of PBST, 75.5% B-C12-cCDF was released over a period 
of 34 days. However in STF, polymeric nanomicelles rapidly released B-C12-cCDF by 91.09% 
in 34 days. These results suggest that STF can alter nanomicelle permeability to a larger extent 
relative to PBST as measured by prodrug release. Thus, it is anticipated that topical application 
of B-C12-cCDF-loaded nanomicelles will sustain the release of B-C12-cCDF under 
Figure 5-15 1H-NMR spectroscopies for (a) B-C12-cCDF in d6-DMSO; (b) B-C12-cCDF-loaded 
nanomicelles; (c) Blank nanomicelles; (d) OC-40 and (e) HCO-40 in D20 
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physiological conditions leading to therapeutic concentrations in ocular tissues with low dosing 
frequency. However, one must also take into consideration the presence of the lipid monolayer 
on top of the tear film and its possible interaction with the polymers. The physicochemical 
properties and possible tear fluid factor(s) responsible for the observed increase in permeability 
still remains to be explored. In essence, CDF itself or its prodrug (B-C12-cCDF) can benefit 
immediately on short-term basis in reducing the viral load, but B-C12-cCDF-loaded 
nanomicelles may be effective for a longer time period due to slow release of prodrug from 
nanomicelles. Therefore, higher drug doses in nanomicelles can be administered and at the 
same time a single dose may produce a therapeutic effect for a prolonged time period given 
the IC50 of cidofovir to inhibit CMV plaque formation is just 0.9 μg/mL for Davis and 1.6 
μg/mL for AD-169 CMV strains, respectively256. In contrast, CDF or B-C12-cCDF may 
require frequent dosing leading to poor patient compliance.  
 
Table 5-2 Summary of fit for kinetic models and associated parameters for release of B-C12-
cCDF from nanomicelles 
Release 
medium 
Kinetic and Mechanistic Models 
Higuchi 
Model 
Korsmeyer-Peppas 
model 
Hixson-
Crowell 
model 
Zero 
Order 
First order 
R2 R2 n R2 R2 R2 Rate 
constant k 
(Hour-1) 
PBST 0.9433 0.9686 1.0085 0.9570 0.8878 0.9169 0.1045 
STF 0.9292 0.9888 1.0226 0.9889 0.9169 0.9325 0.1239 
 
The release data was fitted to various mechanistic models including Higuchi, Hixson-
Crowell and Korsmeyer-Peppas models to determine the kinetics of B-C12-cCDF release 
(Table 5-2). The best fit was found with the Korsmeyer-Peppas model with R2 of 0.9686 for 
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PBST and Hixson-Crowell model with R2 of 0.9889 for STF compared to other models. For 
STF, Korsmeyer-Peppas model also showed high R2 value of 0.9888 with n value 1.0085 and 
1.0226 for PBST and STF respectively. Value of diffusion exponent n >1 for Korsmeyer-
Peppas model suggests that mechanism of release followed super case II transport which 
mainly involves relaxation of polymer chains. The relatively close value obtained from 
Hixson-Crowell indicates that the drug release might be controlled by diffusion and erosion of 
polymer to some extent as well. Data was also fitted to zero- and first- order equations to 
determine the order of release. Process of release followed first order kinetics with R2 values 
of 0.9169 and 0.9325 for PBST and STF respectively indicating release rate is proportional to 
the prodrug concentration. Compared to PBST, release rate was faster in STF, as indicted by 
first order rate constant which can attributed to the higher concentration of surfactant in STF.  
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Figure 5-16 (A) Release and (B) amount remaining from B-C12-cCDF from B-C12-cCDF-loaded 
nanomicelles in PBST and STF (pH 7.4). The standard deviation for each data point was averaged 
over three samples (n=3) 
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5.4.8. Effect of molecular weight cut-off (MWCO) on drug release 
Apart from the release media, selecting an appropriate molecular weight cut-off 
(MCWO) for the dialysis membrane is crucial. It is anticipated that the prodrug released from 
the nanomicelles will diffuse rapidly from the inner compartment, through the dialysis 
membrane into the outer compartment due to concentration gradient. Although the rationale 
for selecting a MWCO is rather subjective, a sufficiently high membrane MWCO are often 
selected for in vitro release studies so that drug transport is not a limiting factor. For instance, 
a MWCO of 10–14 kDa was used to study drug release of small molecules like risperidone 
(MW: 410.493 g/mol) and indomethacin (MW: 357.79 g/mol), and a MWCO of 1 kDa for 
assessing in vitro release of a large molecule, pDNA, and cefuroxime axetil, a cephalosporin 
antibiotic (MW: 510.474 g/mol)257. Herein, results from in vitro release studies suggested, 
dialysis membrane with MWCO 1 kDa proved to be limiting for the diffusion of B-C12-cCDF 
(<20% released in 34 days). While MWCO of 2 kDa (>75% released in 34 days) was able to 
sufficiently permit prodrug transport across the dialysis membrane (Figure 5-17). 
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Figure 5-17 Cumulative prodrug release (percentage) from B-C12-cCDF-
loaded nanomicelles in PBST and STF (pH 7.4) in 34 days using dialysis 
membranes with molecular weights 1kDa and 2kDa. The standard deviation 
for each data point was averaged over three samples (n=3) 
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5.4.9. In vitro cytotoxicity assay 
D407, HCE-T or CCL 20.2 cells were co-cultured with B-C12-cCDF-free nanomicelles 
(HCO-40/OC-40) at concentrations ranging from 0.24 to 7.0 mg/mL. As shown in Figure 5-18 
A, D407, HCE-T or CCL 20.2 cells were not influenced by the addition of nanomicelles at any 
concentration compared with blank control, demonstrating the non-cytotoxic effect of the 
polymeric nanomicelles.  
 
 
In vitro cytotoxicity of B-C12-cCDF and B-C12-cCDF-loaded nanomicelles against 
D407, HCE-T or CCL 20.2 cells were determined by the MTT assay. As shown in Figures 5-
18 B, C and D, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles demonstrated dose-
Figure 5-18 (A) MTT assay of HCO-40/OC-40 polymeric nanomicelles in HCE-T, CCL 20.2 and 
D407 cell lines. Cytotoxicity of B-C12-cCDF and B-C12-cCDF-loaded nanomicelles in (B) D407, 
(C) HCE-T and (D) CCL 20.2 cell lines 
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dependent cytotoxicity to all cell lines studied. Compared to B-C12-cCDF, B-C12-cCDF-
loaded nanomicelles exhibited lower toxicity to D407, HCE-T or CCL 20.2 cells at the same 
concentration. Both, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles are internalized into 
cells solely by endocytosis releasing the drug at the target site. More importantly, more rapid 
release of drug from the prodrug in comparison to B-C12-cCDF-loaded nanomicelles can be 
the reason for their low cytotoxicity. Toxicity studies for cCDF have been previously reported 
and showed by our laboratory 145.  
In addition, the LDH assay was performed to confirm the results obtained from the 
MTT assay. Polymeric nanomicelles can interact with the cell membrane and enter into cells 
through endocytosis 258-259. Therefore, estimating the amount of LDH released into the 
surrounding culture medium could be a preferred way to estimate the extent of cell wall 
damage and thus cytotoxicity of polymeric nanomicelles.  The percentage of LDH released 
from D407, HCE-T and CCL 20.2 cells following 24 h of exposure to B-C12-cCDF, B-C12-
cCDF-free and B-C12-cCDF-loaded nanomicelles appeared to be negligible indicating no 
membrane damage. Approximately 17.16% and 19.01% LDH were released from CCL 20.2 
cells treated with CDF 100 µM and 250µM respectively (Figure 5-19). However, prodrug and 
the prodrug-loaded nanomicellar formulation did not cause any membrane damage or toxicity. 
Therefore, it appears that this nanomicellar formulation is suitable for ocular application. 
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5.4.10. In vitro biocompatibility studies 
RAW-264.7 cells are widely utilized as in vitro cell culture model for determining the 
biocompatibility of polymeric materials intended for human applications. In this study, we 
examined the cytokine (TNF-α, IL-6, and IL-1β) release into the culture supernatant following 
24 h of exposure to CDF, B-C12-cCDF, B-C12-cCDF-free and B-C12-cCDF-loaded 
nanomicelles. Samples were analyzed via a sandwich ELISA assay. Results depicted in Figure 
5-20, indicate significant release of TNF-α, IL-6, and IL-1β following LPS exposure. However, 
no significant release of TNF-α, IL-6, and IL-1β was observed when sample were treated with 
Figure 5-19 LDH assay after 24 h of exposure to CDF, B-C12-cCDF, B-C12-cCDF-free 
nanomicelles and B-C12-cCDF-loaded nanomicelles to D407, HCE-T and CCL 20.2 cells  
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different concentrations of CDF, B-C12-cCDF, B-C12-cCDF-free and B-C12-cCDF-loaded 
nanomicelles relative to negative control (cells without treatment). These results suggest that 
B-C12-cCDF-loaded nanomicelles are suitable for in-vivo applications. 
 
 
5.4.11. In vitro cellular uptake of B-C12-cCDF-loaded nanomicelles 
Experiments on cellular uptake and prodrug release from B-C12-cCDF-loaded 
nanomicelles were performed on D407 and HCE-T cells by FCM and CLSM. To validate 
cellular uptake, D407 and HCE-T cells were incubated with FITC-tagged CDF, B-C12-cCDF 
and B-C12-cCDF-loaded nanomicelles for 2, 12 and 24 h and then monitored with CLSM. As 
Figure 5-20 In vitro release of TNF-α, IL-6, and IL-1β from RAW 264.7 cells following 24 h 
exposure of CDF, B-C12-cCDF, B-C12-cCDF-free micelles and B-C12-cCDF-loaded 
nanomicelles. Results are given as mean ± SD, n = 4 
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illustrated in Figures 5-21 A and B, B-C12-cCDF-loaded nanomicelles show weak FITC 
fluorescence in the cytoplasm after 2 h, indicating slow internalization of nanomicelles into 
the cells. After 12 h of incubation, significant amounts of FITC-tagged B-C12-cCDF and B-
C12-cCDF-loaded nanomicelles were observed inside the cell cytoplasm. In contrast, weaker 
FITC fluorescence was observed in cells treated with FITC-tagged CDF. With further 
incubation for 24 h, the FITC fluorescence intensity inside the cells increased and the 
accumulation of FITC-tagged B-C12-cCDF-loaded nanomicelles in the cell cytoplasm and 
nuclei became more evident. Cells incubated with B-C12-cCDF-loaded nanomicelles 
exhibited strong FITC fluorescence indicating accumulation of prodrug loaded nanomicelles 
inside the cells. Consequently, no burst release was observed for B-C12-cCDF-loaded 
nanomicelles. These results are consistent with the cytotoxicity results for B-C12-cCDF-
loaded nanomicelles. These prodrug-loaded nanomicelles showed minimal cytotoxicity 
because of slow and sustained release of B-C12-cCDF from the hydrophobic core of the 
nanomicelles. However, relatively lower fluorescence signals of FITC-tagged B-C12-cCDF 
and B-C12-cCDF-loaded nanomicelles in D407 cells could be attributed to higher expression 
of tight junction proteins, including zonula occludens-1 (ZO-1), occludin, claudin-1, claudin-
2, claudin-3, claudin-4, and claudin-5. Additionally, the trans epithelial electrical resistance 
(TEER) offered by D407 cell monolayer is ~300 Ωcm2 which increases rapidly during the 
initial 7 days of culture unlike HCE-T cells (~300-600 Ωcm2) 260-261. The higher resistance 
offered by D407 cells impedes the penetration of the treatment groups to an extent thus 
justifying the difference in cellular accumulation of B-C12-cCDF and B-C12-cCDF-loaded 
nanomicelles in D407 and HCE-T cells.   
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The drug accumulation was further evaluated in D407 and HCE-T cells incubated with 
FITC-tagged CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles by FCM (Figures 22 
A and B). The outcome was consistent with the CLSM results. Figures 23 A and B show the 
mean FITC fluorescence intensity in D407 and HCE-T cells after incubation with FITC-tagged 
CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles for 0.5, 2, 6, 12 and 24 h. Mean 
Figure 5-21 Confocal laser scanning microscopy images of (A) D407 and (B) HCE-T cells after incubation 
with (i) CDF, (ii) B-C12-cCDF and (iii) B-C12-cCDF-loaded nanomicelles. CDF, B-C12-cCDF and B-C12-
cCDF-loaded nanomicelles were added at a final concentration of 15 µg/mL. Blue and green fluorescence 
shows the nuclei and FITC conjugated drug/prodrug respectively. Scale bar is 20 µm 
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fluorescence intensity (MFI) of cells treated with B-C12-cCDF-loaded nanomicelles was 
higher than cells incubated with CDF and B-C12-cCDF at 24 h. The fluorescence signals are 
associated with the accumulation of B-C12-cCDF-loaded nanomicelles. Enhanced 
intracellular fluorescence in cells treated with FITC-tagged B-C12-cCDF-loaded nanomicelles 
at 24 h was due to higher stability and permeation of nanomicelles across various ocular 
barriers efficiently. These results are in accordance with our expectation that the blend of 
polymers can impart higher stability to the prodrug conjugate in the hydrophobic core of the 
nanomicellar structure and would sustain the release of the prodrug correlating with the CLSM 
and in vitro cytotoxicity results. 
 
 
A 
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Figure 5-22 FACS analysis of uptake of CDF (blue), B-C12-cCDF (green) and B-C12-cCDF-
loaded nanomicelles (yellow) for 0.5 h, 2 h, 6 h, 12 h and 24 h in (A) D407 and (B) HCE-T cell 
lines. CDF, B-C12-cCDF and B-C12-cCDF-loaded nanomicelles were added at a final 
concentration of 50 µg/mL. *P ≤ 0.05, compared to corresponding control group (red). #P ≥ 0.05, 
compared to corresponding control group 
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Figure 5-23 Overlay of FACS analysis of B-C12-cCDF-loaded nanomicelles uptake in 
comparison to CDF and B-C12-cCDF for 0.5 h (i), 2 h (ii), 6 h (iii), 12 h (iv) and 24 h (v) 
in (A) D407 and (B) HCE-T cell lines. CDF, B-C12-cCDF and B-C12-cCDF-loaded 
nanomicelles were added at a final concentration of 50 µg/mL. *P ≤ 0.05, compared to 
corresponding control group. #P ≥ 0.05, compared to corresponding control group 
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5.4.12. In vitro cellular transport of B-C12-cCDF-loaded nanomicelles 
Previous results showed significant uptake of FITC-tagged B-C12-cCDF-loaded 
nanomicelles at 24 h in both corneal and retinal cell monolayers. However, the question 
remains whether the drug loaded nanomicelles would be able to permeate corneal layers and 
reach retinal cells in vivo. For a delivery system to be effective to deliver drugs to back of the 
eye, drug molecules must cross the corneal barriers and reach the retinal cells. Although, 
corneal permeability of lipophilic drugs has been reported to be greater in comparison to 
hydrophilic drugs, their poor solubility and chances of getting detected by the RES system 
render them ineffective. 
In this study, we investigated the permeability of B-C12-cCDF-loaded nanomicelles in 
comparison to CDF and B-C12-cCDF. As shown in Figure 5-24, corneal cells (HCE-T) were 
grown on transwell filters in the upper chamber while bottom chamber contained retinal cells 
(D407). FITC-tagged B-C12-cCDF-loaded nanomicelles were added to the upper transwell 
filters which traversed to the bottom chamber through corneal monolayers reaching D407 cells. 
In contrast to previous uptake results, transport across corneal cells was negligible at 0.5 and 
2 h. However, significant transport was observed at 24 h as evidenced by a 7-fold (MFI) higher 
fluorescence in D407 cells by FITC-tagged B-C12-cCDF-loaded nanomicelles in comparison 
to the control group. Additionally, the amount of CDF and B-C12-cCDF transported across 
HCE-T cells remained almost the same at all-time points probably due to non-specific binding 
and precipitation of hydrophobic prodrug in the culture medium (Figures 5-25 and 5-26). 
Hence, these results suggest that HCO-40/OC-40 based polymeric nanomicelles might be a 
suitable carrier for back of the eye delivery of anti-viral prodrugs (B-C12-cCDF). 
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Figure 5-24 Schematic drawing of the preparation of the in vitro corneal-retinal 
model. Human corneal epithelial cells (HCE-T) were grown for 10 days in the 
transwell inserts until all the different layers of corneal cells were established 
completely. Similarly, retinal pigment epithelial cells (D407) were seeded at the 
bottom chamber of 12-well plates and were grown for 10 days. Cells were 
grown in DMEM culture medium. Experiments were performed on day 11 
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Figure 5-25 FACS analysis of uptake of CDF (blue), B-C12-cCDF (green) and B-C12-cCDF-
loaded nanomicelles (yellow) for 0.5 h, 2 h, 6 h, 12 h and 24 h in transwell diffusion chamber with 
HCE-T & D407 cell lines. CDF, B-C12-cCDF and B-C12-cCD-loaded nanomicelles were added at 
a final concentration of 50µg/mL. *P ≤ 0.05, compared to corresponding control group. #P ≥ 0.05, 
compared to corresponding control group 
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Figure 5-26 Overlay of FACS analysis of B-C12-cCDF-loaded nanomicelles uptake 
in comparison to CDF and B-C12-cCDF for 0.5 h (i), 2 h (ii), 6 h (iii), 12 h (iv) and 
24 h (v) in transwell diffusion chamber with HCE-T & D407 cell lines. CDF, B-
C12-cCDF and B-C12-cCDF-loaded nanomicelles were added at a final 
concentration of 50 µg/mL. *P ≤ 0.05, compared to corresponding control group. #P 
≥ 0.05, compared to corresponding control group 
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5.5. Conclusions 
A clear, stable aqueous B-C12-cCDF-loaded polymeric nanomicelle was prepared and 
optimized by full factorial statistical DOE using JMP. A specific blend of polymers (HCO-
40/OC-40) at a wt. % ratio of 2.5:1.0 produced excellent drug entrapment, loading, small size 
and narrow PDI. In vitro release studies revealed that in the presence of STF, B-C12-cCDF-
loaded nanomicelles released B-C12-cCDF more rapidly relative to PBST. Cell experiments 
showed that self-assembled B-C12-cCDF-loaded nanomicelles were highly stable and able to 
permeate various ocular barriers efficiently with minimal toxicity in D407, HCE-T or CCL 
20.2 cells. Biocompatibility studies further unraveled the non-cytotoxic nature of these 
polymeric nanomicelles. Cellular uptake studies in D407 and HCE-T cells revealed 
internalization of B-C12-cCDF-loaded nanomicelles in the cytoplasm and nuclei after 24 h. 
Permeability experiments across HCE-T /D407 cells further confirmed the potential of B-C12-
cCDF-loaded nanomicelles in transporting the prodrug across multiple cell layers. Therefore, 
HCO-40/OC-40 based polymeric nanomicelles hold potential as promising carriers for the 
delivery of anti-viral prodrugs such as B-C12-cCDF for a prolonged period of time, affording 
enhanced CDF effects in the back of the eye. 
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CHAPTER 6 
6. OCULAR DELIVERY OF PROTEINS AND PEPTIDES: CHALLENGES AND 
FORMULATION APPROACHES 
6.1. Rationale 
In the past few decades, since the first approval of a protein- based biopharmaceutical 
in 1982 (Humulin®; recombinant human insulin; Eli Lilly, Indianapolis), the approval rate of 
protein and peptide based biopharmaceuticals has grown significantly 262. Of the top 10 
pharmaceutical products by sales in 2014, a majority was biopharmaceuticals including 
recombinant therapeutic proteins, peptides, enzymes, monoclonal antibodies and antibody-
drug conjugates. From 1982 to 2014, the total number of licensed biopharmaceutical products 
advanced from 13 to 246 in the United States (US) and European Union (EU; Brussels). The 
worldwide sales of biopharmaceutical drugs was estimated to be $289 billion in 2014 and are 
projected to grow to $445 billion by 201998. Among these, the rapidly growing monoclonal 
antibody (mAb) therapeutics market itself has currently resulted in global sales of over US$50 
billion 263. Likewise, the ophthalmic protein- and peptide-based biopharmaceutical drug 
market has witnessed a tremendous growth since the introduction of the anti-vascular 
endothelial growth factor (anti-VEGF) aptamer in 2004 (Macugen®; Pegatanib sodium; OSI 
Pharmaceuticals, New York) and monoclonal antibody in 2006 (Lucentis®; Ranibizumab; 
Genentech, California). The global sales of biopharmaceutical drugs for ophthalmic 
indications had exceeded $8 billion in 2016, with about 16% annual growth rate (2011-
2016)264. A recent survey of ophthalmology market research revealed biologics and drug 
delivery systems to be the sectors that are anticipated to show strong growth in the next five 
years265 (Figures 6-1 and 6-2). 
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Figure 6-1 Numbers of Phase 3 products by technology type for ophthalmic 
indications (Till Nov., 2015): MIGS (minimally invasive glaucoma surgery); 
NCE (New chemical entity). 
 
Figure 6-2 Number of companies classified by technology as well as global areas 
for ophthalmology market: This analysis does not include multinational 
companies, as these entities cannot be defined by a single technology and any one 
country. Note that the classification “Europe” excludes Scotland to avoid double 
counting 
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In addition to global sales and market, ophthalmology has garnered quite startling 
investments in terms of research funding in comparison to other disease areas indicating the 
urgent need for advanced therapeutic approaches for the treatment of chronic ocular diseases266 
(Figure 6-3).   
 
 
While over 900 new biopharmaceutical entities are in pipeline, targeting diseases 
across a wide range of therapeutic areas, the emergence of biosimilars is anticipated to 
represent the biggest shift in biologic approval landscape267. The U.S. patents for blockbuster 
Lucentis® will be expiring in 2019 and several biosimilar manufacturers are already targeting 
that molecule268. The current ophthalmic drug delivery technologies are tailored to non-
targeted small molecules/drugs.  
Biopharmaceuticals including proteins and peptides have shown great promise as novel 
therapeutics in the treatment of ocular diseases. These large molecules offer several advantages 
Figure 6-3 Novel drug R&D venture funding by disease area, 2004-2008 vs 
2009-2013 
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compared to small molecule drugs with respect to high potency, activity, low unspecific 
binding, less toxicity, minimization of drug-drug interaction, biological and chemical diversity 
269-270. However, these macromolecules also face various challenges such as physical and 
chemical degradation, short in vivo half-lives, circulation, and distribution. Additionally, 
macromolecules lack efficient and specific delivery to the target sites. Besides these, clearance 
by the mononuclear phagocytes (MPS) of the reticuloendothelial system (RES), risk of 
immunogenic effect, high molecular weight (MW), structural complexity, and failure to 
permeate cell membranes further reduce their therapeutic efficacy 271. For these reasons, there 
is a need to develop novel ophthalmic biopharmaceutical drugs and delivery systems, ideally 
targeting these macromolecules to biologically relevant ocular tissues.   
In this chapter, an introduction on proliferative diabetic retinopathy (PDR), role and 
mechanism of action of octreotide in PDR, challenges associated with large molecules and 
designing ocular formulation, routes of delivery and a multi-layered nanomicelle approach will 
be discussed.  
6.2. Proliferative diabetic retinopathy (PDR) 
Diabetes mellitus is an epidemic with global prevalence that is dramatically inflating 
and is predicted to reach 592 million by 2035 272. Diabetic retinopathy (DR) is the most 
common microvascular manifestation of diabetes significantly affecting visual acuity on a 
global scale and is the leading cause of blindness in American adults273. DR can be broadly 
categorized into the earlier stage of nonproliferative diabetic retinopathy (NPDR) and the 
advanced stage of PDR and/or diabetic macular oedema (DMO) 274. In PDR/DMO, progressive 
nonperfusion of the retinal vascular bed occurs resulting in regions of ischemia and impaired 
oxygenation of the metabolically demanding retinal neurons. The resultant ischemic retina is 
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driven by hypoxia and expression of pro-angiogenic growth factors that further stimulate 
aberrant new blood vessels formation in the retina protruding into the preretinal space (Figure 
6-4). Such retinal neovascularization leads to vitreous hemorrhage or retinal detachment 
leading to severe vision loss 1. 
  
6.3. Role of octreotide in PDR 
PDR has multifaceted pathogenesis. Thus, pharmacological therapies targeting 
multiple PDR mechanisms may provide more effective treatment strategies. Currently 
available therapies include anti-VEGF medication, laser photocoagulation and vitrectomy 275. 
With the early identification of role of pituitary gland in PDR, somatostatin, a naturally 
Figure 6-4 An illustrated schematic of normal retina compared with early proliferative diabetic 
retinopathy (PDR). Reprinted with permission from Duh et al. 1 
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occurring pituitary growth hormone (GH) secretion inhibitor was realized to play a potential 
role in mitigating retinal neovascularization 3. GH secretion from anterior pituitary results in 
the synthesis of insulin-like growth factor-1 (IGF-1) that acts as a mediator of GH’s mitogenic 
actions and results in acute retinopathy progression. Octreotide, a somatostatin analog (Figure 
6-5) inhibits GH, glucagon and insulin secretion more actively than native somatostatin 276. 
Octreotide also acts via G-protein coupled receptors, exerting its direct antiproliferative effect 
by cell cycle arrest via somatostatin receptor-2 (SSTR2), apoptosis via SSTR3 stimulation and 
SSTR1-mediated effects on angiogenesis 277-279. However, poor bioavailability in ocular 
tissues due to short half-life (2 hours) and large molecular weight (1,019.24 g/mol) has limited 
its therapeutic success.  
 
Figure 6-5 Amino acid compositions for both native somatostatin 14 and 
the synthetic octapeptide analog octreotide. Reprinted with permission 
from Grant et al. 3 
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6.4. Ocular diseases: current biologics based treatments 
Millions of people worldwide suffer from a wide variety of ocular diseases. A majority 
of these pathologies lead to irreversible blindness thereby substantially reducing quality of life. 
The number of visually impaired people has escalated to 285 million worldwide currently. In 
the United states alone, one million people were legally blind (visual acuity of 20/200 vision 
or worse) while 3.2 million suffered from visual impairment and another 8.2 million had vision 
problems due to uncorrected refractive error in 2015. The number of these conditions are 
projected to double by 2050280.  
The last few decades have witnessed a considerable growth in the understanding of the 
pathogenesis and genetics of ocular diseases. Deciphering various compliment pathways, gene 
associations and pharmacological interventions for retinal diseases have led to substantial 
development of effective therapies281. The major ocular diseases that have significantly 
impacted vision worldwide include age-related macular degeneration (AMD), cataracts, 
diabetic retinopathy (DR), dry eye conditions and glaucoma. The treatment market for 
glaucoma had the largest market share in 2013 with product sales (both branded and generic) 
exceeding US$ 4.5 billion (£ 2.9 billion) in the United States, Europe and Japan combined. 
Age related diseases including cataracts, AMD and diabetic retinopathy are expected to 
become more common with aging populations in developed countries265. Table 6-1 lists FDA 
approved biopharmaceuticals for ocular indications. 
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Table 6-1 List of FDA approved biopharmaceutical drugs for ocular delivery 
Drug MW (kDa) 
Route of 
administration 
Half-life 
FDA 
approval 
Indication 
Adalimumab 
(Humira®) 
148 Subcutaneous  ~2 weeks 
(human) 
July 2016 Uveitis 
Aflibercept 
(Eylea®) 
115 Intravitreal 3.63 days 
(rabbit); 7.1 
days (human) 
November 
2011 
Wet AMD 
Ranibizumab 
(Lucentis®) 
48 Intravitreal 2.88 days 
(rabbit); ~9 days 
(human) 
June 2006, 
August 
2012 
Wet AMD, 
DME 
Pegatanib 
sodium 
(Macugen®) 
50 Intravitreal ~10 days 
(human) 
December 
2004 
Wet AMD 
Bevacizumab 
(Avastin®) 
150 Intravitreal 4.32 days 
(rabbit); 4.9 
days (human) 
Off-label Wet AMD 
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Table 6-2 Proteins and peptides currently in clinical trials for various ocular complications 
Protein/peptide 
drug 
Description MW 
(kDa) 
Target/a
ctivity 
Half-
life 
Company Current 
indicati
on 
Phase Ref. 
AGN-150998 
(Abiciparpegol) 
Recombinant 
ankyrin repeat 
protein 
34 VEGF-
A 
~2 
weeks 
Allergan Wet 
AMD 
Phase 
III 
NCT02462
486; 
NCT02462
928 
ALG-1001 
(Luminate®) 
Integrin peptide 1 Integrin 
receptor
s 
~3 
month
s 
Allegro 
Ophthal
mics 
DME, 
NPDR 
Phase II NCT02348
918 
Conbercept 
(Lumitin®) 
Recombinant 
fusion protein 
143 VEGF-
A/B, 
PGF-1 
~1 
week 
Chengdu
-
Kanghon
g 
Wet 
AMD, 
DME 
Chinese 
FDA 
Phase 
III/ 
Phase II 
NCT01809
236 
GSK933776 Anti-amyloid β 
antibody 
NA Amyloid 
β fibrils 
~12 
days 
GlaxoSm
ithKline 
Dry 
AMD 
Phase II NCT01342
926 
iSONEPTM 
(SphingomabTM) 
Humanized 
antibody 
~49 S1P More 
than 4 
days 
Lpath Wet 
AMD 
Phase II NCT01414
153 
Lampalizumab Antigen-
binding 
fragment of a 
47 CFD ~6 
days 
Roche Geogra
phic 
atrophy 
Phase 
III 
NCT02247
479 
147 
Protein/peptide 
drug 
Description MW 
(kDa) 
Target/a
ctivity 
Half-
life 
Company Current 
indicati
on 
Phase Ref. 
humanized 
monoclonal 
antibody 
seconda
ry to 
AMD 
RN6G (PF-
4382923) 
Anti-amyloid β 
antibody 
NA Amyloid 
β fibrils 
NA Pfizer Dry 
AMD 
Phase II NCT01003
691 
RTH258 
ESBA1008 
Antibody 
fragment 
26 VEGF-
A 
~5 
days 
Novartis 
AG 
Wet 
AMD 
Phase 
III 
NCT02507
388 
VGX-300 (OPT-
302) 
Recombinant 
fusion protein 
NA VEGF-
C/D 
NA Circadian 
Opthea 
Wet 
AMD 
Phase I NCT02543
229 
HI-con1 Recombinant 
fusion protein 
NA Tissue 
factor 
NA Iconic 
Therapeu
tics 
AMD Phase II NCT02358
889 
Zimura Aptamer ~50 Comple
ment 
factor 
C5 
 Ophthote
c 
Corporati
on 
AMD, 
IPCV 
Phase 
II/III 
NCT02686
658 
NCT02397
954 
NPDR, nonproliferative diabetic retinopathy; S1P, sphingosine 1-phosphate; IPCV, Idiopathic polypoidal choroidal vasculopathy 
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6.5. Proteins and peptides: challenges in ocular delivery 
Proteins and peptides, as a class of biopharmaceuticals, pose significant challenges 
owing to their large size, poor permeation and susceptibility to degradation.  Understanding 
the intrinsic properties associated with the complex macromolecular nature of proteins and 
peptides is often required for achieving high biological activity. However, such structural 
complexity also renders them as one of the most challenging classes of therapeutics to be 
formulated and delivered. Short half-lives of peptides and low stability especially of protein 
drugs at physiological pH and temperature or during storage, leads to loss of activity, thus 
putting significant burden on formulation technologies (Table 6-2).  
6.5.1. Adverse physicochemical properties of proteins and peptides 
6.5.1.1. Hydrophilicity  
Most of the therapeutic proteins and peptides are highly hydrophilic (log P<0) which 
hinders their permeability across biological membranes. Bioavailability of proteins and 
peptides depends on their ability to cross these membranes. Poor membrane permeation of 
macromolecules often embodies added challenge in development of protein- and peptide-based 
drug formulations to intracellular target sites. The lipophilic nature of biological membranes 
restricts these macromolecules from spontaneously entering cells. The absorption of these 
macromolecules is not governed by simple diffusion or passive absorption. Rather active 
transport which involves binding to specific receptor, pinocytocis or endocytosis are the major 
mechanisms responsible for absorption 282-283. Permeation of hydrophilic molecules is hindered 
by the tight junctions present in the cornea and the lipophilic nature of the corneal epithelium 
284-285 whereas hydrophobic molecules permeate corneal epithelium easily. Additionally, the 
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collagen fibers present in the hydrophilic stroma may impede penetration of hydrophobic drugs 
to some extent. Under certain circumstances, small peptides or even small particles are taken 
from the extracellular space into cells by an active transport mechanism known as receptor-
mediated endocytosis [60]. One of the major disadvantages of proteins and peptides entering 
into the cell via endocytic pathway is their entrapment into the endosomes and eventually in 
lysosomes, where majority of the degradation processes undergoes by the action of lysosomal 
enzymes286. This leads to only a small fraction of unaffected proteins/peptides appearing in the 
cytoplasm. So far, multiple and partially successful attempts have been made to deliver protein 
and peptide based biopharmaceuticals directly into the cell cytoplasm bypassing the endocytic 
pathway. Mechanical delivery methods like microinjection and electroporation have been used 
for decades for cell cytoplasm delivery, but are low-throughput and invasive and require 
specialized equipment to physically puncture membranes287. The delivery of biologics via most 
favored “oral route” is highly challenging due to GI mucosa and degradative acidic 
environment. A large fraction of approved and investigational protein and peptide molecules 
are administered via parenteral routes (IV, IM or SC), intravitreal and sub conjunctival 
injections288. However, non-targeted delivery of protein- and peptide-based formulations may 
lead to distribution into normal tissues requiring large quantities of drug administration, which 
is often not economical and sometimes complicated owing to non-specific toxicity289. 
6.5.1.2. Large molecular weight  
Another major challenge for the delivery of protein and peptide based drugs is their 
high molecular weight and poor membrane permeability across ocular tissues and barriers. 
Such challenges have promoted highly invasive intravitreal injection as the primary mode 
administration for protein and peptide based drugs.  The molecular weights of peptides and 
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proteins are generally > 1000 Da with large hydrogen bonding donor/ acceptor groups 290. Such 
large size of macromolecules limits  diffusion and renders patient compliant topical treatment 
highly inefficient (Table 6-3). The cornea, sclera and retina have tight junctions that 
significantly limits diffusion of hydrophilic large molecules 291-292. The tight junctional space 
of conjunctival epithelium is generally wider than cornea, but still insufficient for the 
penetration of these large molecules 130, 293.  The human retina limits the diffusion of molecules 
greater than 76 kDa due to the inner and outer plexform layers. Macromolecules greater than 
150 kDa fail to reach the inner retina 291. Additionally, choriocapillaries may wash out the 
molecules that traverse through choroid thus reducing therapeutic concentrations. The ocular 
anatomy and tissue barriers are shown in Figure 6-6. 
 
 
 
Figure 6-6 Ocular anatomy and tissue barriers 
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Table 6-3 Permeability of proteins, peptides and macromolecules across ocular barriers 294 
Compound MWa (Da) Tissue Animalb Permeability 
Serum albumin 66000 cornea H 5.48E-07 
Inulin 5000 cornea R 5.50E-07 
Cyclosporine 1201 cornea R 1.10E-05 
Deoxycorticosterone 330 cornea R 4.00E-05 
Progesterone 314 cornea R 2.00E-05 
Testosterone 288 cornea R 4.20E-05 
     
Immunoglobulin 140000 stroma R* 8.00E-09 
Hemoglobin 64500 stroma O 5.70E-07 
Serum albumin 65000 stroma R 1.40E-07 
     
Dextran 75000 endothelium R 7.50E-07 
Serum albumin 65000 endothelium R 8.30E-09 
Poly(vinylpyrrolidone) 45000 endothelium R 3.80E-07 
Dextran 16000 endothelium R 2.70E-05 
Inulin 5000 endothelium R 1.40E-06 
     
Bevacizumab 145000 sclera H 5.30E-07 
Dextran-70 70000 sclera H 1.90E-06 
Serum albumin 65000 sclera C 1.30E-07 
Hemoglobin 64500 sclera C 3.60E-07 
Dextran-40 40000 sclera H 4.30E-06 
Dextran-10 10000 sclera H 6.20E-06 
Inulin 5000 sclera C 1.90E-06 
Inulin 5000 sclera H 9.00E-06 
Inulin 5000 sclera R 2.50E-06 
Hydrocortisone 362 sclera C 6.50E-06 
    0 
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Compound MWa (Da) Tissue Animalb Permeability 
Inulin 5000 conjunctiva R* 3.80E-06 
     
FITC-dextran 77000 RPE-choroid C 2.70E-08 
 
a (MW) Molecular weight  
b Source of tissue (R) rabbit, (C) cow, (O) ox, (H) human 
All permeability measurements were obtained from in vitro experiments except those followed by an asterix (*), 
which were obtained from in vivo.  
6.5.1.3. Metabolic instability  
Proteins and peptides also suffer from a number of physical, chemical and biological 
instability issues due to their complex secondary, tertiary and quaternary structures. Various 
physical degradation pathways are involved in the instability of proteins and peptides including 
denaturation, adsorption, aggregation and precipitation. Moreover, conformational 
transformation of proteins to inactive forms occur due to pH, temperature, high salt 
concentration; dissociation of subunit proteins; complexation of enzymes and cofactors; non-
covalent complexation with ions, proteolytic degradation under the influence of esterases and 
proteases. Chemical modifications by different compounds (for instance oxidation of SH-
groups in sulfhydryl containing enzymes and Fe (II) atoms in heme containing proteins; thiol-
disulfide exchange and destruction of labile side-chains of tryptophan and methionine) may 
also lead to inactivation of various biologically active protein- and peptide-based drugs in 
ocular tissues 270. 
In the body, the chemical degradation pathways of peptides and proteins include 
deamidation, oxidation and reduction, proteolysis, disulfide exchange and β-elimination 295. 
Any alteration in “active” confirmation may lead to loss of activity and irreversible aggregation 
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of proteins. Vulnerability towards enzymatic degradation under in vivo condition results into 
shorter half-lives even with parenteral administration. Inside the vitreous humor the half-life 
of large molecule tends to be in the range of days to weeks 125. For instance, the average 
apparent plasma half-life of pegaptanib is 10 days after 3 mg dose whereas ranibizumab 
remains for 2.88 days in rabbit296. Half-life of bevacizumab is 4.32 days with maximum 
concentration 162 μg/ml in vitreous cavity 297. In AMD, the vitreous elimination of ranizumab 
is just 9 days and intrinsic systemic elimination half-life is 2 hours followed by multiple 
intravitreal injection dose of 0.3-2.0 mg/eye biweekly or monthly 298. Such short half-lives of 
proteins requires frequent parenteral administrations to maintain therapeutic levels. Frequent 
parenteral administrations reduce patient compliance and/or are not well tolerated and often 
associated with complications including cataract, retinal hemorrhage and detachment 299.    
6.5.2. Challenges in designing protein and peptide based ocular formulations 
The formulation of protein- and peptide-based bio therapeutics poses unique challenges 
that are not often experienced with small molecules. Overcoming the instability of protein- and 
peptide-based agents due to structural properties and environmental factors is one of the key 
challenges in the development of formulations. Several agents have been incorporated 
including small sugars (e.g. trehalose) and polysaccharides (e.g. dextrans) to enhance the 
stability of protein and peptide based biopharmaceuticals 300-301. Pluronics and non-ionic 
surfactants such as polysorbates at low concentrations are widely applied to decrease protein 
and peptide aggregation 302.  
Another major drawback of biopharmaceutical drug formulations is high and variable 
viscosity. For topical ophthalmic formulations, corneal contact time is longer with increased 
viscosity of formulations up to 20 centipoise (cP) 303. However, a further increase in viscosity 
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leads to reflex tearing and blinking in order to regain the original viscosity of the lacrimal fluid 
(1.05–5.97 cP). With a rise in clinical application of monoclonal antibodies, the need for high 
protein doses (concentrated formulations) is often crucial. The FDA does not permit the 
intravitreal injection of large volumes of drug formulations in patients with ocular diseases239. 
Such requirements render formulation of protein- and peptide-based biopharmaceuticals very 
difficult as solutions with high protein content are exceedingly viscous. High viscosity of 
protein and peptide based biopharmaceuticals also greatly affects the syringeability (time 
required to complete the injection) as well as the force required to deliver the solution with 
appropriate needles (18 mm in length, 27-30G) 269. Thus, approaches to achieve lower viscosity 
formulations with hydrophobic/inorganic salts or lysine and arginine may be useful.   
It is also important for protein- and peptide-based biopharmaceutical formulations to 
have the same pH as the lacrimal fluid to achieve maximum activity. However, proteins and 
peptides are often not stable at physiological pH leading to their folding and aggregation. 
Additionally, the buffer capacity of such formulations is of equal importance for proper 
preservation. Although, the buffering action of the tears is capable of neutralizing the effect of 
topically applied biopharmaceutical formulations304, intraocular hyperosmotic solutions have 
been reported to elicit transient desiccation of the anterior chamber tissues while hypotonic 
solutions may cause edema leading to corneal clouding305. For this reason, pH of such 
formulations are compromised and maintained by buffers to achieve maximum activity and 
maintain stability306.  The effect of buffers on tonicity should also be taken into account 
considering the permissible limits of osmolarity for ophthalmic formulations (171-1711 
mOsm/kg).  Although many of these agents utilized for maintaining the stability and activity 
of such protein- and peptide-based biopharmaceutical formulations have been proven to be 
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effective, their use requires careful consideration in terms of local toxicity and potential 
immunogenicity.  
A better understanding of the viscosities of biological solutions, characteristics of 
nascent proteins and peptides, dynamics and behavior of protein- and peptide-based topical 
and injectable formulations is crucial. Towards this goal, utilization of chemical chaperones to 
inhibit protein misfolding as well as reactivate non-native protein structures,307-308 and/or co-
administration of recombinant human hyaluronidase with drug to degrade hyaluronic acid (a 
key structural component of tissues) to facilitate protein and peptide delivery may prove to be 
useful in addressing formulation challenges309. 
6.6. Routes of protein and peptide delivery to ocular tissues 
Challenges to ocular delivery of biopharmaceuticals are noteworthy, and considerable 
opportunities remain to be optimized for delivery approaches, formulation and processing 
conditions for each peptide- and protein-based therapeutics.  
6.6.1. Systemic delivery 
Oral administration and parenteral injections are the most common methods of 
systemic delivery. However, attempts to deliver large hydrophilic protein and peptide based 
biopharmaceuticals for ocular indications have seen limited success310. The small size of the 
eye and presence of ocular barriers prevent drug partitioning into the eye even for small 
molecules. Furthermore, dilution effect of the systemic blood volume, first-pass metabolism 
by the liver and clearance by kidney require larger drug doses which can result in high costs, 
systemic side-effects and possible toxicity311.  
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The integrity of ocular barriers seems to play a major role in the penetration of 
biopharmaceuticals. A clinical study showed an increase in visual acuity by 14 letters after 
treatment with 3 doses of systemic bevacizumab (5mg/kg) in patients with classic choroidal 
neovascularization (CNV) probably facilitated by the compromised RPE layer 312. Rohrer and 
co-authors also reported reduced CNV size and preserved retinal function after intravenous 
administration of fusion protein CR2-fH (where CR2 is complement receptor 2 and fH is factor 
H) indicating CR2-fH accesses the site of CNV by way of the impaired BRB. CR2-fH plays a 
critical role in regulating the inflammatory responses by inhibiting complement activation 
products in AMD 313-314. Although, no serious ocular or systemic side-effects were observed 
in both the cases, high concentration of injected drug or fusion proteins should be taken into 
consideration. Such shortcomings preclude systemic administration of protein- and peptide-
based biopharmaceuticals for ocular delivery expensive and rare. 
6.6.2. Extraocular delivery 
6.6.2.1. Topical delivery  
Topical instillation of ophthalmic drops has been the method of choice for 
administering pharmaceutical agents for the treatment of ocular diseases particularly that 
manifest on the ocular surface and/or the anterior segment239.  This route has been extensively 
utilized clinically for the treatment of diseases affecting cornea, conjunctiva, sclera, iris, ciliary 
body and aqueous humor. However, the limited capacity of lacrimal fluid and constant tear 
drainage from precorneal area leads to wash out of a majority of eye drop within minutes315. 
Additionally, only a few experimental studies have demonstrated their efficacy for posterior 
segment diseases. The properties of corneal barriers allow significant passage of moderately 
lipophilic small molecules, whereas highly hydrophilic large molecular weight 
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biopharmaceuticals undergo restricted permeation generating insufficient concentrations for 
therapy. Nomoto and co-authors demonstrated the incompetence of topical bevacizumab to 
reach therapeutic concentrations in the iris, choroid, retina and vitreous of rabbits even after 
aggressive dosing of 1.25mg/0.05mL six times daily for a week 316.  In another study, topical 
administration of bevacizumab (10mg/kg, 3 times for 7 days) in mice did not generate any 
appreciable concentrations into the healthy corneal stroma 317. In a recent study, Moisseiev and 
group also failed to generate detectable drug levels in both aqueous and vitreous samples of 
human eyes after topical administration of bevacizumab (25mg/mL, four drops with 10 min 
interval) 318. In contrast, Hernandez and coworkers provided the first evidence that 
somatostatin (SST) reached the retina not through the cornea but by the trans-scleral route 
following topical administration. Such topical administration of SST prevented retinal 
neurodegeneration in streptozotocin induced diabetes mellitus (STZ-DM) rats and opened up 
new preventive pharmacological strategy targeted to early stages of DR. 319. 
6.6.2.2. Periocular delivery 
6.6.2.2.1. Subconjunctival delivery  
An injection into the subconjunctival area i.e. space underneath the conjunctiva is 
widely used as a route for periocular delivery. The delivery of biopharmaceuticals into the 
subconjunctival space deep into the bulbar conjunctiva and superficial to the sclera may 
provide a way to directly deliver therapeutics transscleraly into intraocular tissues. 
Subconjunctival routes can be used for sustained delivery since a depot can be formed in the 
space that can expand and accommodate up to 500 µL volume 130. However, drugs injected 
into the subconjunctival space are often rapidly cleared via conjunctival blood and lymphatic 
flow247. In addition, pore diameter and intracellular spaces of scleral fiber matrix regulate drug 
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permeation to a large extent. Longer in vivo half-life in the iris/ciliary body and retina/ choroid 
after subconjunctival injection of bevacizumab relative to intravitreal injection may possibly 
be attributed to binding with negatively charged scleral proteoglycans 316. In another in vivo 
study, high bevacizumab concentration was detected in the whole cornea 24 h post 
subcutaneous injection which remained almost unchanged in all layers of stroma over the next 
14 days 317. Various drug delivery technologies including microparticles/nanoparticles may be 
combined with physical techniques such as ultrasound and iontophoresis to achieve therapeutic 
concentrations of protein and peptide based biopharmaceuticals following periocular 
administration 320-321.   
6.6.2.2.2. Sub-tenon delivery 
Sub-tenon route is widely utilized for administering anesthetics during ocular surgery. 
It involves the injection of drug into a fibrous membrane, called tenon’s capsule which along 
with the sclera binds the sub-tenon space. Although upto 4 mL of drug formulation could be 
injected through this route, administration complications including pain, chemosis, 
subconjunctival hemorrhage, retrobulbar and/or orbital hemorrhage, optic nerve damage, 
retinal ischemia, orbital swelling and rectus muscle dysfunction limit its use for the delivery 
of protein- and peptide-based biopharmaceuticals 322-323. In patients with clinically significant 
macular edema, sub-tenon’s injection of bevacizumab (2.5 mg in 0.1 mm volume) resulted in 
significant short-term visual improvement in eyes 324. Thus, sub-tenon’s injection may serve 
as an alternative to intravitreal injection for ocular delivery of biopharmaceuticals.   
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6.6.3. Intraocular delivery 
Intraocular delivery techniques involve direct delivery of therapeutic agents to the 
target site thus reducing the distance traversed by the drug generating higher local drug 
concentrations, reducing off-target effects, and bypassing various ocular barriers to improve 
ocular drug bioavailability.   
6.6.3.1. Intrastromal delivery 
Intrastromal administration entails direct drug delivery into the corneal stroma to 
overcome the corneal epithelial barrier along with tear fluid drainage. The densely packed 
collagen fibrils and proteoglycans hinder the diffusion of proteins and peptides inside the 
corneal stromal structure allows it to serve as a reservoir for large hydrophilic 
biopharmaceuticals. Hashemian and co-authors reported that intrastromal injection of 
bevacizumab (2.5 mg/1 mL) using a hypodermic needle led to regression of corneal stromal 
vascularization in a patient 325. Recently, in vivo studies by Kim and group have demonstrated 
corneal vascular regression after intrastromal administration of bevacizumab (4.4 μg) with 
microneedles (MNs) 326. These studies further confirm intrastromal delivery as an attractive 
modality for delivering biopharmaceuticals directly into the cornea.   
6.6.3.2. Intracameral delivery 
Intracameral delivery is intended to place the drug solution directly into the anterior 
segment of the eye. Although, intracameral injection has been extensively explored to improve 
delivery of biopharmaceuticals to both the anterior as well as posterior segments of the eye, it 
has not been possible to achieve therapeutic drug concentrations in the posterior segment of 
the eye following intracameral administration. However, intracameral administration of 
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antibiotic prophylaxis for cataract surgery to prevent endopthalmitis 327-328 and antifungal 
agents for deep corneal infections such as fungal keratitis 329 is widely used to deliver drugs to 
the anterior segment of the eye.  Additionally, a combination of intrastromal and intracameral 
injections was recently shown to be effective in reducing fungal mass not only in the anterior 
segment but also in the corneal stroma where fungal invasion may lead to corneal perforation 
330.   
Several in vitro and in vivo studies have demonstrated the effectiveness of intracameral 
bevacizumab in treating neovascularization with no effects on corneal endothelial cells or 
thickness 331-333. Patients with neovascular glaucoma and iris rubeosis have also responded well 
to the intracameral bevacizumab therapy and did not show any morphological changes of 
corneal endothelial cells 334-336. Intracameral injection of bevacizumab-loaded polymeric 
delivery systems may sustain drug release into the anterior segment 337. However, repeated 
injections to maintain therapeutic concentrations over prolonged time periods and sparse 
degradation of polymers may obstruct the aqueous flow, thereby elevating intraocular pressure 
and increasing risk of ocular infections.   
6.6.3.3. Intravitreal delivery 
To date, intravitreal injection remains the main modality for delivering 
biopharmaceuticals to the posterior segment of the eye. It is an invasive procedure that involves 
injection of a drug solution or suspension into the vitreous cavity in the center of the eye after 
penetrating through all layers of the ocular globe. The vitreous cavity can generally 
accommodate a volume of 20-100µL drug solution/suspension without adversely affecting the 
visual acuity338. However, various complications associated with the intravitreal injection 
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include edopthalmitis, retinal detachment, uveitis, iritis, intraocular hemorrhage, cataract and 
hypotony which may lead to permanent vision loss if untreated339.  
Currently, most of the biopharmaceuticals including pegatanib sodium, ranibizumab, 
bavcizumab and aflibercept for the treatment of neovascular AMD are given as intravitreal 
injections. A comparative pharmacokinetic analysis revealed concentration (Cmax) of 
bevacizumab in retina/choroid after an intravitreal injection (1.25 mg/0.05 mL) to be ~317-
fold higher than a subconjunctival injection at 1 week in rabbits 316. Intravitreal injection of 
Avastin® generated significant bevacizumab concentrations in the retina, the retinal pigment 
epithelium, the choroid and particularly the photoreceptor outer segments in cynomolgus 
monkeys 340. Although, biopharmaceutical drugs tend to prevent immediate elimination from 
the vitreous unlike small molecules due to their large molecular weight, their vitreous half-
lives of just few days to weeks may not be sufficient to achieve long term therapeutic effect. 
Therefore, novel delivery methods and/or long-term controlled release formulations for 
protein- and peptide-based biopharmaceuticals are warranted in order to significantly reduce 
complications caused by repeated injections.  
6.6.3.4. Suprachoroidal delivery 
It is often overlooked that the tissue site of action for most of the biopharmaceuticals 
is not the vitreous but the choroid and retina. Therefore, delivering drug directly in the target 
tissues (i.e., choroid and retina) may provide more effective therapy to chorioretinal diseases. 
Suprachoroidal injections, that involve the placement of a drug in the suprachoridal space 
(SCS), a potential space between the sclera and the choroid, holds potential in achieving higher 
drug levels in target tissues. SCS can expand to accommodate a drug suspension or solution 
up to 1 mL 341. Previously, SCS was accessed surgically with a scleral incision and insertion 
162 
of a long cannula or hypodermic needle through the SCS, often leading to SCS collapse due to 
deformability of the chorioretina and the hydrostatic pressure in the eye. Recent advancements 
in suprachoroidal delivery using MNs, has enabled higher local drug concentrations in the 
choroid with fewer side effects and minimal obstruction of the visual axis. However, high 
blood flow in choriocapillaries render the half-lives of small molecules and biopharmaceuticals 
in SCS in the order of hours. In fact, sustained delivery systems (20 nm - 10 µm) are retained 
in the SCS for longer periods indicating the utility of SCS injections 342-343.   
Several studies have demonstrated the effectiveness of suprachoroidal injections for 
localized delivery of therapeutics to the choroid-retina region 344. Although, intravitreal 
injections of bevacizumab have been shown to be superior to microcannula suprachoroidal 
injections in sustaining bevacizumab release for one week 345, MNs have demonstrated 
potential in delivering bevacizumab (100 μl) to the SCS without any serious adverse effects as 
noted in Phase I clinical trials 346-347. Figure 6-7 depicts current and emerging routes for protein 
and peptide delivery to ocular tissues. 
Inflammation, is a common side effect of ocular diseases including neovascularization, 
significantly affects the integrity of corneal epithelium, choroid and the RPE layer. Such 
incompetent barrier function allows protein- and peptide-based biopharmaceuticals, that have 
limited access to the intact eye, to gain significant access through the compromised barriers of 
inflamed eyes. Several studies to date have shown the effectiveness of systemic, intravitreal 
and SCS delivery in compromised tissues and confines compelling implications for other 
biological approaches in the treatment of ocular diseases. Some characteristics of various 
routes of administration for ocular drug delivery are provided in Table 6-4. Additionally, a list 
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of controlled-release systems for protein and peptide therapeutics for ocular implications are 
depicted in Table 6-5.  
 
 
 
 
 
 
 
 
Figure 6-7 Current and emerging routes for protein and peptide delivery to ocular tissues 
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Table 6-4 Characteristics of various routes of administration for ocular drug delivery294 
Routes Notes 
Topical 
Drug entry pathways Corneal, conjunctival, and sclera pathways. 
Delivery barriers Membrane barriers and elimination pathways on the eye surface, cornea, 
BRB, and tight conjunctions. 
Elimination pathway Tear wash out; nasolacrimal drainage 
Advantages 
High patient compliance; less systemic side effects; relatively easy and 
safe to administer. 
Limitations 
Small retention time of drug or dosage forms; blurring of vision; irritation; 
precorneal drug losses; drainage through the nasolacrimal duct; low 
bioavailability; limited volume of administration (approx. 30 μL); fast 
clearance from ocular surface; metabolism by tear enzymes; 
nonproductive uptake into systemic circulation via highly vascularized 
conjunctiva, choroid, uveal tract and inner retina; aqueous humor outflow 
gradient. 
Approaches for improvement 
in therapeutic efficacy 
Bioadhesive formulations may reduce precorneal clearance and increase 
corneal surface contact time. Positive charge of formulations may enhance 
the contact time with cornea to interact with negatively charged mucosa. 
Nanowafers approach may be beneficial for long-term and sustained drug 
release. 
 
 
 
Systemic 
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Routes Notes 
Drug entry pathways 
Choroid and conjunctiva 
Delivery barriers 
Choroid and BRB (selectively permeable to highly lipophilic molecules). 
Elimination pathway 
Hepatic clearance; conjunctival and choroid capillaries and phagocytic 
clearance. 
Advantages 
Better patient compliance relative to intraocular injection. 
Disadvantages 
Low bioavailability due to the BRB, hence higher doses required which 
may produce systemic side effects. 
Approaches for improvement 
in therapeutic efficacy 
Large molecules and/or hydrophilic drugs are able to penetrate the choroid 
from the systemic circulation, but are unable to cross the inner BRB into 
the retina. Therefore, drugs must exit the choroidal circulation and 
permeate the outer BRB. 
 
 
Intravitreal 
Drug entry pathways 
Directly to the vitreous chamber 
Delivery barriers 
Diffusion through the vitreous chamber, neural retina, and BRB. 
Elimination pathway 
Movement through aqueous chamber and retina; dynamic clearance 
mechanisms, such as anterior bulk aqueous flow or posterior vitreoretinal-
choroidal flow, and elimination from the site of deposition. 
Advantages 
Local and direct delivery; high therapeutic concentration; no barrier to 
reach macula. 
Disadvantages 
It is necessary to administer the drug frequently to maintain adequate 
intraocular concentrations; frequent injections have been associated with 
adverse events especially retinal detachment, cataract, vitreous 
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Routes Notes 
hemorrhage and endophthalmitis; linked to degeneration of PRs and 
cataracts and increase in IOP; only about 50–100 μl is administrable in 
human via intravitreal; high cost of administration of drugs (anti-VEGF). 
Approaches for improvement 
in therapeutic efficacy 
Extended drug release formulation for longer duration and/or drug 
modifications including specific properties such as size, charge, and 
lipophilicity; also need stimuli-responsive approach for drug release.  
 
 
Periocular 
Drug entry pathways 
Trans-scleral pathway to effectively deliver drugs next to the choroid. 
Delivery barriers 
Scleral thickness, choroidal blood circulation and BRBs. 
Elimination pathway 
Conjunctival and choroidal blood and lymphatic flow; losses from the 
periocular space, BRB, and choroidal circulation; drug binding to tissue 
proteins. 
Advantages 
Less invasive; high therapeutic drug levels; possible repetitive periocular 
administration under local anesthesia without direct interference with the 
vision. 
High volumes of drug solution can be administered in human and can 
bypass the BRB without intraocular penetration. 
Disadvantages 
Rapid drug clearance; systemic side effects; tissue hemorrhage; and low 
retinal bioavailability compared to intravitreal injections; the injected drug 
still has to traverse the sclera, which is less permeable to larger molecules. 
The drugs have to pass through several layers including the episclera, 
sclera, choroid, BM, and RPE-while overcoming choroid circulatory 
clearance; the delivery is not as effective as intraocular injections in 
targeting retinal tissue. 
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Routes Notes 
Approaches for improvement 
in therapeutic efficacy 
Improvements to formulations that either increase residence time or 
promote diffusion from the middle coat may be effective in overcoming 
the barriers to periocular delivery; nano-size formulations may provide 
superior diffusion; charge of formulations determines the interaction or 
diffusion process. 
 
 
Suprachoroidal (SC) 
Drug entry pathways 
Flow across the sclera is quick along the inner surface of the eye and 
subsequently into the posterior chamber. 
Delivery barriers 
Choroid and basement membrane. 
Elimination pathway 
High blood flow in the chorio-capillaries can wash away therapeutic 
molecules deposited in the SC space. 
Advantages 
Preferred site for drug delivery to the posterior tissues such as choroid, 
RPE and macula, due to its non-interference with the optical pathways and 
improved diffusional access to the choroid; this allows larger volumes of 
drugs with minimally invasive procedure; SC space can accommodate up 
to 1 ml of fluid, which rapidly diffuses into the posterior segment; 
injections of 10–50 µL into the SC space have been demonstrated to be 
well tolerated with lower risks for ocular complications. 
Disadvantages 
Injection of a drug solution into the SC space can result in rapid drug 
diffusion to cover the entire SC surface which may potentially induce 
drug-related toxicities of the surrounding tissues; rapid clearance of 
macromolecules occurs following suprachoroidal administration; 
postoperative inflammation and choroidal hemorrhage remain a concern 
and needs to be overcome while injecting into the SC space. 
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Routes Notes 
Approaches for improvement 
in therapeutic efficacy 
Diffusion kinetics from the SC space could be optimized using sustained 
release formulations such as nano and microparticles; drug delivery 
systems that can provide controlled and continuous drug release are likely 
to minimize side-effects; such controlled devices might help overcome 
rapid fluctuation of the dosed drugs from conventional injectable solutions 
into the SC space and hence reduce toxicity to the surrounding tissues;  
MNs appear to offer a viable option for delivery of drugs to the back of the 
eye, especially when delivered through the SC route; these needles help to 
deposit drug or carrier system into sclera or into the SCS which may 
facilitate diffusion of drug into deeper ocular tissues, choroid and neural 
retina. 
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Table 6-5 Controlled-release systems being investigated for protein and peptide therapeutics 
for ocular implications294 
Formulation 
Approaches 
Drug Description Release Status 
Particulate systems 
Biodegradable polymeric microspheres 
PLGA MPs Bevacizumab Fabricated by Double emulsion 
method; particle size, 2–10 µm 
62% 
released 
within 91 
days 
Preclinical, in 
vitro 
PLA NPs within 
PLGA MPs 
Bevacizumab Fabricated by supercritical infusion 
and pressure quench technology 
67% 
released 
within 120 
days (4 
months) 
Preclinical, in 
vivo, rat 
model 
PLGA MPs Bevacizumab Fabricated by solid-in-oil-in-
hydrophilic oil method; particle size, 
2–7 µm 
NA Preclinical, in 
vivo, rabbit 
model 
Silicon dioxide MPs Bevacizumab Synthesized by electrochemical 
etching and oxidation of silicon wafer 
in hydrofluoric acid followed by 
ultrasonic fracture; particles with a 
pore size of 100 nm 
165 days 
(5 months) 
Preclinical, in 
vitro 
Biodegradable polymeric nanospheres 
PLGA – albumin NPs Bevacizumab Fabricated by w/o/w double emulsion 
in presence of albumin as a stabilizer; 
particle size ~ 197 nm 
165 days 
(5 months) 
Preclinical, in 
vivo, rabbit 
model 
Liposome Bevacizumab EPC-Chol and DPC-chol liposomes 
formed by dehydration and 
rehydration method followed by 
freeze drying 
NA Preclinical, in 
vivo, rabbit 
model 
Liposome – annexin Bevacizumab PC-PS-Chol-Toc liposomes fabricated 
by dehydration and rehydration 
method and subsequently coated with 
annexin; particle size, 100 nm 
NA Preclinical, in 
vivo, rabbit 
mode 
Biodegradable and non-biodegradable polymeric implants 
 
ENV705 (intravitreal) 
Envisia therapeutics 
Bevacizumab Drug dispersed into biodegradable 
hydrogel-based matrix made by 
PRINT technology and molded into 
implants 
2 months Preclinical 
animal test 
Nano-pores film 
device (intravitreal) 
Zordera Inc. 
Ranibizumab Biodegradable DDS based on PCL; 
drug pellet sandwiched between a 
nanopore and impermeable layer (total 
thickness 40 mm) 
3 months Under 
investigation 
Posterior micropump 
system 
(subconjuctival) 
Ranibizumab Nonbiodegradable refillable DDS 
drug loaded with preprogrammed 
micropump; drug delivered in 
controlled nanodroplets 
Long-term 
(refillable) 
Phase I 
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Formulation 
Approaches 
Drug Description Release Status 
Port delivery system 
(PDS) 
(subconjuctival) 
Genentech 
Ranibizumab Semipermeable nonbiodegradable 
membrane with a refillable port; 
several exit ports to release drug into 
vitreous humor 
Long-term 
– 1 year 
(refillable) 
Phase II 
Verisome IB20089 
(intravitreal) Icon 
bioscience 
Triamcinolon
e/ 
ranibizumab 
Biodegradable with liquid gel or solid 
core; liquid injectable formulation; 
coalesces after intravitreal injections 
to form spherules 
1 year Phase II 
In-situ gelling formulations 
 
Hyaluronic acid-
dextran 
Bevacizumab Catalyst-free chemical crosslinking 
between vinylsulfone functionalized 
HA/thiolated dextranin under 
physiological conditions; transparent 
gel formed in vitreous after injection; 
better sustained release observed in 
vivo compared with in vitro release 
6 months Preclinical, in 
vivo, rabbit 
model 
Alginate-chitosan 
hydrogel/PLGA 
microspheres 
Bevacizumab/ 
ranibizumab 
Antibody-loaded PLGA microspheres 
encapsulated into alginate hydrogels 
196 days 
(6.5 
weeks) 
Preclinical, in 
vitro 
Silk-based hydrogels Bevacizumab On the basis of physically crosslinked 
silk fibroin heavy chain (Mw = 350 
kDa); biocompatible crosslinking 
reaction 
Up to 3 
months 
Preclinical, in 
vitro 
Diels–alder hydrogels Bevacizumab On the basis of PEG macro-
monomers, chemically crosslinked by 
Diels–Alder reaction; mechanical 
stability enhanced 
Up to 6 
weeks 
Preclinical, in 
vitro 
Poly(2-ethyl-2-
oxazoline)-b-
poly(caprolactone)-b-
poly(2-ethyl-2-
oxazoline) 
Bevacizumab Reversible sol–gel transition; good in 
vitro and in vivo biocompatibility 
20 days Preclinical, in 
vitro 
Poly(n-
isopropylacrylamide) 
pnipaam and 
poly(ethylene glycol 
diacrylate) peg-da 
Bevacizumab/ 
ranibizumab 
Enhanced mechanical properties; good 
biocompatibility; thermoresponsive 
hydrogel; PNIPAAm shows LCST 
behavior 
3 weeks Preclinical, in 
vivo, rat 
model 
PEG-poly-
(serinolhexamethylene 
urethane) 
Bevacizumab Sol-to-gel phase transition when kept 
at in vivo temperatures; good in vitro 
and in vivo biocompatibility 
17 weeks Preclinical, in 
vivo, rabbit 
model 
Delivery using living cells 
 
Renexus NT-501 
(surgical) Neurotech 
Inc.  
Cell line 
secreting 
CNTF 
Nonbiodegradable; cell encapsulated 
in a semipermeable polysulfone 
capsule; Phase 2 results not 
encouraging because of adverse 
effects 
18 months Phase II/III 
NT-503 (surgical) 
Neurotech Inc. 
Cell line 
secreting 
VEGFR-Fc 
Nonbiodegradable implant; 
semipermeable hollow fiber 
membrane encapsulating cells 
12 months Phase I 
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CNTF, ciliary neurotrophic factor; DDS, drug delivery systems; DPC-chol, 1,2 dipalmitoyl-
sn-glycero-3-phosphocholine; EPC-chol, egg phosphatidylcholine-cholesterol; MPs, 
microparticles; NPs, nanoparticles; PLGA, polylactic-co-glycolic acid; PC-PS-Toc, egg 
phosphatidylcholine-porcine brain phosphatidylserine-tocopherol; PCL, polycaprolactone; 
PEG, polyethylene glycol; PLA, polylactic acid. 
 
6.7. A multi-layered nanomicellar approach  
Despite the major hurdles in ocular delivery of proteins and peptides, technological 
breakthroughs in formulation, delivery approaches and manufacturing methods have facilitated 
the growth and improvement in the biopharmaceutical market. Some of the work with the 
delivery of biopharmaceutical drugs have shown encouraging results. However, many needs 
remain unmet for the delivery of relatively smaller biologics, and greater challenges keep 
arising for developing formulations for larger biopharmaceutical drugs. Current 
biopharmaceuticals suffer from poor intracellular delivery leading to low ocular 
bioavailability, reduced stability (including storage, handling and administration), incompetent 
formulation development strategies and scalability and high manufacturing costs. Developing 
new biomaterials for effective protection of proteins and peptides and improving intracellular 
delivery will significantly improve biopharmaceutical delivery. Earlier Nomoto et al. has 
reported three-layered polyplex micelles for light-induced gene delivery for solid tumors 348. 
Similarly, Abebe et al. has reported triblock copolymers based three-layered biodegradable 
micelles as efficient gene delivery system 349.  
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In this approach, we have developed self-assembling multi-layered nanomicelles 
composed of two polymers, HCO-40 and OC-40 designed to combine hydrophilic interactions 
and solvent-induced encapsulation of peptides and proteins. HCO-40 and OC-40 polymers are 
employed to encapsulate various biologics including octreotide in the core of the organo-
nanomicelle with chloroform as a dispersant. The individual organo-nanomicelle is further 
encapsulated with another layer of the same polymers allowing formation of an aqueous stable 
amphiphilic nanomicellar solution (Figure 6-8). The multi-layered nanomicelles are 
hypothesized to permeate through the conjunctival/scleral route similar to nanomicelles. The 
aqueous nanomicellar formulation with size ranging from ~16-20 nm could be administered 
topically to generate improved octreotide concentrations in the back of the eye over a period 
for the treatment of PDR.  
Figure 6-8 A schematic illustration showing the preparation of multi-layered nanomicelles by 
a modified multi-step solvent evaporation/rehydration method 
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CHAPTER 7 
7. MULTI-LAYERED NANOMICELLES AS SELF-ASSEMBLED NANOCARRIER 
SYSTEMS FOR OCULAR PEPTIDE DELIVERY 
 
7.1. Rationale  
Peptide engineering, recombinant advancements and hybrid technologies combining 
solid and liquid syntheses have generated new classes of biologic-based therapeutics with 
bioactivities significantly higher compared to small molecules 350-351. A particular success is in 
the area, where peptides have been engineered to bind to extracellular targets with superior 
specificity and affinity. At the same time, peptides are relatively safe and well tolerated and 
thus have shown incredible promise for a variety of indications including ocular and 
autoimmune diseases, inflammation and cancer 352. Furthermore, peptide therapeutics are 
associated with lower production complexity and thus reduced production costs in comparison 
to other biopharmaceuticals. Despite the successes of peptides, they have several intrinsic 
weaknesses including poor chemical and physical stability and short circulating plasma half-
lives 353. Peptide engineering is a powerful tool that has facilitated growth of peptide-based 
therapeutics in clinical trials.  However, it requires manipulation of peptide conformations or 
sequences for therapeutic applications 354. Arguably, the primary reason there are only a few 
peptide-based therapeutics in the market, is the unmet challenge in delivering sufficient 
amounts of functional peptides in their native forms. Successful design and implementation of 
a functional ocular delivery system that is generally applicable to therapeutic peptides would 
have significant impact on human health. Such a nanocarrier system may open up a new 
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paradigm for a host of new peptide-based therapies for the treatment of a wide variety of 
diseases. 
Approaches in the peptide-based biotherapeutics delivery include polymer 
modifications, encapsulation of divalent cations and chemical modification of peptides at 
reactive amines to minimize acylation using maleic anhydride and PEG355. Alternatives to 
PEG, the negative charge of sialic acid as well as the glycosaminoglycan hyaluronic acid and 
hydroxyl ethyl starch also hold potential in prolonging half-lives of peptides269. The low pH 
resulting from degraded products of PLGA polymers was shown to catalyze acylation at the 
lysine residue of peptides 356. For instance, more than 60% of octreotide, an octapeptide is 
released in acylated form over 3 months from Sandostatin LAR® depot. Similar challenges 
have been reported for other peptides and biologic drugs including bovine serum albumin, 
human atrial natriuretic peptide, human parathyroid hormone, leuprolide, insulin and salmon 
calcitonin357. Conjugation of maleic anhydride to octreotide has demonstrated to inhibit 
acylation to less than 10% from PLGA films358. Polymer poly(D,L-lactide-cohydroxymethyl 
glycolide) has been modified to minimize nucleophilic attack of octreotide amine on glycolide 
and thus reducing acylation up to 30% during in vitro release. Utilization of hydrophobic ion-
pairing (HIP) complexation by our laboratory in the past was demonstrated to maintain native 
chemical structure of octreotide to more than 95% during release from PLGA microparticles-
in-gel composite formulation 357. However, generation of lactic and glycolic acid from PLGA 
over long term usage may possess potential toxicity concerns. Furthermore, the large size of 
microparticles may hinder diffusion of peptides across cornea or through conjunctival pathway 
after topical administration.  
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In order to overcome these drawbacks, a blend of polymers, polyoxyethylene 
hydrogenated castor oil 40 (HCO-40) and octoxynol 40 (OC-40) have been utilized to develop 
a self-assembling nanocarrier for small peptides. A combination of these polymers in the past 
has resulted into a highly stable and water soluble self-assembling nanomicellar formulation. 
The formulation has completed Phase 3 clinical trials and has shown promising results as a 
highly biocompatible nanocarrier for the treatment of dry eye disease (NCT02254265). 
 
7.2. Objective  
(i) In this study, we newly designed a multi-layered nanomicellar formulation for topical 
administration of small peptides. The key to forming three layered compartments within a 
single nanocarrier platform is the sequential self-assembly of peptide with HCO-40 and OC-
40 composed of segments with distinct functionality in an aqueous solution. The nanocarrier 
thus has a hydrophilic core compartment for stable packaging of peptides, an intermediate 
hydrophobic compartment and an outer hydrophilic compartment that renders it highly soluble 
in water. The design is general, capable of carrying small peptides 348-349. Though we test this 
proof of concept in ocular cell lines for octreotide delivery, a wide range of human diseases 
could be treated with intracellular biologic administered by an effective nanocarrier system. 
(ii) Physicochemical properties, in vitro release and drug entrapment and loading capacities of 
organo and multi-layered nanomicelles were evaluated utilizing dynamic light scattering 
(DLS) and ultra-fast liquid chromatography (UFLC).  
(iii) The cytotoxicity of multi-layered nanomicelles was studied in HRPE (Human retinal 
pigment epithelial, D407), CCL 20.2 (Human conjunctival epithelial) and RF/6A (rhesus 
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choroid-retinal endothelial) cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay.  
(iv) The uptake behavior and permeability of coumarin-6, coumarin-6-loaded nanomicelles, 
rhodamine and rhodamine-loaded multi-layered nanomicelles were demonstrated in D407, 
CCL 20.2 and RF/6A cells using flow cytometry (FCM). 
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7.3. Experimental 
7.3.1. Materials 
Dipeptide (Gly-Sar) was purchased from Bachem (Bubendorf, Switzerland). Tripeptide 
(Gly-Gly-Gly) and Tetrapeptide (Gly-Gly-Gly-Gly) were obtained from Sigma-Aldrich (St. 
Louis, MO). Octreotide, Human recombinant insulin, and Immunoglobulin G (IgG) were 
procured from ChinaPeptides Co., Ltd. (Shanghai, China), MP Biomedicals (Santa Ana, CA) 
and LEE BioSolutions, Inc. (St. Louis, MO) respectively. Hydrogenated castor oil-40 (HCO-
40) of pharmaceutical grade was procured from Barnet Products, USA and octoxynol-40 (OC-
40 or Igepal CA-897) was purchased from Rhodia Inc., New Jersey, USA. For buffer and 
formulation preparation double distilled deionized water was utilized. HPLC grade DMSO and 
methanol were purchased from Fisher Scientific Co. (Pittsburgh, PA, USA). TrypLETM 
Express Stable trypsin solution, Dulbecco’s modified Eagle’s medium (DMEM) were received 
from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum (FBS) was obtained from Atlanta 
Biologics (Lawrenceville, GA, USA). Micro-BCA assay kit was obtained from Fisher 
Scientific Inc., (Rockford, IL). All other chemicals were of analytical reagent grade procured 
from Thermo Fischer Scientific or Sigma Aldrich and were utilized without any further 
purification. 
7.3.2. Cell culture 
Human retinal pigment epithelial cell line D407 was kindly provided by Dr. Richard 
Hunt (University of South Carolina, Columbia, SC, USA). Human conjunctival CCL 20.2 and 
rhesus choroid-retinal endothelial RF/6A cell lines were obtained from the American Type 
Culture Collection (ATCC, Manassas, VA). D407 and CCL 20.2 cell lines were cultured in 
T75 flasks in DMEM medium containing high glucose and glutamine concentration, 1% 
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nonessential amino acids and 10% FBS (heat-inactivated). RF/6A cells were cultured in RPMI-
1640 medium containing sodium bicarbonate and 15% FBS (non heat-inactivated). All the 
culture mediums contained 100 IU/ml streptomycin and 100 IU/ml penicillin. The pH of the 
mediums were maintained at 7.4. Cells were maintained at 37ºC in an atmosphere containing 
5% CO2 and 90% relative humidity. The mediums were replaced every alternate day until cells 
reached 80-90% confluency (5-7 days for D407, CCL 20.2 and 19-21 days for RF/6A cells). 
7.3.3. Preparation of multi-layered nanomicelles  
The multi-layered nanomicellar formulation was prepared following a 2-step process. 
The first step involved the solvent-induced encapsulation of various agents used herein in terms 
of organo-nanomicelle formation. To encapsulate a macromolecule, 2.5 wt. % HCO-40 and 
1.005 wt. % OC-40, were dissolved separately in ethanol and mixed to generate a homogenous 
solution. Macromolecule, 0.1 wt. % was dissolved in ethanol/DI water and added to polymer-
ethanol solution drop-wise. The resulting transparent solution containing the organo-
nanomicelle was evaporated under high-speed vacuum (Genevac, Ipswich, Suffolk, UK) 
overnight (∼10 h) to obtain a solid thin film. The solid thin film was dissolved in chloroform 
and filtered with a 0.2 μm nylon membrane filter to remove unentrapped drug aggregates and 
other foreign particulates. The transparent solution was characterized for size, polydispersity 
index (PDI) and zeta potential.   
The second step in the overall nanomicelle preparation process is the formation of 
highly stable and aqueous soluble three-layered nanomicelle incorporating the 
macromolecule/polymer complex (organo-nanomicelle). For this step, 5.0 wt. % HCO-40 and 
2.01 wt. % OC-40 were separately dissolved in ethanol and mixed in a vial. The polymer 
ethanol solution was added dropwise to the vial containing organo-nanomicelle chloroform 
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solution and mixed thoroughly. The solvent was then removed by evaporation under high-
speed vacuum and subsequently rehydrated in DI water to the desired volume. The resulting 
viscous multi-layered nanomicelle solution was filtered through 0.2 μm nylon membrane filter 
and characterized for size, PDI and zeta potential using DLS.    
7.3.4. Characterization 
Hydrodynamic diameter, PDI and zeta potential of both organo-nanomicelles and milti-
layered nanomicelles were determined with Zeta Sizer (Zetasizer Nano ZS, Malvern 
Instruments Ltd, Worcestershire, UK) at RT.  Briefly, 1ml of nanomicellar solution (2 mg/mL) 
was placed into a glass cuvette. The samples were measured at a scattering angle of 173 º and 
25 ºC. Average values were calculated from three replicate measurements of each sample. 
7.3.5. 1H-NMR spectroscopy  
To perform 1H-NMR spectroscopy, Octreotide, Blank and Octreotide-loaded multi-
layered nanomicelles were prepared in D2O for NMR analysis. Spectra were recorded with 
Varian-400 NMR instrument. NMR data was processed using VNMRJ or ACD labs software.  
7.3.6. Entrapment and loading efficiency 
The total amount of macromolecule entrapped in the formulation was determined by 
bicinchoninic acid assay (BCA). Ten milliliters of each organo-nanomicellar formulation was 
collected and centrifuged at 10,000 rpm for 10 min at 4 ºC. One milliliter of supernatant was 
carefully collected from each centrifuge tube and transferred into fresh vials and lyophilized 
to obtain a solid pellet. Five hundred microliter of DI water was added to each vial in order to 
reverse the organo-nanomicelles and release the macromolecule in the surrounding aqueous 
solvent. Micro BCA protein estimation kit (Thermo Scientific, IL) was employed for the 
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estimation of total protein/peptide content. The percent entrapment and loading efficiency of 
peptides and proteins were calculated according to the following formula: 
Percent entrapment = (mass of a macromolecule in organo-nanomicelles)/ (mass of a 
macromolecule added in formulation) x 100               [Eq. 14] 
Loading efficiency = (mass of a macromolecule in organo-nanomicelles)/ (mass of a 
macromolecule added + mass of polymers used) x 100               [Eq. 15] 
7.3.7. In vitro cytotoxicity: MTT assay 
Cytotoxicity of HCO-40, OC-40 and multi-layered nanomicelles against D407, CCL 
20.2 and RF/6A cells were assessed in vitro by MTT assay. All the three cell lines were seeded 
into a 96-well plate at a density of 1x104 cells/well in 100 µL complete DMEM solution 
containing 10% FBS. Cells were cultured for 1 day at 37 ºC in 5% CO2 atmosphere. Different 
concentrations of HCO-40, OC-40 and multi-layered nanomicelles were prepared in serum 
free medium and filtered with 0.22 um sterile nylon membrane filters under laminar flow hood. 
Afterwards, the media were replaced with 100 µl of different treatment groups and incubated 
for 24 h at 37 ºC. After 24 h of incubation, MTT stock solution (5 mg/mL in potassium 
phosphate buffer, PBS 20 µL) was added to each well and incubated for 2.5 h. The absorbance 
was measured with a microplate reader (BioRad Hercules, CA, USA) at 450 nm. Cell viability 
was expressed according to the following formula:  
Cell viability (%) = (Abs of sample- Abs of negative control)/ (Abs of positive control- Abs of 
negative control) * 100               [Eq. 16] 
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7.3.8. In vitro release of octreotide from octreotide-loaded multi-layered nanomicelles 
A fixed volume (1 mg/mL) of octreotide-loaded multi-layered nanomicelles was 
transferred to a membrane tubing (MWCO 8000-10000 Da, Spectrum labs, CA, USA). The 
tubing was subsequently immersed in 5 mL PBST (PBS-Tween, pH 7.4) or STF (simulated 
tear fluid) solution in a shaking water bath fixed at 60 rpm and 37 ºC to maintain sink condition. 
At predetermined time points, entire 5 mL of external buffer was withdrawn and replaced with 
5 mL of fresh buffer solution. The amount of octreotide released was determined by a RP-
HPLC method. Release study was performed in triplicates. The results were plotted as 
mean±SD. The release data was fitted for zero order, first order, Higuchi and Korsmeyer-
Peppas model to determine the kinetics of DEX release. 
7.3.9. Evaluation of cellular uptake by flow cytometry (FCM) 
D407, CCL 20.2 and RF/6A cells were seeded into 12-well plates at a density of 
2.5x104 cells/well in 24 mL complete DMEM/RPMI containing 10% FBS, and maintained 
until they achieved 80-90% confluency (6-7 days) at 37 ºC in 5% CO2 atmosphere. Afterwards, 
cells were incubated with coumarin-6, coumarin-6 loaded nanomicelles, rhodamine and 
rhodamine-loaded multi-layered nanomicelles at a final coumarin-6/rhodamine concentration 
of 50 µg/mL in serum free medium for predetermined time points at 37 ºC. At each time point, 
the culture medium was removed and cells were washed twice with DPBS to remove the 
various treatment groups that were not ingested by the cells. Cells were detached with trypsin 
for 10 min, and then centrifuged at 1550 rpm for 10 min to obtain a solid pellet. The solid cell 
pellet was washed twice with DPBS. After removal of the supernatant, the cells were 
resuspended in 500 µL of 4% (w/v) paraformaldehyde aqueous solution and stored at 4 ºC. 
The mean fluorescence intensity of coumarin-6, coumarin-6 loaded nanomicelles, rhodamine 
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and rhodamine-loaded multi-layered nanomicelles in cells were analyzed by FCM (Becton 
Dickinson, Franklin Lakes, NJ, USA) with an excitation wavelength of 490 nm (coumarin-6) 
and 660 nm (rhodamine) for comparative studies.  
 
7.4. Sample and Data Analysis 
7.4.1. Ultra-fast liquid chromatography (UFLC) analysis 
The octreotide concentration in released media was quantified by UFLC assay. A 
Shimadhu (Shimadzu Scientific Instruments, Columbia, MD, USA) HPLC system coupled 
with pumps having built-in system controller (LC-20AT), degasser (DGU-20A3R), DAD 
detector (SPD-20AV) and autosampler (SIL-20AHT) were employed. Phenomenax column 
(Phenomenex C18 kinetex column 100 x 4.6 mm, 5 mm) along with a guard column 
(Phenomenex SecuritGuard Catridges, C18, 4 x 2 mm) was used at a flow rate of 0.5 mL/min. 
A gradient elution method was employed. Mobile Phase A (HPLC water with 0.1% formic 
acid) at 10% and mobile phase B (ACN with 0.1% formic acid) at 90% were ran for first 2 min 
followed by a linear gradient to reach 100% of Phase B at 18 min. Standards were prepared in 
PBS buffer ranging from 3.1 to 100 mg/ml. DAD detector was set at 280 nm to determine UV 
absorbance. Injection volumes was 50 µl. 
7.4.2. HPLC–MS analysis 
HPLC–MS analysis was performed with electrospray ionization (ESI) in a positive ion 
mode on QTrap® API-3200 mass spectrometer equipped with Shimadzu quaternary pump, 
vacuum degasser, DAD detector and autosampler (Shimadzu Scientific Instruments, 
Columbia, MD, USA). Data acquisition and data processing were performed by Analyst 1.4.2 
software package (Applied Biosystems, Foster City, CA, USA). LC conditions including 
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column and gradient composition remains same as explained in the earlier UFLC assay. 
Injection volumes were 30 µL for all samples. UV detector was set on 280 nm and MS was set 
in a range of 200–1700 amu. The extracted ion chromatogram (EIC) from the total ion current 
(TIC) chromatogram was compared with UV chromatogram to identify the native octreotide 
and confirm absence of any acylated adducts. 
7.5. Statistical analysis 
All experiments were conducted at least in triplicate and results were expressed as mean 
± S.D. Student t-test was employed to determine statistical significance among groups. A value 
of p ≤ 0.05 was considered to be statistically significant. 
 
7.6. Results and Discussion 
7.6.1. Preparation of multi-layered nanomicelles 
The process of a peptides and proteins encapsulation and formation of a stable multi-
layered nanomicellar formulation is shown in Figure 7-1 A. The overall process was 
accomplished in two steps. The first step involves the process of peptide encapsulation, 
achieved via formation of an organo-nanomicelle or reverse nanomicelle. Self-assembly of the 
organo-nanomicelle occurs spontaneously as the polar ethanol/water mixture is replaced with 
the organic or less-polar chloroform.  This allows water soluble peptide to get entrapped into 
the hydrophilic core of the organo-nanomicelles and thus reduces interaction with the organic 
solvent. The organo-nanomicelle can be described as a core-shell structure, where the core is 
composed of polymer/peptide complex with chloroform as a dispersant. In the conventional 
aqueous system, encapsulation of hydrophilic peptides and proteins within hydrophobic 
compartment suffer from low loading efficiency due to the high solubility of these molecules 
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in aqueous solutions. Thus, we performed the encapsulation step in organic solvent 
(chloroform) which is a non-solvent for peptides and proteins. The drastic change in solubility 
drives the aggregation of the organo-nanomicelle and preferential fractionation of peptide into 
the nanomicelle core. Using this method, we were able to achieve an encapsulation efficiency 
of approximately 76% for a peptide (octreotide). The loading results of various other peptides 
and proteins have been shown in the Table 7-1. 
The peptide-loaded organo-nanomicelles were then formulated into a stable aqueous 
solution in the second step shown in Figure 7-1 A. We used the same polymers, HCO-40/OC-
40 (double concentration), to form a protective aqueous solubilizing layer on the surface of the 
organo-nanomicelles. The resulting nanomicelle is a multi-layered system comprising of three 
regions: hydrophilic core: peptide/polymer; intermediate hydrophobic layer, and outer 
hydrophilic shell (Figure 7-1 B). Appearance of the nanomicelle solution at different settings 
are shown in Figure 7-2. In the first step, the peptide loaded organo-nanomicelle solution was 
obtained in chloroform without any precipitation. The formation of stable aqueous multi-
layered nanomicelle in the second step was evident by the absence of precipitation when HCO-
40/OC-40 outer layer was added (Figure 7-1 D). In contrast, when the stabilizing outer layer 
is not included in the formulation, we observed immediate precipitation of the peptide loaded 
organo-nanomicelle in the aqueous environment (Figure 7-2 C).  
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Figure 7-1 Synthesis of multi-layered nanomicelles: (A) A schematic illustration shows the processes 
of preparing multi-layered nanomicelles by a modified multi-step solvent evaporation/rehydration 
method. (B) The multi-layered nanomicelles are comprised of a hydrophilic organ-nanomicelle core, a 
hydrophilic HCO-40/OC-40 shell and an intermediate hydrophobic layer between hydrophilic core and 
shell. (C) By varying the mixture 1/mixture 2 ratio, we can tune the multi-layered nanomicelles size in 
a physiological environment. The effect of formulation parameters on the (D) size of orgno-
nanomicelles and (E) zeta potential of multi-layered nanomicelles. Data represent mean ± S.D (n= 3-4) 
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Table 7-1 Loading and entrapment efficiency of multi-layered nanomicelles for a series of 
peptides and proteins with varying molecular weights. Data represent mean ± S.D (n= 3-4) 
 
 
Drug MW (Da) Loading efficiency 
(%) 
Entrapment efficiency 
(%) 
Gly-Sar 146.15 0.99±0.12 70.77±0.93 
Gly-Gly-Gly 189.2 1.39±0.23 99.18±0.66 
Gly-Gly-Gly-Gly 246.23 1.41±0.37 100.41±1.84 
Octreotide 1013.24 1.10±0.22 78.52±2.01 
Insulin 5733.55 0.17±0.08 12.48±0.67 
IgG 150,000 0.16±0.06 11.60±0.49 
Figure 7-2 The images of various nanomicellar formulations: (A) 
Deionized (DI)-water, (B) Octreotide-loaded organo-nanomicelles in 
chloroform, (C) Precipitated octreotide-loaded organo-nanomicelles 
after adding to an aqueous solution, (D) Octreotide-loaded multi-
layered nanomicelles 
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7.6.2. Characterization of organo and multi-layered nanomicelles 
The ability of an amphiphilic polymer to condense a peptide or macromolecule is 
primarily influenced by the hydrophilic interactions of hydrophilic groups (i.e. oxyethylene) 
and flexibility of the molecular structure359. Nanomicellar constructs from a single amphiphilic 
polymer are not very thermodynamically stable360. The inclusion of a second polymer can 
cause interlock hydrogen bonding with the primary polymer to generate very stable 
nanomicelles up to 65 ˚C. Moreover, the oxygen and hydrogen atoms of hydroxyl groups may 
form intramolecular hydrogen bonding with adjacent polymer chain affording some degree of 
stability, and control the release behavior. We have screened different combinations of HCO-
40 and OC-40 for use in the preparation of organo-nanomicelles. No significant difference in 
nanomicellar size was observed (Figure 7-1 D). Thus, HCO-40/OC-40 combination which 
demonstrated the highest entrapment and loading efficiency (Table 7-2) was used for the inner 
core of the multi-layered nanomicelle formulations evaluated in this study. Table 7-3 shows 
the DLS measurements of hydrodynamic diameters, PDI and zeta potential obtained for the 
HCO-40/OC-40 derived multi-layered nanomicelles. For organo-nanomicelles, variation in 
polymer concentration significantly affected the entrapment efficiency (Table 7-2). 
For the octreotide encapsulated multi-layered nanomicelles consisting of 2.5 wt. % 
HCO-40 and 1.005 wt. % OC-40 as inner core and 5.0 wt. % HCO-40 and 2.01 wt. % OC-40 
as outer layer, the expected increase in multi-layered nanomicelle diameter from organo-
nanomicelle was observed (Figure 7-1 C). The obtained hydrodynamic diameters were in the 
range ca. 17 nm for all multi-layered nanomicellar formulations (Figure 7-8). This is 
particularly important as the lower size of the nanomicelles would promote passive diffusion 
of the nanoconstructs into the scleral aqueous channels (size ranging from 20-80 nm) to reach 
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back of the eye. More importantly, Cequa®, Sun Pharmaceuticals, a nanomicellar formulation 
of cyclosporine (~15-20 nm) was recently approved by the US FDA for the treatment of dry 
eye syndrome and has demonstrated improved drug absorption into human ocular tissues. We 
also characterized the zeta potential of multi-layered nanomicelles using electrophoretic light 
scattering. The zeta potential was shown to have a value close to zero (neutral) (Figure 7-1 E). 
Additionally, continuous dilution by the tear fluids in the cul de sac and the limited capacity 
of the precorneal pocket leads to poor drug concentrations after topical application. In this 
regard, PVP K90 has been employed in order to enhance the viscosity of the nanomicellar 
formulation resulting in improved retention at the site of administration and/or ocular tissues. 
 
Table 7-2 Loading and entrapment efficiency of organo-nanomicelles for octreotide at 
varying wt. % ratio of polymers, HCO-40 and OC-40. Data represent mean ± S.D (n= 3-4) 
Organo-
nanomicelle 
Composition (HCO-40: 
OC-40) (wt. %) 
Loading efficiency 
(%) 
Entrapment efficiency 
(%) 
F1 0.5:2 0.90 ± 0.02 61.86 ± 1.03 
F2 1.68:0.75 0.99 ± 0.06 71.07 ± 0.62 
F3 2.5:1.005 1.08 ± 0.02 78.52 ± 2.01 
F4 0.5:0.01 0.86 ± 0.05 58.21 ± 0.57 
F5 2.5:0.01 1.01 ± 0.03 76.36 ± 1.56 
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Table 7-3 Changes in average diameter, zeta potential and polydispersity of octreotide-loaded 
multi-layered nanomicelles by varying the layer 1/layer 2 polymer ratio. Data represent mean 
± S.D (n= 3-4) 
 
 
 
7.6.3. 1H-NMR spectroscopy of multi-layered nanomicelles  
The process of multi-layered nanomicelle formation and octreotide encapsulation in 
multi-layered nanomicelle core were studied with proton NMR spectroscopy. 1H-NMR 
spectra for blank and octreotide-loaded multi-layered nanomicelles were recorded and 
compared. Sharp 1H-NMR signals from oxyethylene (-CH2-CH2-O) (δ=3.8 ppm) protons and 
weak signals from methyl (δ=0.9 ppm) and methylene (δ=1.3 ppm) protons of the hydrophobic 
chains were recorded. In addition, very weak signals from aromatic protons (δ=7.3 ppm) on 
phenyl ring were also recorded. Moreover, there was no significant difference observed in the 
spectra for blank and octreotide-loaded multi-layered nanomicelles (Figures 7-3 and 7-4). No 
characteristic peaks from octreotide were observed in octreotide-loaded multi-layered 
nanomicelles implying that the drug was molecularly dispersed in the nanomicellar core 
(Figures 7-5 and 7-6). 
Multi-layered 
nanomicelles 
Z-Ave Diameter (nm) Zeta-potential (mV) Polydispersity 
F1 17.07 ± 0.05 -2.44 ± 0.52 0.16 ± 0.01 
F2 16.59 ± 0.08 -1.49 ± 0.18 0.15 ± 0.01 
F3 16.56 ± 0.04 0.39 ± 0.18 0.14 ± 0.01 
F4 16.26 ± 0.41 -0.85 ± 0.26 0.17 ± 0.02 
F5 15.97 ± 0.04 -1.06 ± 0.67 0.15 ± 0.01 
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Figure 7-3 1H-NMR spectra for Blank multi-layered nanomicelles in D20 
Figure 7-4 1H-NMR spectra for Octreotide in D20 
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Figure 7-5 1H-NMR spectroscopies for (a) Octreotide; (b) Octreotide-loaded multi-layered 
nanomicelles; (c) Blank multi-layered nanomicelles; (d) OC-40 and (e) HCO-40 in D20 
Figure 7-6 1H-NMR spectra for Octreotide-loaded multi-layered nanomicelles in D20 
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7.6.4. Encapsulation efficiency  
Entrapment of hydrophilic peptides and proteins within the hydrophobic core of 
polymeric nanocarriers typically leads to poor encapsulation efficiency. In aqueous solutions, 
a vast majority of amphiphilic polymers utilized as delivery vehicles exhibit low CMC and fast 
micellization kinetics183. Although these nanomicelles are highly stable and allow for 
prolonged circulation lifetime, the fast micellization kinetics may limit the amount of 
hydrophilic peptides and proteins getting entrapped159. Additionally, hydrophilic peptides and 
proteins often exist as water-soluble ionic species. Accumulation of such species into the 
hydrophobic core is thermodynamically unfavorable. A common approach to achieve higher 
encapsulation efficiency is the use of double emulsion technique361. However, this method 
requires precise control to obtain uniform sized particles.  The method we report here is a 
highly robust method for the encapsulation of highly water-soluble small peptides within the 
multi-layered nanomicelle. Our method is unique in its approach and tries to overcome the 
problems associated with poor encapsulation efficiency of hydrophilic molecules. In principal, 
the core-shell structure of our organo-nanomicelles contains a hydrophilic core and a 
hydrophobic shell. The incorporation of the peptide within the hydrophilic core is 
thermodynamically favorable. Second, micellization of the organo-nanomicelles occurs via 
chain reorganization as the water-insoluble polymer/peptide complex aggregate and further 
solvent-induced condensation of peptide occurs. Although we have not yet studied the 
micellization kinetics, we anticipate chain reorganization to occur on a timescale long enough 
to allow internalization of the water-insoluble polymer/peptide complex into the core.  
The encapsulation efficiency of the multi-layered nanomicelle was investigated as 
described above. The amount of entrapped macromolecule was compared to the initial added 
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amount to determine the encapsulation efficiency. We investigated the encapsulation 
efficiency as a function of differing polymer concentrations. Figure 7-7 show the percentage 
of various peptides and proteins entrapped in the multi-layered nanomicelles at polymer 
concentrations of 2.5 wt. % HCO-40 and 1.005 wt. % OC-40 and 2 mg of peptides and proteins. 
We observed a decrease in percentage of macromolecule encapsulated as the molecular 
weights increased. However, the percentage of dipeptide (Gly-Sar) encapsulated in the 
nanomicelles was just 70%. This may be due to the lower hydrophilicity of dipeptide in 
comparison to tri- and tetra- peptides. In contrast, higher amounts of octreotide, insulin, and 
IgG resulted in diminished encapsulation efficiency of the multi-layered nanomicelles. 
Consequently, higher hydrophilicity and lower molecular weight may increase the possibility 
of hydrophilic interactions in the hydrophilic core of the multi-layered nanomicelles and thus 
may enhance the encapsulation efficiency. Detailed investigation on the solvent-induced self-
assembly is needed to fully understand the micellization process and encapsulation of peptides 
and proteins within the core.  
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Figure 7-8 Size distribution from DLS measurements of multi-layered 
nanomicelles (F3, Z-Ave Diameter 16.56±0.04 nm). Data represent mean ± S.D 
(n= 3-4) 
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Figure 7-7 Encapsulation or entrapment efficiency of multi-layered 
nanomicelles for various macromolecules or biologic. Data represent mean ± 
S.D (n= 3-4) 
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7.6.5. Release kinetics 
Once circulating, multi-layered nanomicelles are internalized by target cells, the 
payload is released from the endosome and merges with lysosome and finally reaches the 
nucleus. We examined the release profile of multi-layered nanomicelles using PBST and STF 
at 37°C to simulate the environment of a human eye. The release profile as a function of time 
is shown in Figure 7-9. Previously, we have shown that HCO-40/OC-40 nanomicelles could 
sustain the release of hydrophobic drugs for more than a month. In this study, octreotide was 
used as a model large molecule drug. We observed excellent octreotide release of up to 100% 
from the multi-layered nanomicelles in 264 h (11 days) and 648 h (27 days) in PBST (Figure 
7-9 A) and STF (Figure 7-9 B)  respectively. A sustained release of octreotide from the 
hydrophilic core of the multi-layered nanomicelles was achieved without any significant burst 
release. Unlike hydrophobic drugs, where the higher concentration of surfactant in STF 
improved the release rate, the octreotide release was delayed in this case compared to PBST. 
In addition, the faster release of octreotide from the multi-layered nanomicelles could be 
explained by the weak hydrophilic interactions between octreotide and hydrophilic segments 
of polymers in comparison to much stronger interactions of hydrophobic drugs at the 
hydrophobic nanomicellar core.  
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Figure 7-9 Octreotide release profiles of multi-layered nanomicelles: A) in 
PBST, pH 7.4 and B) in STF, pH 7.4 with circled region showing the 
release pattern for first 32 hours. Data represent mean ± S.D (n= 3-4) 
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Table 7-4 Summary of fit for kinetic models and associated parameters for release of 
octreotide from multi-layered nanomicelles. Data represent mean ± S.D (n= 3-4) 
Release 
medium 
Kinetic and Mechanistic Models 
Higuchi 
Model 
Korsmeyer-Peppas 
model 
Hixson-
Crowell 
model 
Zero 
Order 
First order 
R2 R2 n R2 R2 R2 Rate 
constant k 
(Hour-1) 
PBST 0.8169 0.9483 0.3450 0.7854 -0.2180 0.8731 0.4810 
STF 0.9675 0.9708 0.3892 0.8892 0.5540 0.9105 0.1599 
 
Further, the release data was fitted to various mechanistic models including Higuchi, 
Hixson-Crowell and Korsmeyer-Peppas models to determine the kinetics of octreotide release 
(Table 7-4). The best fit was found with the Korsmeyer-Peppas model with R2 of 0.9483 and 
0.9708 compared to other models for PBST and STF respectively. The n value was found to 
be 0.3450 and 0.3892 for PBST and STF respectively. Value of diffusion exponent  n < 0.5 
suggests that mechanism of release was pseudo-Fickian diffusion. In both pseudo- and non-
Fickian diffusion mechanisms, drug release is controlled by the thickness of the polymer. Data 
was also fitted to zero- and first- order equations to determine the order of release. Process of 
release followed first order kinetics with R2 values of 0.8731 and 0.9105 for PBST and STF 
respectively indicating release rate is proportional to the drug concentration. Compared to 
PBST, release rate was slower in STF, as indicted by first order rate constant which can be 
attributed to the higher concentration of surfactant in STF impeding the drug release. 
Moreover, the released octreotide from the multi-layered nanomicelles in PBST and 
STF was analyzed in HPLC-MS for native and acylated forms. In contrast to marketed PLGA 
formulation of octreotide (Sandostatin LAR® depot) where >60% of octreotide is acylated 
during in vitro release over a 3 months period, no acylation was observed in our case. Such 
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impediment of acylation may be explained by absence of acidic pH conditions and faster 
release or low incubation time of octreotide with the polymers. One hundred percent (100%) 
of octreotide was chemically intact following the release relative to Sandostatin LAR® depot 
where <20% was released in native form. HPLC–MS analysis was performed to identify the 
peaks associated with native and/or acylated peptide in the LC chromatogram. HPLC–MS 
profile for release samples on day 11 and 27 from PBST and STF are represented in Figures 
7-11 and 7-12 respectively in comparison to blank (Figure 7-10). Native octreotide eluted at 
8.29 min in extracted ion-chromatogram as m/z of 1020.1 corresponding to peak at 8.28 min 
in UV chromatogram. Presence of 1020.1 m/z suggest that the peptide maintained its native 
cyclic chemical structure. 
Several groups have investigated the use of delivery systems to deliver biologics for 
the treatment of back of the eye diseases such as age-related macular degeneration (AMD), 
diabetic retinopathy (DR)362. Intravitreal administration of such delivery systems has been 
shown to greatly sustain biologic release abilities for longer period363. Consequently, our 
unique multi-layered nanomicelles proved the hypothesis based on those references for the 
effective topical peptide delivery.    
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Figure 7-10 HPLC-MS spectrum of blank: A) total ion current (TIC) chromatogram 
for the enhanced multiply charged (EMC) scan and B) UV chromatogram 
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Figure 7-11 HPLC-MS spectrum of release sample (Day 11) from multi-layered 
nanomicelles in PBST: A) total ion current (TIC) chromatogram for the enhanced multiply 
charged (EMC) scan, B) extracted ion chromatogram (EIC) for octreotide, m/z 1020.1 and 
C) UV chromatogram 
201 
 
Figure 7-12 HPLC-MS spectrum of release sample (Day 27) from multi-layered 
nanomicelles in STF: A) total ion current (TIC) chromatogram for the enhanced multiply 
charged (EMC) scan, B) extracted ion chromatogram (EIC) for octreotide, m/z 1020.1 and 
C) UV chromatogram 
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7.6.6. Effect of release media on drug release  
In addition to the development of suitable apparatus to assess in vitro drug release, 
selection of an appropriate release media cannot be overlooked. In contrast to oral dosage 
forms where release media typically mimics pH of the gastrointestinal tract, release media 
selection for nano-sized dosage forms vary depending on the site of administration and site of 
action of the formulation. We have utilized two released media in here: PBST i.e. PBST 
containing 0.002 wt. % Tween 20 in order to solubilize the hydrophobic prodrug and STF 
containing 0.5 wt. % Tween-80 which closely mimics the tear fluid i.e. the site of 
administration. Results from in vitro release studies indicated significantly higher rate of 
prodrug release in STF (k=0.1239 hr-1) in comparison to PBST (k=0.1045 hr-1). Such behavior 
could be attributed to improved solubilization of the hydrophobic prodrug resulting from 
higher concentration of surfactant (Tween-80) in the release media, STF.  In contrary, the 
higher concentration of Tween-80 in STF interfered with the hydrophilic drug release and thus 
significantly lowered the release rate in STF (k=0.1599 hr-1) in comparison to PBST (k=0.4810 
hr-1).  
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Figure 7-13 Cumulative drug release (percentage) in PBST and STF (pH 7.4) 
from hydrophobic (B-C12-cCDF) and hydrophilic (octreotide)-loaded 
nanomicelles for 34 and 11 days respectively using dialysis membrane with 
molecular weight 2kDa. The standard deviation for each data point was 
averaged over three samples (n=3) 
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7.6.7. Cell cytotoxicity 
A major drawback of polymer based delivery vehicles is the often observed high cell 
toxicity. Polymer toxicity increases with increasing cationic charge density and flexibility364. 
Cell toxicity is caused when normal cell activities are constrained by accumulation of cationic 
charges at cell surface or internal compartments thus leading to high osmotic pressure. We 
investigated the potential toxicity of the multi-layered nanomicelles using a cell viability assay. 
At the lowest tested concentrations, we observed 100% cell viability for the multi-layered 
nanomicelles as well as for the individual polymers in all the three cell lines. While, OC-40 
did not exhibit any toxicity in D407 and CCL 20.2 cells, a slight decrease in cell viability was 
observed in RF/6A endothelial cells. Increase in HCO-40 concentration led to decrease in cell 
viability as expected. The multi-layered nanomicelles gradually lowered cell viability, while 
HCO-40 at higher concentrations reached a minimum plateau of ~15% and ~25% cell viability 
in D407 and CCL 20.2 cells respectively.  The toxicity results can also be explained in terms 
of IC50 values, which is the concentration required to cause toxicity in the 50% of the cells 
measured. As shown in Figure 7-14 the multi-layered nanomicelles showed IC50 larger than 
the individual polymer, HCO-40 in D407 cells. However, highest concentrations of OC-40 and 
the multi-layered nanomicelles did not reach IC50 values in CCL 20.2 and RF/6A cells.  The 
lower toxicity in RF/6A endothelial cells in contrast to D407 and CCL 20.2 epithelial cells 
could be attributed to low paracellular permeability of endothelial cells. In fact, the residues 
generated from the nanomicellar formulation following a slower release pattern and increased 
residence time might generate limited toxicity to other ocular tissues due to the biocompatible 
nature of the surfactants/polymers at lower concentrations. Additionally, utilization of these 
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surfactants/polymers has recently demonstrated improved biocompatibility in Phase 3 human 
clinical trials (NCT02845674).   
 
 
 
 
 
 
Figure 7-14 MTT assay of multi-layered nanomicelles prepared with HCO-40/OC-40 polymers to 
evaluate the toxicity in A) D407, B) CCL 20.2 and C) RF/6A cell lines. Data represent mean ± S.D 
(n= 8) 
206 
7.6.8. Intracellular accumulation of multi-layered nanomicelles 
To exploit the potential of multi-layered nanomicelles, cellular uptake of a hydrophilic 
dye, rhodamine and rhodamine loaded multi-layered nanomicelles were compared with the 
hydrophobic dye, coumarin-6 loaded nanomicelles by FCM (Figure 7-15). The cellular uptake 
in D407, CCL 20.2 and RF/6A cells was validated by incubating the cell lines with various 
treatment groups for 0.5, 2, 6, 12 and 24 h (Table 7-5). Coumarin-6 and coumarin-6 loaded 
nanomicelles generated ~15-20 fold higher accumulation compared to rhodamine and 
rhodamine loaded multi-layered nanomicelles in D407 and CCL 20.2 cell lines. The difference 
in cell accumulation of coumarin-6 and coumarin-6-loaded nanomicelles was much higher 
(~100 fold) in RF/6A cell line in comparison to rhodamine and rhodamine loaded multi-layered 
nanomicelles (Figure 7-16). Coumarin-6 being hydrophobic in nature generated much higher 
loading into the hydrophobic core of nanomicelles and permeated effectively into the cells in 
comparison to rhodamine. The lower intracellular accumulation of rhodamine could be 
attributed to lower loading in the hydrophilic core of multi-layered nanomicelles and loss of 
drug during cell processing. The massive difference in accumulation of rhodamine and 
coumarin-6 in RF/6A is due to low paracellular permeability of the endothelial cells, which is 
in accordance with the in vitro cytotoxicity results. Most importantly, since octreotide, is 20 
times more effective than the native somatostatin in suppressing growth hormone (GH) release, 
even lower concentrations of octreotide generated from the multi-layered nanomicellar 
formulation (0.078% octreotide) is anticipated to induce significant therapeutic effects in the 
back of the eye. In addition, lower concentrations of octreotide (0.40 mg/kg*h) following 
continuous subcutaneous (sc) infusion have shown to reduce serum GH levels by 3.5-fold in 
patients156. Considering the improved in-vivo cyclosporine (CsA) concentrations generated in 
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the retina (13.03 ng/ml) by the nanomicellar formulations (0.1% CsA) developed in our 
laboratory248 and the tremendous potency of octreotide in reducing GH levels, this octreotide-
loaded nanomicellar constructs presents a novel approach for delivering therapeutic peptides 
and thus holds remarkable potential in impeding the progression of PDR.   
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Figure 7-15 FACS histogram for A) coumarin-6, coumarin-6-loaded 
nanomicelles and B) rhodamine, rhodamine-loaded multi-layered 
nanomicelles in CCL 20.2 cells. Data represent mean ± S.D (n= 3-4) 
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Figure 7-16 Intracellular accumulation of multi-layered nanomicelles: FACS analysis of 
rhodamine and rhodamine-loaded multi-layered nanomicelles in comparison to coumarin-6 and 
coumarin-6-loaded nanomicelles in A) D407, B) CCL 20.2 and C) RF/6A cell lines. Data 
represent mean ± S.D (n= 3-4)  
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Table 7-5 Time dependent uptake of coumarin-6, coumarin-6-loaded nanomicelles, rhodamine and rhodamine-loaded multi-layered 
nanomicelles in A) D407, B) CCL 20.2 and C) RF/6A cell lines. Data represent mean ± S.D (n= 3-4) 
Treatment 
groups 
D407 CCL 20.2 RF/6A 
0.5 h 2 h 6 h 12 h 24 h 0.5 h 2 h 6 h 12 h 24 h 0.5 h 2 h 6 h 12 h 24 h 
Coumarin-6 24.53 
±  
2.09 
50.35 
± 
1.25 
62.53 
±  
1.18 
68.50 
± 
0.34 
73.33 
± 
1.38 
75.13 
± 
1.33 
81.60 
± 
0.83 
84.40 
± 
0.43 
87.55 
± 
0.38 
86.78 
± 
1.60 
41.53 
± 
0.70 
44.68 
± 
0.95 
49.50 
± 
0.47 
56.40 
± 
0.92 
63.08 
± 
1.00 
Coumarin-6 
loaded 
nanomicelles 
13.98 
±  
1.34 
33.58 
± 
1.61 
39.20 
±  
1.12 
45.20 
± 
2.13 
62.63 
± 
2.00 
38.45 
± 
1.53 
50.45 
± 
0.96 
53.40 
± 
0.98 
55.88 
± 
1.98 
58.45 
± 
1.54 
9.85 
± 
0.63 
13.25 
± 
0.47 
20.35 
± 
0.72 
34.53 
± 
1.31 
44.30 
± 
1.78 
Rhodamine 1.78  
±  
0.26 
10.05 
± 
0.35 
14.85 
±  
0.80 
25.38 
± 
1.01 
32.90 
± 
1.33 
3.18 
± 
0.41 
4.05 
± 
0.50 
5.65 
± 
1.04 
9.13 
± 
0.19 
12.05 
± 
0.47 
0.25 
± 
0.05 
0.38 
± 
0.04 
0.48 
± 
0.04 
0.58 
± 
0.04 
0.85 
± 
0.05 
Rhodamine 
loaded 
multi-
layered 
nanomicelles 
1.08  
±  
0.18 
4.28 
± 
0.33 
5.58  
±  
0.20 
6.60 
± 
0.34 
8.70 
± 
0.44 
1.85 
± 
0.27 
2.15 
± 
0.05 
2.48 
± 
0.18 
3.05 
± 
0.11 
3.98 
± 
0.46 
0.08 
± 
0.04 
0.08 
± 
0.04 
0.18 
± 
0.04 
0.25 
± 
0.05 
0.38 
± 
0.04 
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7.7. Conclusion   
For the first time, a combination of two polymers, HCO-40 and OC-40 was utilized to develop 
self-assembling multi-layered nanomicelles for sustained delivery of small peptides to back of 
the eye following topical application. The encapsulation method utilized a combination of 
hydrophilic interaction and solvent induced encapsulation to entrap high concentrations of 
octreotide within the hydrophilic core of the multi-layered nanomicelles. The compact micellar 
nanoconstructs sustained and prevented the degradation of octreotide over a long period. This 
is considered to be an important feature of the multi-layered nanomicelles, which can enhance 
long-term delivery of small peptides after topical administration. Additionally, easy and 
reproducible preparation steps, visual clarity, nanosize, improved loading capacity, stability 
and biocompatibility are requisite that render these self-assembling nanoconstructs an 
appealing delivery system for topical application of small peptides. The future modifications 
to the modular design may include extracellular targeting ligands to concentrate peptide-loaded 
multi-layered nanomicelles to a specific cell type or tissue.  This study suggests a 
biocompatible and easy to fabricate small peptide vehicle and future in vivo studies will further 
establish feasibility of therapeutic peptides to treat various deadly “undruggable” diseases.   
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CHAPTER 8 
8. SUMMARY AND RECOMMENDATIONS 
8.1. Summary 
Higher expression of efflux pumps on the human epithelial and brain capillary 
endothelial cells plays a significant role in the disposition of a wide range of therapeutics 
including HIV agents such as LPV. Poor aqueous solubility and higher affinity towards drug 
efflux pumps and metabolizing enzymes (CYP3A4) pose a major challenge to LPV delivery. 
This dissertation project provides an expedient strategy to improve oral and possibly brain 
absorption of LPV using a prodrug approach. Chemical modifications of LPV by conjugating 
amino acid or peptide moieties resulted in significant uptake and evasion of efflux pumps such 
as P-gp and MRP2. In addition, these chemically modified prodrugs were recognized by more 
than one influx or nutrient transport systems at a time, highly expressed on the intestinal 
epithelial and brain capillary endothelial cells. Interestingly, prodrugs generated superior 
aqueous solubility relative to LPV. Leu-LPV and His-Leu-LPV prodrugs demonstrated lower 
affinity towards P-gp and MRP2 relative to LPV. Both the prodrugs were found to be highly 
stable at lower pHs but hydrolyzed rapidly at pH 7.4 relative to pH 4. His-Leu-LPV exhibited 
both PepT1 and PHT1 transporter-mediated cellular uptake. Enzymatic hydrolysis studies 
revealed a steady regeneration of Leu-LPV and LPV from His-Leu-LPV with significant 
contribution by esterases in comparison to peptidases. Overall, histidine based peptide prodrug 
of LPV with dual targeting properties is a state-of-the-art strategy to ameliorate oral and 
possibly brain absorption of LPV. 
Such strategy of targeting influx or nutrient transport systems has further led to 
development of a topical self-assembling nanomicellar formulation of a highly potent 
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transporter targeted prodrug of cyclic cidofovir for cytomegalovirus retinitis (CMV, an 
infection of retina in AIDS patients).  
In contrast to numerous examples of successful ocular drug delivery (ODD) systems, 
nanomicelles have gained significant interest in the past decade for back of the eye delivery. 
Drug delivery especially to the intraocular tissues following topical administration is highly 
challenging due to the complex structure of the eye. The high aqueous solubility of 
nanomicellar formulations allows them to traverse through trans-scleral pathway rather than 
trans-corneal route to deliver drugs to the intraocular tissues. B-C12-cCDF, prodrug although 
being highly potent, has low aqueous solubility and faces the wrath of being detected by RES 
and efflux pumps. In order to overcome such shortcomings, a nanomicellar formulation of B-
C12-cCDF was developed using solvent evaporation-rehydration method. Statistical DOE was 
utilized to screen and achieve desired formulation with highest loading and entrapment and 
minimal micellar size and PDI. Biocompatibility of the polymers and prodrug-loaded 
nanomicelles by in vitro cell cytotoxicity (MTT, LDH and ELISA) in ocular cell lines suggests 
that the prodrug-loaded nanomicelle might be safe for ODD. Interestingly, B-C12-cCDF-
loaded nanomicelles efficiently internalized into D407 and HCE-T cells in 24 h. Significant 
transport across in-vitro corneal-retinal model with a release period of ~33 days indicated the 
potential of nanomicelles in delivering anti-viral prodrugs for prolonged periods to the back of 
the eye.   
Exploiting the nature of such a promising delivery systems, nanomicelles have allowed us to 
explore their potential in entrapping hydrophilic peptides and proteins. Poor chemical and 
physical stability and short circulating plasma half-lives are major challenges in biologic or 
macromolecule delivery. Additionally, acylation at the lysine residue by degraded products of 
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PLGA polymers further impede delivery of proteins and peptides in their native forms. 
Therefore, self-assembling multi-layered nanomicelles were generated to entrap octreotide 
using a combination of hydrophilic interaction and solvent-induced encapsulation. In the first 
step, entrapment of the octreotide in the hydrophilic core of the organo-nanomicelle was 
achieved in chloroform followed by addition of a protective aqueous solubilizing layer on the 
surface of the organo-nanomicelle. The resulting multi-layered nanomicellar system comprised 
of three regions: hydrophilic core: peptide/polymer, intermediate hydrophobic layer, and outer 
hydrophilic shell. The multi-layered nanomicelle displayed a size range of ~16-20 nm with 
zeta potential close to neutral (~-2.44-0.39 mV) at different polymer concentrations. Negligible 
toxicity was observed at lower concentrations in various ocular cell lines with sustained release 
of octreotide for 27 and 11 days in STF and PBST respectively in native form. This work 
demonstrated an all-biologic nanocarrier capable of delivering functional native biologic for 
the treatment of a wide variety of diseases.  
 
8.2. Recommendations 
For improving oral absorption: In the present study, histidine based peptide prodrug 
was developed to improve oral and possibly brain absorption of LPV. Although, the dual 
targeted approach is promising, certain modifications or strategies may be employed to 
facilitate drug penetration into HIV reservoirs and reduce systemic toxicities.   
L-enantiomers of histidine and leucine were utilized herein. Although, L-forms are 
associated with improved affinity towards influx transporters, D-stereo isomeric prodrugs can 
be synthesized to improve the stability of the prodrugs. For instance, D-histidine-L-leuine-
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LPV (DL-LPV) and L-histidine-D-leucine-LPV (LDLPV) can be developed to promote 
metabolic as well as enzymatic stability of prodrugs. 
For long-term prodrug delivery: With the advent of long-acting parenteral (LAP) 
antiretroviral (ARV) drugs, ARV prodrugs may be nanoformulated (e.g. Poloxamer 407) to 
facilitate monocyte-macrophage entry, retention and intracellular drug-depot formation. This 
strategy may not only provide long-term protection against HIV challenge, but also serve to 
extend viral restriction in other HIV residing tissues including lymph nodes and gut associated 
lymphoid tissues and spleen (peptide/histidine transporter, PHT2 is localized in the lymphatic 
system as well).   
 
For both receptor and transporter mediated prodrug delivery: TAT peptide, a 
small polypeptide of 86 amino acids derived from HIV-1 may be used as a targeting ligand for 
ARV prodrug nanoformulations. TAT peptide will allow receptor-mediated permeation of the 
nanoformulation into the cell membrane while the released prodrug will traverse through 
transporter-mediated mechanism, allowing much higher concentrations across the BBB in HIV 
residing tissues.  
 
For topical ocular hydrophobic molecule delivery: In this project, biotin receptors 
targeted prodrug of cidofovir (B-C12-cCDF) was encapsulated into nanomicelles for retinal 
drug delivery. The available free hydroxyl group of one of the polymers, OC-40 may be 
conjugated to ascorbic acid to target the high-affinity ascorbate transporters expressed on the 
retina for drug delivery.   
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For topical ocular biologic delivery: Hydrophobic-ion pairing (HIP) complexation 
can help in neutralizing the charges on proteins and peptides rendering them insoluble in 
aqueous solvents. Such an approach may help in improving the loading capacity of proteins 
and peptides and further delaying the release to more than a month from nanomicelles.     
Another alternative approach may be to suspend the multi-layered nanomicelles in a clear 
thermoresponsive gel. This strategy may allow better retention, minimization of precorneal 
loss and sustained release of hydrophilic peptides and proteins from the multi-layered 
nanomicelles in gel to the back of the eye.  
 
Evaluation of efficacy of octreotide-loaded multi-layered micelles using choroid 
sprouting assay: Choroid sprouting assay is highly reproducible and pertinent to angiogenesis 
research, particularly in the neovascular AMD field. The choroid sprouting assay can be used 
to evaluate pro- and anti-angiogenic pharmacological interventions. Importantly, the choroid 
sprouting assay allows for analysis of the interaction between choroidal endothelial cells and 
their adjacent cells (e.g. RPE cells) to uncover mechanisms that control choroidal vascular 
growth of specific relevance (but not exclusively) to sub-retinal proliferative disorders. 
RPE/choroid/sclera complex obtained from enucleated eyes from mice can be embedded in 
matrigel and evaluated for microvascular sprouts after pretreatment with octreotide and 
octreotide-loaded multi-layered nanomicelles. 
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